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Receptor tyrosine kinase (RTK) signalling regulates the activation of numerous cellular 
processes in response to various external stimuli. Spatio-temporal regulation of protein 
recruitment  to  activated  tyrosine  kinase  receptors  is  important  for  the  generation  of 
specific cellular responses to various external stimuli. The involvement of the signalling 
proteins  She,  FRS2,  Grb2  and  Sos and the formation of distinct signalling complexes 
downstream of three RTKs (TrkA, EGFR, FGFR) was assessed to analyse their role in 
maintaining  signalling  specificity.  All  four signalling proteins played  a role  in  TrkA, 
EGFR  and  FGFR  signalling,  but  their  recruitment  to  and  involvement  in  signalling 
complexes varied depending on the stimulus. The observations indicated that formation 
of unique multiprotein assemblies provides a mechanism for different receptors to elicit 
specific signals despite employing the same signalling proteins. Detailed analysis of She 
recruitment to the FGFR2 revealed co-localisation and co-precipitation with the receptor 
but  no  direct  interaction.  This  finding  provided  additional  insight  into  how  the 
availability of binding sites on different receptors regulates the recruitment of individual 
proteins to receptor-specific signalling complexes.
Secondly,  the  effects  of  mutations  in  the  FGFR2  extracellular  region  on  protein 
recruitment to the receptor and its overall signalling specificity were investigated. Two 
substitution mutations in the FGFR2, which cause Apert syndrome, result in increased 
affinity of FGFR2 for FGF. Detailed analysis of the FGFR2 itself and signalling from it 
in  the  presence  of these  mutations  indicated  that  they  also  result  in  altered  receptor 
glycosylation,  phosphorylation  and  glycosaminoglycans  dependency  as  well  as 
enhanced Erkl/2 activation. Additionally, recruitment and phosphorylation of She were 
altered in cells expressing the Apert syndrome mutations. The effects of the mutations 
on the FGFR2  and the  signalling complex formed profoundly altered FGFR2-induced 
signals and cellular responses. These findings highlight the importance of retaining the 
integrity of protein recruitment and signalling complex formation to achieve signalling 
specificity.
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1.1  Receptor tyrosine kinase signalling
1.1.1 Signalling from the cell surface
Cell  surface receptors  are the means by which cells receive  specific  signals  from  the 
outside  environment  and  transmit  them  to  their  interior  via  activation  of  signalling 
pathways. The number and types of signals that a given cell can receive and respond to 
is dependent on the range of receptors it expresses on the cell surface.
1.1.2 Tyrosine kinase receptors
LI.2.1 Overall molecular structure of receptor tyrosine kinases
The  human  genome  encodes  59  genes  for  receptor  tyrosine  kinases  (RTKs)  that  are
classed  into 20 distinct families on the basis of specific  structural  differences  (Figure 
1.1)  [1].  All  RTKs  portray  a  similar overall  structural  arrangement:  They  are  single 
membrane-spanning  proteins  that  contain  an  often  highly  glycosylated  extracellular 
ligand-binding  region  and  an  intracellular  region.  The  latter  consists  of the  tyrosine 
kinase  moiety  and  various  regions  that  form  docking  sites  for  numerous  adaptor 
proteins.
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Figure  1.1:  Diagrammatic  overview  of the  structural  differences  between  the  different  receptor 
tyrosine  kinase  families  Abbreviations  of the  prototypic  receptors:  EGFR:  epidermal  growth  factor 
receptor,  InsR:  insulin  receptor,  PDGFR:  platelet-derived  growth  factor  receptor,  VEGFR:  vascular 
endothelial  growth  factor  receptor,  FGFR:  fibroblast  growth  factor  receptor,  CCk:  colon  carcinoma 
kinase, Trk: tyrosine receptor kinase, Ror: receptor orphan, MuSK: muscle-specific kinase, Tie: tyrosine 
kinase  receptor  in  endothelial  cells,  EphR:  ephrin  receptor,  Ret:  rearranged  during transfection,  Ryk: 
receptor  related  to  tyrosine  kinases,  DDR:  discoidin  domain  receptor,  ROS:  receptor  tyrosine  kinase 
expressed in some epithelial cell types, LTK: leukocyte tyrosine kinase. Adapted from [2, 3].
1.1.2.2  Differences between individual RTKs
The  different RTKs  vary  mostly  in the  composition of the  extracellular region.  The 
assembly of recurring motifs in different combinations and orders gives rise to a number 
of different receptors (Figure 1.1). The reason for the greatest variation being found in 
this region is obvious when considering that each receptor has to be exactly matched to 
bind only a specific type of ligand.  The different domains assemble to form specific 
binding pockets that allow recognition of a diverse range of ligands that bind to the 
receptors [2].
Further differences between RTKs are present in the intracellular region,  such as for 
example the presence and length of kinase insert that results in a split-kinase domain in
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some RTKs  [2]. More importantly, different docking sites for various adaptor proteins 
are present on different receptors. For example, FGFR1 and TrkA both contain an FRS2 
binding site, but these differ from each other in amino acid sequence [4], whereas other 
RTKs may not contain a binding site for this protein altogether. Thus although certain 
features such as the tyrosine residues in the activation loop may be conserved between 
many receptors,  differences  in the motifs that act as adaptor protein docking  sites are 
present  in  their  intracellular  domains.  A  specific  complement  of  tyrosine  residues 
becomes phosphorylated on each receptor upon activation, thereby providing docking 
sites for proteins with SH2 or PTB domains. The resultant differences in adaptor protein 
recruitment are an important aspect for the creation of individual and specific  signals 
downstream of different ty rosine kinase receptors.
1.1.3  Regulation of receptor activation
1.1.3.1 Regulation of cellular responses by specific receptor expression
To  obtain  specific  cellular  responses  to  stimulation  during  development  and  on  the
organismal  level,  the  tight regulation  of the  signals  that  cells  can  respond  to  is  very 
important. By regulating whether a certain receptor is expressed on the cell surface, the 
response  to  specific  extracellular  signals  can  be  controlled,  which  is  of  particular 
relevance during development.  Additionally,  specific expression patterns of individual 
receptors  as  well  as  individual  receptor  isoforms  are  important  in  regulating  tissue- 
specific responses to growth factors.
1.1.3.2 Availability of different ligands for RTKs
In  addition  to  cell-  or  tissue-specific  expression  of receptor  families  and  isoforms, 
receptor tyrosine kinase signalling is regulated by the existence of several ligands and 
their specific expression patterns. PDGFa and PDGFp (platelet-derived growth factors) 
can  form  homo-  or  hetero-dimers  that  are  linked  by  disulphide  bridges.  The  type  of 
dimer determines which specific combination receptors (i.e. PDGF receptor a/a, p/p or 
a/p dimers) can be activated. The epidermal growth factor receptor (EGFR) family can 
be  activated  by  a  number  of  different  ligands,  including  EGF,  TGFa  and  various 
neuregulins.  Similarly, the 23  different fibroblast growth factors (FGFs) discovered to 
date have been shown to exhibit a certain degree of specificity for the different isoforms 
of the  four FGF receptor subgroups  [5-8].  Thus by  regulating both the  expression of 
receptors  and  ligands,  tight  control  over  cellular  responsiveness  to  stimulation  of 
different receptor pathways can be exerted.
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1.1.4  Activation of RTKs by ligand binding
1.1.4.1 Formation of ligand-receptor complexes
With the exception of the insulin receptor, engagement of a tyrosine kinase receptor by 
its respective ligand leads to dimerisation followed by activation of the kinase moiety 
and  fra«s-autophosphorylation  on  tyrosine  residues.  Depending  on  the  ligand,  active 
receptor  dimers  are  formed  in  various  ways.  Growth  factors  such  as  the  vascular 
endothelial growth factor (VEGF) exist as homodimers, which bind to their respective 
receptors  in  a 2:2  complex.  In the  case  of the  EGFR,  a  2:2  complex  is  formed,  but 
receptor  dimerisation  is  only  driven  by  receptor-receptor  interactions  and  no  ligand- 
ligand interactions. The fibroblast growth factor (FGF) also binds to its receptor in a 2:2 
fashion,  but  the  FGF-FGFR  interactions  alone  are  not  sufficient  to  stabilise  dimer 
formation. The stable formation of receptor dimers is only achieved in the presence of 
glycosaminoglycans  (GAGs)  such as heparan sulphate proteoglycans  (HSPGs).  These 
molecules allow further regulation of the specific activation of the FGFR (reviewed in 
[9]  and  refer  to  section  1.4.2.2).  Thus  depending  on  the  ligand  and  the  receptor, 
different types of receptor/ligand dimers are formed.  This is important for productive 
RTK  activation  and  signalling  and  also  contributes to  regulation  of specific  receptor 
activation in different cellular contexts.
1.1.4.2 Formation of larger multimeric structures
Although  the  model  of  receptor  dimerisation  upon  ligand  binding  is  still  widely 
accepted, more recent studies have indicated that receptor dimers may also form in the 
absence of ligand (reviewed in [10,  11]). In the unstimulated state, receptor monomers 
are  in  equilibrium  with  receptor  dimers,  but  only  a  very  small  proportion  would  be 
found in the active dimer state in which the quaternary structure is such to allow kinase 
activation  and  rnms-autophosphorylation.  Ligand  binding  to  the  receptor  causes 
stabilisation of the dimer and transition into the active dimer state, which leads to full 
activation and downstream signalling. In addition, evidence exists that receptor dimers 
are only the smallest possible functional unit and that the formation of larger complexes 
is possible, leading to receptor aggregation in certain regions of the plasma membrane 
[12,13].
1.1.4.3 Intracellular effects of ligand binding
The  ligand  binding  event  is  transmitted  to  the  kinase  domain  and  trans- 
autophosphorylation of two subunits in a receptor dimer on numerous tyrosine residues 
takes place. The location of these tyrosine residues and their presence within different
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amino acid motifs is specific for each receptor. Kinase activity is often regulated by the 
presence  of  activation  loops  which  contain  tyrosine  residues  that  need  to  be 
phosphorylated first in order for the kinase to reach full activity (reviewed in [14]).
Using  the  FGFR1  as  a  model,  its  has  recently  been  shown  that  all  phosphorylation 
events  occur  in  a  highly  ordered,  sequential  manner  [15].  Additionally,  the 
phosphorylation of Y653  and Y654 in the activation loop led to 50-100 fold and 500- 
1000 fold increase in kinase activity respectively. These findings may be representative 
of the  way  in  which  most  RTKs  function  and  indicate  that  phosphorylation  of the 
various tyrosine residues does not occur in a random fashion.  Such a mechanism adds 
further  temporal  regulation  to  the  recruitment  of  proteins  and  the  activation  of 
downstream pathways.
1.1.5 Recruitment of adaptor proteins to activated RTKs
Recruitment of signalling adaptors  such  as FRS2,  She  and  Grb2 to the  activated and
phosphorylated RTKs  occurs  primarily  via  interaction  of SH2  or PTB  domains  with 
phosphotyrosine  residues/motifs  on  the  receptor.  Once  recruited,  these  signalling 
proteins may be phosphorylated on tyrosine residues themselves or form platforms for 
the recruitment of other proteins. Recruitment of enzymes such as for example PLCyl, 
PI3K,  or  Akt  can  lead  to  activation  by  phosphorylation,  conformational  change  or 
simple  recruitment  to  the  membrane  respectively.  This  allows  recruitment  of other 
signalling  proteins  via  secondary  interactions  as  well  as  formation  of  secondary 
messengers which play important roles in downstream signalling. Overall, a variety of 
proteins  are  recruited  directly  to  the  activated  receptor  or  its  vicinity  via  multiple 
protein-protein interactions mediated by a range of modular domains. The implications 
and importance of specific recruitment of proteins and activation of signalling proteins 
will be described in more detail in later sections.
1.1.6 Cellular roles of RTKs and activation of downstream targets
1.1,6.1  Overall cellular responses regulated by RTK signalling
RTKs are involved in the activation of a number of different cellular processes. These
range  from  developmental  control,  cell  division  and  regulation  of the  cell  cycle  to 
migration  and  alteration  of cell  shape,  differentiation,  apoptosis  and  cell  metabolism. 
The specific responses to activation of any given receptor are often cell type specific. 
For  example,  activation  of  the  fibroblast  growth  factor  receptor  leads  to  neurite 
outgrowth and differentiation in PC 12 cells but to proliferation in NIH3T3  cells  [16].
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Thus cellular context and specific expression patterns of certain types of receptors are 
important  in the regulation of downstream  responses to  RTK activation  in  vivo.  The 
following sections briefly outline the activation of the three major signalling pathways 
activated downstream of RTKs.
1.1.6.2 The Ras/Raf/MEK/Erkl/2pathway
Activation  of RTKs  leads  to  the  recruitment  of Grb2/Sosl  complexes  to  the  plasma 
membrane via interaction of the Grb2 SH2 domain with the RTK itself or other tyrosine 
phosphorylated adaptor proteins such as She or FRS2. Grb2 interacts with a proline-rich 
region  in  the  C-terminus  of Sosl  (from  hereon  referred  to  as  Sos)  via  its  two  SH3 
domains  [17].  Once  in  proximity  at  the  plasma  membrane,  Sos  acts  as  a  guanine 
nucleotide exchange  factor for the  small  G-protein Ras  (which  is  itself constitutively 
membrane  anchored  via  a  famesyl  moiety  [18]).  The  activated,  GTP-bound  Ras 
interacts with and recruits members of the Raf kinase family, which are  subsequently 
activated by highly regulated dephosphorylation and phosphorylation events. Raf is able 
to phosphorylate the MAPK/Erk kinase 1   (MEK1, referred to as MEK), which in turn is 
activated  by  this  phosphorylation  event.  MEK  is  a  dual  kinase  that  subsequently 
phosphorylates  Erkl/2  (extracellular  signal  regulated  kinase,  also  known  as  mitogen 
activated protein kinase, MAPK) on threonine and tyrosine residues. Activated Erkl/2 
can  phosphorylate  and  interact  with  various  cytoplasmic  targets,  but  is  also  able  to 
translocate  to  the  nucleus.  Here  it  is  involved  in  regulation  of gene  transcription  by 
phosphorylating  various  transcription  factors  such  as  STAT3  and  Elk-1  as  well  as 
kinases such as p90RSK (reviewed in [19-21]).
1.1.6.3 Activation of the phosphatidylinositol-3-kinase (PI3K) pathway
The PI3K pathway is most strongly activated in response to stimulation of the insulin
receptor but is also activated in response to a number of other RTKs. The SH2 domain 
of the p85 regulatory subunit of PI3K allows binding to phosphotyrosine motifs on the 
receptors  or  on  adaptor proteins  such  as  IRS1  or  Gabl  [22-27].  The  conformational 
change induced in the pi 10 catalytical subunit as a result of this binding event leads to 
PI3K  activation.  PI3K  phosphorylates  the  D-3  position  of 
phosphatidylinositol(4)phosphate  and  phosphatidylinositol(4,5)bisphosphate 
(PtdIns(4)P)  and  PtdIns(4,5)P2  respectively) to  create  second  messengers  that  lead  to 
membrane recruitment of proteins via their PH domains. Of particular importance is the 
generation of PtdIns(3,4,5)P3, which leads to recruitment and activation of the protein 
kinase  B  (PKB  or  Akt)  and  phosphatidylinositol-dependent  kinase 1   (PDK1).  These
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serine-threonine kinases are involved in signal relay to other effector proteins  such as 
the  kinases  GSK3  and  p70S6K,  transcription  factors  like  FKHR-L1  or  survival 
regulators  such  as  BAD.  Other  non-receptor  protein  kinases  and  adaptor  proteins 
containing PH domains can also be recruited to the membrane as a result of the creation 
of  these  second  messengers  in  the  membrane.  The  PI3K  pathway  is  important  in 
regulating  cell  survival,  growth,  migration,  cell  cycle  entry  and  nutrient  sensing 
(reviewed in [28]).
1.1.6.4  The role of  phospholipase Cy-1
Phospholipase  Cy-1  (referred  to  as  PLCy  from  hereon)  can  directly  bind  to 
phosphotyrosine  sites on RTKs via its  SH2  domain.  It becomes activated by tyrosine 
phosphorylation and subsequently cleaves the membrane lipid Ptd(4,5)P2 to produce the 
two  second  messengers  diacylglycerol  (DAG)  and  inositol-(l,4,5)-phosphate  (IP3). 
Whereas DAG is involved in activation of the protein kinase C (PKC) and subsequent 
pathways  downstream  of this  kinase,  IP3  triggers  the  release  of calcium  from  the 
endoplasmic  reticulum.  The  released  calcium  binds  to  calmodulin  which  causes 
activation of calmodulin-dependent kinases and is also involved in leading to complete 
activation of PKC.  Activated PKC  can also feed into the Erkl/2  pathway by causing 
phosphorylation of Raf [29]. By activation of numerous pathways via the two different 
second  messengers,  PLCy  regulates  various  intracellular  signalling  events  and  is 
involved in activation of various transcription factors (reviewed in [9, 30]).
1.2 Epidermal growth factor receptor signalling
1.2.1 ErbB receptors and their ligands
1.2.1.1 ErbB receptor  family
The  epidermal  growth  factor  receptor  (EGFR)  was  the  first  tyrosine  kinase  receptor 
discovered  in  1978  [31].  Since  then,  four  genes  encoding  ErbBl  (EGFR),  ErbB2 
(HER2),  ErbB3  and  ErbB4  have been discovered  in mammals.  ErbB4  is  additionally 
subject to alternative splicing, which leads to expression of four different variants of this 
receptor.  The  ErbB  receptors  can  homo-  or  heterodimerise.  The  latter  property  is 
particularly important in the case of ErbB3  and ErbB2, which lack kinase activity and 
ligand-binding ability respectively (reviewed in [32]).
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1.2.1.2 ErbB receptor ligands
Eleven  ligands  with the  ability  to  interact  with  the  ErbB  receptor  family  have  been 
described, including EGF, heparin-binding EGF (HB-EGF), transforming growth factor 
alpha  (TGFa),  betacellulin,  amphiregulin,  epiregulin,  epigen  and  the  neuregulins 
(NRGs)  1-4  [33].  Whereas  some  of these  ligands  are  specific  to  one  type  of ErbB 
receptor  (for  example  EGF  binds  only  to  EGFR/ErbBl),  others  such  as  NRG1  and 
NRG2  can  bind  to  different  ErbB  receptors.  Several  of  the  ligands  are  initially 
expressed  as  membrane  anchored  proteins  and  need  to  be  released  by  proteolytic 
cleavage, whereas others are bound to cell surface proteoglycans, which thereby provide 
a reservoir from where ligand can be made available for receptor activation (reviewed in 
[34]).  Such differences may be important in regulation of activation of different ErbB 
receptors in various cellular contexts.
1.2.2 Structure and activation
1.2.2.1 ErbB structure
Like other RTKs, the ErbB receptors are made up of an extracellular region,  a single 
transmembrane  domain  and  an  intracellular region containing the  kinase  domain  and 
autophosphorylation sites that allow adaptor protein binding. The extracellular domain 
can effectively be divided into four subdomains, two homologous cysteine-rich regions 
(SI  and S2) and two regions that form the ligand binding site (LI  and L2) (Figure  1.1). 
The cysteine residues in the  SI  and  S2 domains do not form disulphide  bridges.  The 
structure of the extracellular domain of the EGFR in the presence of EGF and TGFa has 
been solved and revealed that the interaction of the LI and L2 regions creates the ligand 
binding pocket [35, 36].
1.2.2.2 Ligand binding
The  crystal  structures  of the  EGFR with  ligand revealed  an  important  role  of the  SI 
region in receptor dimerisation  [35, 36].  Each SI  domain projects out a  ‘dimerisation 
loop’, which are thought to interact with each other via interactions that stabilise dimer 
formation. Receptor dimers have been shown to have both greater stability and ligand- 
binding affinity than the respective monomers [37].
1.2.2.3 ErbB homo- and hetero-dimerisation and receptor activation
In the case of the different receptors found in the ErbB family, it has been demonstrated
that hetero-oligomerisation can occur.  In particular, the ErbB2 receptor,  for which no 
ligand  has  been  described  to  date,  can  oligomerise  with  the  EGFR,  leading  to  its
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activation [38, 39]. Other members of this family have since been found to form hetero­
oligomers  and this  may  be  an  important  aspect  in providing  further control  over the 
downstream signalling pathways that can be activated in particular cells [40, 41].
The EGFR can exist in a dimeric state in the absence of EGF, but the addition of the 
growth factor shifts the equilibrium from a monomeric to a dimeric state [12, 42]. EGF 
and the EGFR form 2:2 complexes upon dimerisation. This dimerisation is not ligand- 
dependent,  and  occurs  purely  on  the  basis  of receptor-receptor  interactions  (i.e.  no 
EGF:EGF  contacts  are  made)  [35].  EGF:EGFR  dimer  formation  is  regulated  by 
interaction of the dimerisation loop of the Cl domain with the other receptor [35, 43]. In 
addition  to  the  dimerisation  loop,  contacts  mediated  by  the  helical  transmembrane 
domains  may  also  contribute  to  the  dimer  formation.  The  transmembrane  region 
regulates  aspects  such  as  receptor  association  and  spatial  arrangement,  which 
subsequently influence downstream signal output (reviewed in [32]).
In contrast to many other RTKs, the activation loop of the EGFR does not need to be 
phosphorylated to assume the active conformation, so that the EGFR can be active  in 
the  absence  of  ligand  [44].  The  addition  of  EGF  however  is  important  to  allow 
conformational changes to take place that normally act to prevent dimerisation of the 
extracellular  domain  in  the  absence  of ligand  [45].  Dimerisation  of the  intracellular 
domain and correct positioning of the kinase domain to allow trans-autophosphorylation 
seem  to  be  sufficient  to  allow  complete  activation  of the  receptor  and  subsequent 
recruitment of various signalling proteins [46].
1.2.3  Signalling downstream of the EGFR
Once  dimerised  and  activated  by  the  addition  of  EGF  ligand,  the  EGFR  is 
phosphorylated  on  ten  tyrosine  residues  (Y845,  Y891,  Y920,  Y992,  Y1045,  Y1068, 
Y1086,  Y1114,  Y1148  and  Y1173),  not  all  of which  are  required  for  recruitment  of 
signalling proteins such as She, Grb2 or PLCy (reviewed in [33]).  Instead of having a 
single, specific binding site, several of these proteins are able to bind multiple sites on 
the  EGFR.  In comparison with  other RTKs,  it also  interesting to  note  that  all  of the 
tyrosine residues are located in the very C-terminal region of the intracellular domain. 
Figure  1.2 provides a simplified diagram of the main pathways activated by the EGFR 
and the roles of the signalling proteins relevant to this work are discussed below.
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Figure 1.2:  Overview of the main signalling pathways initiated by the EGFR The proteins  involved 
in  signalling  from the  EGFR and the  activation  of the three  main downstream  signalling pathways  are 
indicated. Negative-feedback signalling pathways are not shown. Adapted from [47].
1.2.3.1 Grb2
The  SH2/SH3  domain-containing adaptor protein Grb2  (growth factor receptor bound 
protein 2) can bind directly to the EGFR at various sites through interaction of its SH2 
domain with phosphotyrosine motifs surrounding Y1068 (major site) and Y1086 (minor 
site)  [48].  By recruitment to the membrane,  Grb2  leads to translocation of Sos to the 
plasma membrane.
1.2.3.2 She
The Src homology and collagen containing protein (She) adaptor binds to the EGFR at 
two  sites,  namely  Y1173  (major  site)  and  Y992  (minor  site)  in  response  to  EGF 
stimulation,  although other sites are able  to  compensate  for the  loss  of these  binding 
sites for She [48]. She interacts with the EGFR via its N-terminal PTB domain or its C- 
terminal SH2 domain [49, 50]. However, it can still be tyrosine phosphorylated in the 
absence of the main EGFR autophosphorylation sites, so receptor phosphorylation is not 
directly coupled to She activation [51, 52]. Once phosphorylated,  She provides further 
binding sites for the Grb2/Sos complex, which act in conjunction with the direct Grb2 
binding sites on the EGFR.
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1.2.33 FRS2
The  fibroblast  growth  factor  receptor  substrate  2  (FRS2)  is  a  myristoylated  adaptor 
protein that is tyrosine phosphorylated in response to TrkA and FGFR activation and 
acts as a docking site for the recruitment of proteins to the plasma membrane [53, 54]. A 
recent report has implicated FRS2 with a possible role in EGFR signalling, since it was 
observed to bind directly to the EGFR and has been suggested to play a role in Erkl/2 
activation. Moreover, it can be serine/threonine phosphorylated by Erkl/2 in response to 
EGF  stimulation,  which  indicates  negative  feedback  via the pathway  that  it  activates 
[55].  In addition,  FRS3  (also known as FRS2|3) plays a role in negative regulation of 
Erk2 in the absence of great levels of tyrosine phosphorylation in response to EGF [56]. 
No  other  studies  revealing  a  direct  role  for  FRS2  in  EGFR  signalling  have  been 
reported, and its exact role downstream of the EGFR needs to be elucidated further.
1.3 TrkA signalling
1.3.1 Neurotrophin receptors and their ligands
1.3.1.1 Neurotrophins and their receptors
To date three different receptor tyrosine kinases have been identified in vertebrates that 
act as  receptors  for neurotrophins:  TrkA,  B  and  C.  Although  structurally  similar,  the 
three  receptors  portray  selectivity  for  ligands.  TrkA  is  the  high  affinity  receptor  for 
NGF,  which  is  to  be  investigated  in  this  work.  In  addition,  p75N TR   is  another 
transmembrane  receptor that  is  able  to  bind NGF.  In  contrast  to  the  neuron-survival 
signal  initiated  by  NGF  binding  to  TrkA,  p75N TR   activates  signalling  pathways  that 
promote neuronal cell death.
1.3.1.2 Neurotrophins
NGF  was  the  first  of  the  neurotrophins  to  be  discovered.  Six  members  of  the 
neurotrophin family have been discovered to  date:  nerve  growth factor (NGF),  brain- 
derived  neurotrophic  factor  (BDNF),  glial-cell-line-derived  neurotrophic  factor 
(GDNF), neurturin, and the neurotrophins NT-3, 4 and 5. NGF and BDNF are ligands 
for TrkA, whereas NT-4 and NT-5  bind specifically to TrkB and NT-3  is the specific 
ligand for TrkC. GDNF interacts with the RET receptor and the GDNFRa, a co-receptor 
lacking a cytosolic  domain that  is  required  for RET activation.  Thus  as  observed  for 
other  RTKs,  the  selectivity  in  terms  of ligand  is  an  important  regulator  of receptor 
activity in different cellular environments.
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1.3.2 Physiological functions of neurotrophin signalling
The  work  presented  in  this  thesis  will  focus  on  TrkA  and  its  activation  by  NGF,
therefore  signalling from this receptor will  be described in more detail.  The different 
neurotrophin receptors show restrictive expression patterns but all are mostly expressed 
in brain and other neural tissues. Expression in particular cellular contexts contributes to 
specific  functions  of  different  neurotrophin  receptors.  This  is  important  for  the 
mediation of various neurotrophin-mediated cellular events such as apoptosis,  survival 
and differentiation [57].
TrkA has been found to co-precipitate with p75NTR. This has opened up the possibility 
that  these  two  receptors  interact  and  that  this  is  important  for  the  regulation  of the 
signals emanated from these receptors. It has been proposed that only the interaction of 
p75N TR with TrkA leads to the formation of high affinity binding sites for NGF  [58], 
although more recently independent functions for p75N TR  have been described [59, 60]. 
Several steps are required for neuronal differentiation to occur, including cell migration, 
directional axonal growth, synaptogenesis and selective survival. All of these processes 
are stimulated or activated through various signalling pathways. Signalling in response 
to  neurotrophin  stimulation  plays  an  important  role  in  regulating  neuronal 
differentiation,  in  addition  to  the  signals  emanated  by  cell  adhesion  molecules  [61]. 
Whereas  p75N TR  is  involved  in  regulation  of  a  variety  of functions  such  as  organ 
development, germ cell maturation and testicular cell differentiation (reviewed in [62]), 
Trk receptors are the main mediators of neurotrophin signalling in developing and adult 
neurons. In addition, NGF has also been shown to carry out important functions in non­
neuronal cells such as acting as an autocrine survival factor in memory B cells [63]. The 
investigation of the signalling events from TrkA investigated in this work will focus on 
its activation of the Erkl/2 pathway, which is an important regulator of differentiation.
1.3.3 Structural aspects of TrkA signalling
The  extracellular region  of TrkA  consists  of five  domains,  namely  two  cysteine-rich 
regions  (domains  1   and  3),  three  leucine-rich  repeats  (domain  2),  and  two 
immunoglobulin-like  domains  (domains  4  and  5)  (Figure  1.1).  Although  all  Trk 
receptors  share  this  domain assembly,  the  extracellular regions  of the  three  receptors 
only portray 50 to 55% sequence homology [64]. The Ig-like domains are sufficient for 
NGF binding.  Whereas domain 5  is required for efficient interaction of TrkA with its 
ligand and single amino acids important in NGF binding have been mapped to the EF 
loop of domain 5, domain 4 is required for correct folding of domain 5 and is therefore
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important  in  regulation  of ligand  binding  (reviewed  in  [65]).  In  addition,  the  Ig-like 
domains have been implicated with a role in prevention of receptor dimer formation in 
the  absence  of ligand,  and are therefore  important regulators  of the  activation of the 
receptor as well as downstream signalling.
The NGF dimer interacts with the TrkA dimer (two copies of domain 5) via its central 
P-sheet  region.  The  residues  on  NGF  important  for  interaction  with  p75N TR  remain 
partially  exposed,  which allows  formation of a complex  involving TrkA,  p75N TR  and 
NGF [66]. Specificity is introduced into the TrkA-NGF interaction by the existence of a 
'specificity  patch’,  which  contains  a  low  level  of  sequence  homology  between  the 
neurotrophins as well as the Trk receptors. Although the neurotrophin binding pocket is 
conserved  between  the  receptors,  the  residues  within  it  vary  greatly,  which  allows 
specific recognition of the different types  of ligands.  In addition,  a second patch,  the 
'conserved  patch’,  is  important  in  ligand-receptor  interaction.  In  contrast  to  the 
'specificity patch’, the residues within this region are highly conserved between the Trk 
receptors and contact is made by the receptor with both NGF  molecules  instead  of a 
single ligand molecule [66].
1.3.4  Signalling downstream of TrkA receptor
Activation of TrkA by binding of NGF leads to the recruitment of numerous signalling 
proteins.  Because of its importance in neuronal differentiation, TrkA activates various 
pathways. The correct interplay between these pathways is important for the activation 
of the  correct  cellular  response  to  NGF.  Only  the  main  proteins  recruited  to  and 
phosphorylated/activated by TrkA that are relevant to the studies presented in Chapter 3 
will be discussed in this section (refer to Figure 1.3 for diagrammatic representation).
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Figure  1.3:  Overview  of the  main  signalling  pathways  initiated  by  TrkA  The  proteins  involved  in 
signalling from TrkA and the activation of the three main downstream signalling pathways are indicated. 
Negative-feedback signalling pathways are not shown. Adapted from [67].
1.3.4.1  Grb2
Grb2 can be recruited to the TrkA receptor via phosphorylated FRS2  or She, but has 
recently  been  shown  to  also  interact  with  TrkA  directly  [68],  Three  sites  for  Grb2 
binding  were  identified,  namely  the  two  tyrosines  in  the  activation  loop  (Y683  and 
Y684) and Y794. Binding to the activation loop tyrosines may be important in keeping 
the receptor activated (i.e. prevent dephosphorylation by phosphatases). This indicates a 
role for Grb2 in addition to Sos recruitment to the plasma membrane.
13.4.2 She
She  binds  to  the  same  site  on  TrkA  as  FRS2  via  its  PTB  domain  [69-71].  Once 
phosphorylated, She recruits the Grb2/Sos complex. This process has been shown to be 
required for NGF induced differentiation of PC 12 cells [72].
13.4.2 FRS2
Exposure  to  NGF  causes  tyrosine  phosphorylation  of  Y490  on  TrkA,  which  is 
embedded  in  a  canonical  PTB  domain  binding  NPXpY  sequence  [4].  Following 
phosphorylation,  this  site  forms  a binding  site  for the  PTB  domain  of the  membrane
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anchored adaptor protein FRS2. FRS2 competes with She for this binding site and it has 
been  proposed  that  this  competition  provides  a  mechanism  to  differentiate  between 
activation of transient and prolonged Erkl/2 signalling in PC12 cells [70]. Inhibition of 
the  PLCy  signalling  pathway  almost  completely  abolishes  FRS2  phosphorylation  in 
response to NGF stimulation of TrkA [73].  In addition to recruitment of the Grb2/Sos 
complex,  FRS2  is  further  involved  in  the  recruitment  of Crk  and  subsequently  the 
guanine nucleotide exchange factor for Rapl, C3G, to the plasma membrane [67].
1.4  Fibroblast growth factor signalling
1.4.1  The FGFR family
1.4.LI FGFR domain composition
The extracellular region of the FGFR comprises three Ig-like domains (Dl, D2 and D3) 
and a stretch of seven to eight acidic residues between Dl and D2 referred to as the acid 
box  (Figure  1.1).  The  FGFR  contains  a  split-kinase  domain  and  numerous  tyrosine 
residues in the cytoplasmic region that become phosphorylated upon activation.
1.4.1.2 Subfamilies, isoforms and alternative splicing
Four FGFR genes (fgfrl-4) with great sequence similarity have been identified [74, 75]. 
The fgfr-1-3 can all be expressed as different isoforms as a result of alternative splicing, 
whereas the FGFR4 exists only as a single isoform. Alternative splicing may result in 
the expression of FGFRs with or without the Ig-like Dl domain [76]. The lack of the Dl 
domain increases affinity of the receptor towards both FGF and heparin [77, 78]. Most 
importantly, alternative use of exons encoding the second part of the D3  domain is an 
important  determinant  of specificity  in  the  FGF-FGFR  interaction,  because  the  D3 
domain (along with the  D2 domain and the D2-D3  linker region) is involved  in FGF 
binding [79, 80]. Restricted expression of the Illb isoform in epithelial cells and of the 
IIIc  isoform  in  mesenchymal  cells  invokes  additional  specificity  to  FGFR  signalling 
[81].
1.4.2 FGFR ligands
1.4.2.1  Fibroblast growth factors
22 human FGFs have been described to date  [82].  Although FGF23  exists, no human 
FGF 15 has been described, and human FGF 19 is believed to be homologous to mouse 
FGF15  [83].  FGFs  are  classed  into  sub-families,  within  which  a  greater  amount  of
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sequence  homology,  similar  expression  patterns  and  receptor  binding  properties  are 
observed.  Some of the residues that make contact with the FGFR are found within an 
internal core region made up of 28 highly conserved and six identical amino acids found 
within most FGFs. The primary heparin binding site on FGF molecules is distinct from 
the FGFR binding site [84, 85].
1.4.2.2  Heparan sulphate proteoglycans
Heparan sulphate proteoglycans (HSPG) are required for the interaction of FGF with the 
FGFR  [86].  The  structure  of the  heparin-FGF-FGFR  complex  has  been  solved  by 
different  groups  and  two  different  models  for  the  formation  of heparin-FGF-FGFR 
complexes were proposed (reviewed in [87]). The first model (proposed by Pellegrini et 
al.)  proposes  dimerisation of the  FGFs by heparin  in the  absence  of any  FGF-FGFR 
interactions, which results in a  1:2:2 heparin:FGF:FGFR complex [88]. In contrast, the 
Schlessinger/Mohammadi  model  proposes  formation  of  a  2:2:2  complex:  FGF  and 
FGFR  make  complex  with  the  respective  other  member  of the  dimer,  the  heparin 
molecules reduce the electrostatic repulsion between them [89]. However, the addition 
of excess heparin did not alter the  1:2:2 complex described by Pellegrini et al., and the 
addition of over  10-fold excess heparin to FGF1  still only led to the formation of 1:2 
heparin:FGFl  complexes  [90,  91].  Additionally,  several  molecules  of  FGF  can 
assemble  on  a long  polysaccharide  molecule,  which would  favour  a model  in  which 
clustering of receptors around few glycosaminoglycans chains occurs [90].
The 'two-end-modeF was formulated taking these observations into account. It suggests 
that upon FGF-FGFR binding, the heparin binding sites on the two FGFs and the two 
D2 domains of the receptors in a dimer come together to form a 'canyon’  in which a 
single HSPG molecule can bind.  Since each FGF will contribute slightly differently to 
the binding site, this model can also explain how specificity and preference for certain 
HSPGs  is  achieved  despite  the  D2  domain  being the  same  in  both  the  Illb  and  IIIc 
isoforms.  In  addition,  the  mode  of binding  in  this  model  is  highly  cooperative,  and 
involves  contacts  of FGF  and  FGFR  with  heparan  sulphate  (HS),  as  well  as  ligand- 
receptor and receptor-receptor interactions that are facilitated by HS binding [87].
1.4.3  Specificity in FGFR signalling
Some  degree  of  redundancy  and  promiscuity  in  FGF-FGFR  binding  exists,  since 
knockout mice of many FGFs are viable or have mild phenotypes  (reviewed in  [92]). 
Nonetheless, certain FGF-FGFR interactions are very specific. The binding affinities of 
individual  FGFs  for the  various  FGFR  isoforms  have  been  assessed  in  two  different
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ways. Mohammadi et al  expressed the D2 and D3 ligand binding region of the FGFRs 
bacterially and measured the affinity for FGFs using surface plasmon resonance [7, 8]. 
In contrast, Omitz et al.  used cellular based assays measuring the mitogenic activity of 
different  FGFRs  in  response  to  various  FGFs  [5,  6].  The  different  approaches  may 
explain  some  of the  differences  observed  in  the  relative  binding  affinities  reported. 
However, the overall pattern reported by both groups is similar and indicates that there 
is some selectivity in FGF-FGFR binding. For example, FGF1  binds to all FGFRs to a 
similar extent, whereas FGF7 shows a great deal of specificity for FGFR2IIIb and does 
not bind significantly to other FGF receptors.
The specificity in ligand recognition is mostly achieved by alternative splicing creating 
the alternative D3 domains, which makes the most contact with the FGF molecule in the 
reported structures. Additional specificity in the FGF-FGFR interaction is achieved by 
the presence  of specific  glycosaminoglycans  (GAGs).  Differences  in the type,  length 
and  sulphation pattern of proteoglycans  are important to  achieve maximal  binding of 
different FGFs to their receptors [93-96]. Different requirements were observed even if 
either the FGF or the FGFR were kept the same, which indicates that various GAGs can 
introduce further specificity into FGFR activation and signalling [97].
Additionally,  highly  regulated  expression  of  both  ligands  and  receptors  allows 
controlled  and  specific  activation  of  receptors to  take  place  [92].  For example,  the 
mesenchymally expressed FGF7 and FGF 10 can only activate the epithelial FGFR2IIIb 
isoform, whereas epithelial  FGFs 2, 4,  6,  8, 9  and  17 bind mesenchymally  expressed 
FGFR2IIIc with higher affinity to avoid autocrine signalling [5, 98, 99].
1.4.4  Signalling downstream of the FGFR
FGFR signalling is important in regulation of a multitude of cellular functions such as 
apoptosis, proliferation, migration, differentiation and survival (reviewed in  [75]).  The 
involvement of FGFR signalling in development and particularly limb formation plays 
an  important  role  in  the  development  of various  skeletal  diseases  (as  discussed  in 
section 1.6).
Most  studies  on  FGFR  signalling  have  been  carried  out  using  the  FGFR1  and  it  is 
widely accepted  that there  is  not much difference  in  signalling pathways  initiated  by 
different receptor types and isoforms due to the high degree of sequence homology in 
the intracellular region [75]. Indeed, an analysis of the overall tyrosine phosphorylation 
of proteins in response to receptor activation by Raffioni et al  seemed to reveal that the 
only difference between FGFR1, 3  and 4 was the level of phosphorylation but not the
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type of proteins that were phosphorylated [100]. This finding was mostly supported by 
the observation that activation of PLOy and Erkl/2 was weaker in cells expressing the 
FGFR4 than the FGFR1  [101]. However, this study also reported an altered activation 
of transcription factors in response to activation of the two different FGFRs and altered 
intracellular trafficking of the four different FGFRs has also been described [102]. Thus 
differences between various FGFRs do seem to exist.
Since  most  studies  focusing  on  signal  transduction  from  the  activated  FGFR  have 
employed  FGFR1,  the  following  descriptions  may  not  necessarily  hold  true  for  all 
receptor isoforms. The FGFR1  is autophosphorylated on seven tyrosine residues (Y463, 
Y583, Y585, Y653, Y654, Y730, Y766), of which Y653 and Y654 are positioned in the 
activation loop and are responsible for autoinhibition. Phosphorylation of all but Y766 
is  not required  for activation of Erkl/2  [103].  Autophosphorylation of these  residues 
occurs in a highly controlled, sequentially manner, which may be important for spatial 
and temporal signalling downstream of the receptor [15]. Figure  1.4 outlines the major 
signalling pathways activated by the FGFR and the roles of the proteins relevant to this 
study as well as several other FGFR effectors are described in more detail below.
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Figure 1.4: Overview of the main signalling pathways initiated by the FGFR The proteins involved in 
signalling  from  the  FGFR  and  the  activation  of the  three  main  downstream  signalling  pathways  are 
indicated. Negative-feedback signalling pathways are not shown. Adapted from [47].
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1.4.4.1 Grb2
Although Grb2  has been shown to bind to  RTKs  like the EGFR directly via its  SH2 
domain, such an interaction could not be detected in the case of the FGFR [104]. Thus 
the  recruitment  of  the  Grb2/Sos  complex  to  the  FGFR  is  mediated  by  indirect 
mechanisms via interaction of Grb2 with tyrosine phosphorylated  sites on  She,  FRS2 
and Shp2.
1.4.4.2 She
Although  its  involvement  in  FGFR  signalling  is  not  entirely  clear,  She  is 
phosphorylated and associates with Grb2  in response to FGFR activation  [101,  104]. 
She  phosphorylation  is  not  dependent  on  receptor phosphorylation  on  residues  other 
than  Y653  and  Y654,  which  are  required  for  kinase  activity  [103].  Although  many 
studies failed to observe interaction of She with the FGFR1, Curto et al.  showed that 
She  and the FGFR1  could be  co-precipitated in v-Src  transformed  cells  [105],  which 
indicates a potential role of She in FGFR signalling. Further, She has been found to co­
precipitate with the FGFR3 [106].
1.4.43 FRS2
FRS2 plays a major role in FGFR signalling, as demonstrated by the fact that FRS2-/- 
mouse embryos die at E7-7.5  [53,  107]. FRS2 binds constitutively to the FGFR1  via its 
PTB  domain  and  is  heavily  tyrosine  phosphorylated  upon  FGFR  activation  [108]. 
Tyrosine phosphorylated FRS2 provides four docking sites for Grb2 and two  sites for 
interaction with the tyrosine phosphatase  Shp2,  which  in turn also  binds  Grb2  [109]. 
Thus altogether, FRS2 leads to the direct and indirect recruitment of a large number of 
Grb2/Sos complexes,  which makes  it a major component in activation of the  MAPK 
pathway.  Further,  FRS2  is  also  directly  involved  in  signal  downregulation. 
Phosphorylation  on  eight  potential  threonine  residues  by  Erkl/2  is  important  for 
downregulation,  since absence of these sites causes continuous FRS2 phosphorylation 
and cellular transformation [110, 111].
1.4.4.4  PLCy
PLCy binds to the site surrounding phosphorylated Y766 of FGFR1 via its SH2 domain. 
Substitution of this residue by phenylalanine abolishes PtdIns(4,5)P2 hydrolysis without 
affecting the mitogenic activity of FGFR 1   [112, 113].
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1.4.4.5 c-Cbl
The E3 ubiquitin ligase c-Cbl is recruited via interaction of a proline-rich region with a 
Grb2  SH3  domain  [114].  In  conjunction  with  the  El  and  E2  components  of  the 
ubiquitylation  machinery,  c-Cbl  results  in  the  ubiquitination  of  the  FGFR,  its 
subsequent internalisation and downregulation of the signalling pathway.
1.4.4.6 Sprouty
Sprouty  (Spry)  is  an  inhibitor  of  the  Ras/Erkl/2  pathway  in  response  to  FGFR 
stimulation [115]. Phosphorylated Spry binds Grb2 and thereby prevents it from binding 
to FRS2 or Shp2. This induces a negative feedback mechanism on activation of Ras and 
subsequently  Erkl/2  [116].  The  overall  mechanism  of  how  Spry  leads  to 
downregulation of receptor signalling and Erkl/2 activation is not fully understood.
1.4.4.7 Shp2
Phosphorylated  FRS2  contains  two  binding  sites  for  the  tyrosine  phosphatase  Shp2, 
which subsequently plays  an important role  in presenting additional  binding  sites  for 
recruitment  of Grb2/Sos  complexes.  In  addition,  its  enzymatic  activity  is  crucial  for 
regulation  of  Erkl/2  activity,  since  inactive  Shp2  is  not  able  to  sustain  Erkl/2 
phosphorylation  in  PC 12  cells  [109].  Shp2  dephosphorylates  Spry  and  causes  its 
dissociation from Grb2, which leads to a decrease in negative regulation via Spry [117].
1.4.4.8 Gabl
Gabl  binds to  the  C-terminal  SH3  domain  of Grb2  via a proline-rich region.  It  was 
demonstrated that formation of the FRS2/Grb2/Gabl  complex upon FGFR stimulation 
induced activation of PI3K as well as subsequent downstream proteins [26].
1.4.4.9 c-Src
To date there are several conflicting reports regarding the role of the Src kinase family 
in  FGFR  signalling.  Although  an  interaction  between  Src  and  the  FGFR1  has  been 
reported [118], other reports failed to observe this direct association, and Src was found 
to be positively or negatively regulated by FGFR activation depending on the cell type 
used  [119].  Recent reports have highlighted roles  for  Src  in cell  migration and  shape 
changes via phosphorylation of cortactin  [120]  and  suppression of Erkl/2  activity  by 
resulting in Sprouty phosphorylation [121].
1.4.4.10 Other FGFR effectors
The adaptor protein Crk has been shown to bind to the FGFR1  at the site surrounding 
tyrosine  463.  It  interacts  with various  proteins  including  Cas,  C3G  and  She,  and has
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been  shown  to  play  a  role  in  the  activation  of the  Erkl/2  and  Jun  kinases  [122]. 
Furthermore,  a  recent  study  using  tyrosine  phosphoproteomics  analysis  by  mass 
spectroscopy  identified  the  insulin  receptor  substrate-4  (IRS-4)  as  a  further  protein 
involved  in  FGFR1  signalling  [123].  The  pl20  Ras  GTPase  activating  protein 
(RasGAP)  has  been  shown  to  interact  with  and  be  phosphorylated  by  FGFRs  in 
Drosophila and has been proposed to be involved in regulating the activation of Ras and 
subsequently the Erkl/2 pathway downstream of these receptors [124].
1.5 Specificity in receptor tyrosine kinase signalling
1.5.1 Multiple RTKs activate the same signalling pathways
All RTKs portray great similarities in the way in which they are activated and trans-
autophosphorylate  on  tyrosine  residues  in  their  cytoplasmic  regions.  Moreover,  they 
often  induce  the  same  cellular  outcomes  such  as  mitogenesis,  apoptosis  or 
differentiation.  This leads to the  question of whether different  growth factors use the 
same  or  different  intracellular  signalling  pathways  to  achieve  these  responses. 
Signalling proteins  such as Grb2,  Sos,  She and Ras are involved in signalling from a 
variety of different RTKs and downstream targets like Erkl/2,  PI3K or PLCy can be 
activated  by  a  plethora  of  different  ligands  (reviewed  in  [125]).  Therefore  the 
recruitment of a unique and specific protein complement to different RTKs cannot form 
the basis of specific and diverse signals.
Individual  cell  types  usually  express  more  than  one  type  of RTK,  which  elicit  very 
different cellular responses such as for example in PC 12 cells, where EGF stimulation 
leads to proliferation, but NGF stimulation leads to differentiation [16]. Hence, although 
it is more efficient for cells to use the same signalling machinery, the knowledge that 
different  receptors  utilise  common  signalling  proteins  and  activate  the  same  overall 
pathways also presents a challenge. Quantitative and qualitative information is required 
to understand how specific signals are achieved and how crosstalk between signals from 
different receptors is avoided.
1.5.2 Avoidance of crosstalk and regulation of specificity
1.5.2.1  Interaction domain specificity
Many  of the  proteins  involved  in  signal  transduction  from  RTKs  are  made  up  of 
different  combinations  of a  limited  pool  of small,  modular  domains.  Each  of these 
domains  introduces  specific  functionality  into  a  protein  such  as  the  ability  to  bind
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phosphotyrosine (Src homology 2 (SH2), phosphotyrosine binding (PTB)), proline-rich 
regions (Src homology 3 (SH3), WW) or particular lipids such as phosphatidylinositols 
(pleckstrin homology (PH), PTB, FYVE). They are found in different combinations in 
many signalling proteins (Figure 1.5).
Signal  transduction  downstream  of RTKs  is  often  represented  in  the  form  of linear 
pathways,  partly  because  of  the  ease  of  two-dimensional  representation,  but  also 
because  techniques  such  as  immunoprecipitation,  in  vitro  pulldown  and  yeast-two 
hybrid  methods  identify  only  high-affinity  binding  partners.  However,  for  signal 
transduction  to  occur  by  linear  protein-protein  interactions,  the  affinity  of  a  given 
protein for its binding partner, would have to be several orders of magnitude greater for 
the specific  ligand over non-specific interactions  [126].  If this was not the  case,  non­
specific  binding  and  activation  of  the  incorrect  signalling  pathway  could  not  be 
excluded and aberrant responses could be activated.
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Figure  1.5:  Diagrammatic  representation  of the types  of proteins  involved  in  signal  transduction 
downstream  of receptor  tyrosine  kinases  Examples  of SH2  domain  containing  proteins  involved  in 
signal  transduction  from  RTKs  are  shown.  Different  combinations  of various  modular  domains  allow 
formation of proteins with different functionality.  Abbreviations of the domains:  SH2:  Src homology 2, 
SH3:  Src  homology  3,  PTB:  phosphotyrosine  binding,  SAM:  sterile  alpha  motif,  PH:  pleckstrin 
homology, Tyr kinase: tyrosine kinase, PTPase: tyrosine phosphatase, PLC: phospholipase, C2: calcium 
and phospholipid binding, RhoGAP: GTPase activating protein, Ring:  Ring domain, EF:  EF-hand, Uba: 
ubiquitin associated, SOCS: suppressor of cytokine signalling. Adapted from [127,  128].
Interactions of various  SH2 domains  with ligands have been analysed  extensively  in 
terms  of binding  affinities  and  specificities  [129,  130].  Analysis  of the  dissociation 
constants for various phosphopeptides from the Src SH2 domain revealed that binding 
to  a  non-specific  peptide  sequence  occurred  with  affinities  of  only  an  order  of 
magnitude less than specific interaction with a pYEEI peptide [126, 131]. The affinities 
of different SH3  domains for various specific and non-specific ligands also varied by 
only two orders of magnitude [131]. Similarly, the Fyn SH3 domain can bind both Sos 
and the PI3K p85 subunit with similar affinities, so that discrimination of binding these 
two proteins  cannot be  achieved.  Moreover,  although  some  PH  domains  are  able to 
differentiate between specific phosphatidylinositols,  many portray  fairly promiscuous
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binding, which again demonstrates that the specificity of domain/ligand interactions is 
not high enough to confer specificity intracellularly [132].
The context of the full-length protein as well as the cellular environment/compartment 
may  affect  the  affinities  that  given  domains  have  for  ‘specific’  and  ‘non-specific’ 
cognate  ligands  and  may  introduce  some  specificity  to  protein-protein  interactions. 
Nonetheless, it has to be noted that the interactions promoted by various domains do not 
confer  enough  specificity  to  introduce  a high  level  of mutual  exclusivity  to  protein- 
protein interactions. These observations indicate that signalling is unlikely to occur via 
linear  pathways  and  that  other  factors  must  contribute  to  the  generation  of specific 
signals.
1.5.2.2  Avoidance of  signal crosstalk
It is absolutely essential  for the correct functioning and overall  integrity of a cellular 
system that the correct responses to extracellular signals are initiated. The lack of a high 
level  of  specificity  in  individual  protein-protein  interactions  and  the  use  of  many 
signalling  proteins  downstream  of  more  than  one  RTK  indicate  the  potential  for 
crosstalk  to  take  place.  Instead  of activating  only  the  correct,  ‘intended’  signal,  the 
accidental  activation  of other pathways  could  occur,  which  would  grossly  affect  the 
ultimate cellular response. One of the questions that arises, is how cells are able to avoid 
such  crosstalk  and  how  specific  downstream  outcomes  such  as  differentiation, 
proliferation or apoptosis  are  achieved  if the  same  signalling machinery  is  employed 
downstream of various RTKs.
1.5.3  Mechanisms regulating RTK signalling specificity
The need for regulation of RTK  signalling beyond the recruitment of certain adaptor
proteins to the activated receptor is apparent.  There are several mechanisms by which 
specificity in RTK signalling is believed to be regulated, all of which are important in 
generating  increased  specificity  in  individual  protein-protein  interactions  as  well  as 
regulating  the  duration  and  level  of downstream  signalling  pathway  activation.  The 
following  sections  will  provide  an  overview  of the  strategies  employed  to  induce 
specific biological responses.
1.5.3.1  Multiprotein complex formation
One  of the  major  regulators  of  specificity  in  RTK  signalling  is  the  formation  of 
multiprotein  complexes.  Their  assembly  allows  more  precise  spatio-temporal  control 
over the signal transmitted from the receptor to the inside of the cell than simple linear
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pathways.  The  combinatorial  recruitment  of proteins  into  complexes  specific  to  the 
respective  receptor  via  their  various  modular  domains  provides  a  means  by  which 
specificity can be achieved.  Differences in the types of proteins recruited and in their 
arrangement in a complex as  well  as  in the duration for which such assemblies  exist 
allow the unique and specific activation of signalling pathways downstream of different 
receptors.  Additionally,  because  different  proteins  donate  various  functionalities  to  a 
multiprotein  complex,  regulated  activation  of the  desired  complement  of signalling 
pathways can be achieved.
Moreover,  the  formation  of  complexes  introduces  more  specificity  into  individual 
protein-protein  interactions  by  allowing  formation  of  multi  valent  interactions.  The 
binding  affinities  of  individual  domains  for  its  target  ligand  can  be  increased  by 
cooperativity in the context of the whole protein [133, 134]. Specificity is introduced in 
the  form  of a  requirement  for  the  complete  and  precise  protein  complement  to  be 
recruited in order to allow unique signals to be generated (Figure 1.6). The formation of 
complexes  affects  factors  such as  affinity  and availability  of binding partners,  which 
allows more specific signals to be generated.
The formation of multiprotein complexes also provides flexibility to the signal created. 
The  composition  of the  complex  and  the  stoichiometry  of proteins  can  change  with 
time,  thereby  providing  tight  system  regulation  throughout  prolonged  receptor 
engagement.  In  linear pathways  such  fine-tuned  control  would  not  be  possible  since 
proteins would either interact or not.  The complexes that assemble upon activation of 
for  example  the  T-cell  receptor  are  highly  dynamic  and  rapid  changes  in  complex 
composition occur, thereby providing a high level of spatial and temporal control [135]. 
Additionally,  the  longevity  of  signals  can  also  be  more  tightly  controlled  because 
proteins  in  complexes  may  for example  be  shielded  from  dephosphorylation.  On  the 
other  hand  the  controlled  recruitment  of  negative  regulators  such  as  protein 
phosphatases  and  ubiquitin  ligases  to  a  complex  is  also  important  in  the  creation  of 
specificity as it allows regulated signal downregulation.
Altogether,  the  spatio-temporal  regulation  of  recruitment  of  proteins  into  these 
complexes  is  an extremely  important  aspect  in  generation  of the  unique  and  specific 
signals generated by various RTKs.
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Figure  1.6:  Signal  transduction  from  RTKs  via  linear  pathways  or  formation  of  multiprotein 
complexes  Linear representation of cell signalling involves each protein binding to a maximum of two 
binding partners and activation of a limited number of pathways.  Individual protein-protein interactions 
would have to be highly specific to allow activation of the correct pathways and to avoid signal crosstalk. 
Formation  of  a  multiprotein  complex  allows  recruitment  of  additional  proteins  via  multivalent 
interactions with various binding partners, which leads to the activation of additional pathways specific to 
the  receptor  activated  and  complex  formed.  Recruitment  of  a  precise  protein  complement  into 
multimolecular  complexes  downstream  of  different  RTKs  introduces  specificity  and  allows  unique 
activation of signalling pathways.
1.5.3.2 Use of scaffold proteins
Scaffold proteins anchor components of signalling pathways to certain cellular locations 
or prevent activation unless the right conditions are present. Thereby scaffold proteins 
can sequester signalling components and prevent activation by closely related pathways 
(reviewed in [136]). Scaffolding proteins such as kinase suppressor of Ras-1   (KSR-1), 
p-arrestin  and  paxillin  are  important  for  the  specific  activation  of  the 
Ras/Raf7MEK/Erkl/2 pathway [137]. Such proteins are also important in regulating the 
avoidance of crosstalk with other pathways and target components to specific locations, 
provide  specific  signal  inhibition  and  affect  assembly  and  turnover  of  different 
components.  Scaffold  proteins  thereby  add  additional  specificity  to  the  signal 
transduced  and  play  an  important  role  in  avoiding  crosstalk  between  different 
pathways/signals.
1.5.3.3 Compartmentalisation of signalling
Many  of the  proteins  involved  in  cell  signalling  are  not  found  ubiquitously  in  the 
cytoplasm, waiting for a given RTK to be activated. Instead, many proteins are already 
targeted to the membrane  or kept  in locations  from which they can be  more readily
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recruited to signalling complexes. For example, the docking protein FRS2 is membrane 
anchored by myristoylation at its C-terminus.  Further, it is constitutively bound to the 
FGFR1  [108], which ensures that it can be immediately phosphorylated upon receptor 
activation. Apart from membrane anchorage via lipid moieties, modular domains such 
as the PH, FYVE or PTB domains, which bind to phosphatidylinositols in the plasma 
membrane, may mediate the recruitment of proteins to the membrane independently of 
receptor  stimulation  or  in  response  to  changes  in  the  lipid  content  upon  receptor 
activation.
The compartmentalisation of proteins at the plasma membrane may play an important 
role  in  activation  of specific  signalling  pathways  by  affecting  availability  of various 
downstream  signalling proteins.  Lipid rafts have  been proposed as regions that allow 
pre-sequestration  of  various  proteins  involved  in  signal  transduction  (reviewed  in 
[138]).  The  recruitment  of  proteins  to  the  membrane  increases  their  effective 
concentration, which may increase the apparent affinity for binding partners up to 1000- 
fold [139]. Recruitment of proteins to the same cellular compartment further affects the 
longevity of complexes as a result of the increase in local concentration [126].
The relocation of proteins as a result of activation by RTKs is another aspect of cellular 
compartmentalisation  that  is  also  important  in the  generation  of specific  and  diverse 
signals. For example, the translocation of Erkl/2 to the nucleus upon exposure of PC 12 
cells to NGF but not to EGF  [140] marks a difference between sustained and transient 
activation and is therefore an important regulator of signal specificity.
1.5.3.4  Regulation of signal duration and amplitude
In PC 12 cells, prolonged Erkl/2 signalling (following NGF or FGF stimulation) leads to 
differentiation,  whereas  transient  activation  of this  kinase  (in  response  to  EGF  or 
insulin)  causes  proliferation  [16].  Other  models  have  also  shown  that  the  difference 
between  transient  and  prolonged  activation  of  the  Erkl/2  pathway  is  important  in 
regulating  signal  specificity  (Figure  1.7).  For  example,  quiescent  fibroblasts  enter  S 
phase  and  begin  to  proliferate  in  response  to  prolonged  but  not  transient  Erkl/2 
activation  [141,  142].  The  amplitude  of a signal  is also  important  in determining the 
ultimate cellular response. In the case of PC 12 cells, overexpression of the EGFR or the 
IR  was  also  able  to  induce  differentiation  [140,  143].  Similarly,  the  survival  of 
carcinoma cells is linked to a strong Erkl/2 activity, whereas a lower level of Erkl/2 
activation leads to cell death by apoptosis [144].
43The quantitative regulation of signals in terms of duration and magnitude is therefore an 
important  factor  in  regulating  cellular  responses  (Figure  1.7).  The  correct  balance 
between  stimulatory  and  inhibitory  signals  is  required to  regulate  both  strength  and 
duration  of  a  signal  and  lead  to  the  correct  cellular  response.  This  provides  an 
interesting  basis  for  investigation  of the  effects  of mutations  in  various  signalling 
components on signal duration and magnitude.
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Figure  1.7:  Schematic  representation  of  the  importance  of  quantitative  regulation  of  Erkl/2 
signalling  for  the  generation  of signalling  specificity  Specific celluar responses  can  be  mediated by 
quantitative  differences  in  the  activation of signalling pathways  such  as the  Erkl/2  pathway.  Adapted 
from [145].
1.5.3.5  Specificity as a result of cellular context
Different expression patterns of receptors and ligands are important in contributing to 
cell-specific activation of signalling pathways and subsequent cellular responses.  For 
example, PC 12 cells do not express any PDGFR, and thus are normally unresponsive to 
PDGF.  However,  when the  gene  encoding the  PDGFRp  is  expressed  in  PC 12  cells, 
PDGFp is able to  induce differentiation  [146].  In addition,  cells may  also  express  a 
certain protein complement, which directs the  specific activation of certain pathways 
but  does  not  allow  other  pathways  to  be  activated.  FGF  stimulation  of NIH  3T3
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fibroblasts  leads  to  proliferation,  but  FGF  stimulation  of PC 12  cells  leads  to  their 
differentiation into neurons  [16].  These differences are most easily explained by cell- 
type  specific  expression of effector proteins that are  able to  mediate  different up-  or 
downregulation  of  transcription  factors  and  gene  expression  in  response  to  RTK 
activation,  which provides  a  further basis  for the  achievement  of specificity  in  RTK 
signalling.
1.6 FGFR2 and Apert syndrome
1.6.1 Mutations in FGFRs and craniosynostosis syndromes
FGFRs  were  first implicated  in diseases  and syndromes related to  bone  development
when  activating  mutations  in  the fgfrS  gene  were  found  to  cause  achondroplasia  (a 
common form of dwarfism) [147,  148]. Since then mutations in the fgfrl-3 genes have 
been  implicated  with  roles  in  various  other  skeletal  disorders.  Craniosynostosis,  the 
premature  fusion  of  the  sutures  of  the  skull,  occurs  in  approximately  1   in  2500 
newborns. Over 100 distinct syndromes are characterised by craniosynostosis, including 
Apert,  Pfeiffer,  Crouzon  and  Jackson-Weiss  syndrome  [149].  Craniosynostosis 
syndromes are the result of dominantly acting mutations that create a gain-of-function 
phenotype in the fgfrl-3 genes. Whereas Pfeiffer syndrome can be caused by a number 
of mutations in FGFR1  or FGFR2, some of the other syndromes are caused by highly 
specific mutations  (reviewed  in  [150]).  Most of the mutations that affect  craniofacial 
development are clustered within the region of the Ig-like domains D2 and D3 and the 
linker region between them.
1.6.2 The molecular basis of Apert syndrome
Apert  syndrome  was  first  described  in  1906  [151].  Besides  craniosynostosis,  Apert 
syndrome  is  characterised  by  severe  syndactyly,  abnormalities  of the  skin,  skeleton, 
brain and other internal organs [152]. Syndromes such as Crouzon syndrome are caused 
by  the  constitutive  activation  of  the  FGFR2,  which  results  in  a  gain-of-function 
phenotype. This phenomenon occurs as a result of creation of unpaired cysteine residues 
that form  intermolecular disulphide bridges,  which cause  ligand-independent receptor 
dimerisation and activation [153-155]. In contrast, Apert syndrome is primarily caused 
by one of two mutations in the linker region between the D2 and D3 Ig-like domains in 
the extracellular region of FGFR2 (Figure 1.8). The S252W and P253R mutations occur 
in approximately 65% and  35% of all  cases respectively  [152,  156].  Other mutations
45can also cause Apert syndrome, but they make up a very small proportion of all cases. 
These mutations include the S252F [150] substitution, a de novo Alu-element insertion 
that  leads to  altered  expression of the  two  FGFR2  splice variants  [157],  and  double 
mutations such as S252L/A315S, which cause syndactyly only when both mutations are 
present [158].
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Figure  1.8:  Location of the S252W and P253R Apert syndrome mutations Both the S252W and the 
P253R mutations are located in the linker region between the Ig-like domains II and III of the FGFR2. 
This region contributes to ligand binding and recognition.  The single base pair substitutions  leading to 
amino acid substitutions S252W and P253R are indicated. Adapted from [159,  160].
1.6.3  Increased binding affinity of Apert syndrome FGFR2 for FGF
Despite resulting in a similar phenotype as the Crouzon mutations, the Apert syndrome
mutations do not cause  ligand-independent dimerisation  [161].  In  contrast,  the  Apert 
syndrome mutations result in increased affinity of the mutant receptors for FGF ligand 
compared to the normal  FGFR2  [7,  161].  Various approaches  have revealed  slightly 
different results regarding the extent to which the Apert syndrome mutations increase 
affinity  for  FGF  ligand,  which  FGFs  portray  this  effect  and  whether  only  the 
dissociation constant (koff) or both the  association and dissociation constants (kon and 
koff)  are  affected.  While  one  group  expressed  and  purified  the  soluble  extracellular 
domain of FGFR2(IIIc) (Ig-like domains D1-D3) in HEK 293 cells [161], another group 
used residues  147-366  of the  FGFR2IIIc  expressed  in E.coli that  had to  be  refolded 
from inclusion bodies [7].  Whereas the construct expressed in mammalian cells would 
be  fully  glycosylated,  the  bacterially  expressed  protein  lacks  this  posttranslational 
modification,  which  would  affect  the  FGFR-FGF  interactions  taking  place  [162]. 
Additionally, the bacterially expressed protein that was refolded from inclusion bodies 
may not possess the correct disulphide bridges, and is lacking the Dl  Ig-like domain, 
which has been shown to be an important regulator of ligand binding  [77].  However,Chapter 1
despite  slight discrepancies,  both  studies  reported  an overall  increased affinity  of the 
Apert syndrome mutant receptors and that this effect was generally more pronounced in 
the case of the S252W mutation.
Despite  extensive  studies  of the  effect  of the  Apert  syndrome  mutations  on  ligand 
binding in vitro, and a report outlining the increased mitogenic response of BaF3  cells 
expressing the S252W mutant receptor compared to the normal FGFR2 to some FGFs 
[160],  no  investigation  of  whether  these  effects  are  mirrored  in  vivo  has  been 
undertaken to date.
1.6.4 Altered ligand binding specificity as a result of the Apert 
syndrome mutations
In addition to the increased affinity for FGF ligand in general, the S252W and P253R 
mutations confer altered ligand specificity to the FGFR2 [160]. Using BaF3 cells, which 
do  not  endogenously  express  FGFRs  or  FGFs,  the  binding  of different  FGFs  to  the 
receptor  was  assessed  by  means  of a  mitogenic  assay.  The  presence  of the  S252W 
mutation  allowed  activation  of  the  FGFR2(IIIc)  by  FGF7  and  FGF 10,  which  are 
normally  high  affinity  ligands  for  FGFR2(IIIb)  and  do  not  activate  the  FGFR2(IIIc) 
isoform. Similarly, cells expressing the S252W FGFR2(IIIb) showed a robust mitogenic 
response upon stimulation with FGF2, 6 and 9, all of which did not elicit any response 
in cells expressing the wild type FGFR2(IIIb).
1.6.5 Structural basis for the increased affinity and altered 
specificity in the presence of the Apert syndrome mutations
The crystal structure of the FGFR2(IIIc) extracellular domain (residues  147-366) does
not  significantly  change  in  the  presence  of the  S252W  or  P253R  mutations  [163]. 
However, additional contacts between the mutant receptors and the  ligand are present 
(Figure  1.9).  In  case  of  the  S252W  mutant,  Trp252  stabilises  the  formation  of  a 
hydrophobic  patch  (involving  Trp252,  Tyr281  and  Ile257)  that  can  be  engaged  by 
Phe21  of FGF2 (refer to Figure  1.9).  Stabilisation of Tyr281  in a single conformation 
allows  formation of a new hydrogen bond  with FGF2  Pro22  and of oxygen-aromatic 
interactions with the backbone oxygen of Gly24 of FGF2. In the presence of the P253R 
mutation, the arginine residue introduced forms three additional hydrogen bonds with 
Leul07,  Glul08  and  A snlll  of FGF2  (Figure  1.9).  In  both  cases  such  additional 
contacts would be expected to result in increased affinity for the ligand. Although these 
findings  support  the  increased  binding  of some  FGFs  to  the  S252W  receptor,  they 
cannot really explain the increased affinity of the receptor for ligands such as FGF 10,
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which do not possess a hydrophobic residue in the position corresponding to Phe21   in 
FGF2.  Thus  other mechanisms  that  rely  on  flexibility  of the  system  that  cannot  be 
represented in a crystallographic model must be involved in order to accommodate the 
increased affinity of mutant receptors for such FGF ligands [163].
Figure  1.9:  Additional contacts  between  FGF2  and  the S252W (A)  and  P253R (B)  Apert  mutant 
receptors  Additional  contacts  are  made  with  FGF2  in the  case  of both  substitution  mutations,  which 
affect  the  affinity  of the  FGFR2  for  FGF  ligand.  The  S252W  and  P253R  receptors  are  presented  in 
different  orientations  as  indicated  (right  hand  panel).  Refer to  section  1.6.5  for  an  explanation  of the 
additional contacts made.  D2 and D3  of FGFR2  are shown in green and cyan respectively, the  D2-D3 
linker is shown in grey. FGF2 is shown in orange. Oxygen atoms are red, nitrogen atoms blue, and carbon 
atoms are coloured in the same shade as the molecule they belong to. Hydrogen bonds are represented by 
dotted lines. Extracted from [163].
One of the major limitations of assessing the differences in ligand binding by the mutant 
receptors using bacterially expressed proteins and crystallography is that regulation of 
ligand binding by posttranslational modifications such as glycosylation and the addition 
of heparan sulphate are not taken into consideration. The system also lacks flexibility, 
which might  be  important  in the  physiological  context,  which  indicates  the  need  to 
further investigate these effects on the cellular level. Thus the effects of the mutations 
observed  in  vitro  may  not  necessarily  hold  true  to  the  same  extent  in  vivo,  where 
additional factors may play a role in terms of mediating the receptonligand interaction.
A
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1.6.6 Models for the manifestation of Apert syndrome phenotypes
Based on early studies reporting increased affinity of the FGFR2(IIIc) mutant receptor
for ligand it was proposed that this could be sufficient to cause craniosynostosis. Since 
FGFR2(IIIc) and FGF  ligand are  only  expressed  in a restricted region of the  coronal 
suture this area would be the most obvious target for the mutation to take effect [161]. 
Since the concentration of FGF2  in this environment is normally low,  the increase  in 
affinity  for  this  ligand  would  be  expected  to  lead  to  increased  differentiation  of 
osteogenic cells as a result of enhanced signal transduction.
More  recently the  altered  ligand binding  specificity  has  been  implicated  as  the  main 
factor leading to  development of Apert syndrome  by  activating  FGFR2  in the  wrong 
context because of autocrine activation of FGFR2(IIIc) in the mesenchyme by FGF7 or 
FGF 10 [5, 81, 99]. Further evidence for this model was gained by the description of two 
de novo Alu-element insertions, which led to expression of the FGFR2(IIIb) splice form 
in the mesenchyme and also caused an Apert syndrome phenotype  [157].  The greater 
increase  in  ligand  affinity  of the  S252W  receptor  compared  to  the  P253R  mutant 
correlates well with the respective severity of the craniofacial abnormalities.
The  FGFR2(IIIb)  has  been  proposed  to  play  a  role  in  syndactyly,  because  the  Alu- 
element insertion that results in ectopic expression of FGFRIIIb instead of IIIc causes 
syndactyly  [157].  However,  syndactyly  is  more  severe  in  patients  with  the  P253R 
mutation, whereas the affinity increase for FGFs was greater in the case of the S252W 
mutation  [7]  This  may  indicate  that  the  FGFR2(IIIb)  is  not  solely  responsible  for 
leading to  the  development  of syndactyly  and that  other  factors  than  the  increase  in 
affinity  of the  receptors  for  ligand  may  play  a  role  in  causing  the  Apert  syndrome 
phenotypes observed.
1.6.7 Effects of Apert syndrome mutations on the cellular basis
1.6.7.1  Effects on osteoblast differentiation
Several  studies  have  reported  an  increase  in  osteoblast  apoptosis  when  the  S252W 
FGFR2  is expressed  [164,  165].  An increase  in premature  apoptosis  of differentiated 
osteoblasts and osteocytes with the S252W mutation was also observed in vivo  [166]. 
Mansukhani et al.  further described lower levels of alkaline phosphatase expression, a 
protein that is indicative of differentiation, as well as decreased mineralisation in cells 
expressing the  S252W receptor compared to the wild type  FGFR2  [164].  In contrast, 
other studies reported an increase in differentiation in cells expressing the Apert mutant 
FGFR2IIIc compared to control cells as well as a reduced apopotic rate in the presence
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of the S252W mutation [167,  168]. The conflicting results reported may be due to the 
different  sources  from  which  cells  were  derived.  The  effects  observed  on  osteoblast 
proliferation and/or differentiation are greatly dependent on the maturation stage of the 
cells [165]. Indeed, opposite effects of FGF on calvaria cell differentiation, apoptosis or 
proliferation  were  observed  in  mature  and  immature  osteoblasts.  Nonetheless,  this 
conflicting  evidence  makes  comparison  and  analysis  difficult  and  prevents  a  clear 
picture of the intracellular effects of Apert syndrome from being formed.
1.6.7.2 Effects on intracellular signalling
Despite the investigations trying to elucidate the cellular basis of Apert syndrome, few 
reports  describe  the  effects  of  the  mutations  on  the  actual  signalling  pathways 
downstream of the FGFR2. In cells expressing the S252W FGFR2, the genes encoding 
PKC, interleukin la and RhoA are upregulated and phosphorylation of PLCy and PKC 
is increased [169,  170]. Additionally, the levels of Src, Fyn and Lyn are downregulated 
by Cbl-mediated targeting for proteasomal degradation in cells expressing the  S252W 
[171].  Several reports have also indicated downregulation of the Apert mutant FGFR2 
in cells expressing the Apert mutant receptors  [166,  171,  172].  In addition,  increased 
levels of E-cadherin and N-cadherin have  been described  in  S252W-expressing  cells, 
which  are  important  in  cell  adhesion  and  may  play  a  role  in  intracellular  signalling 
[169].  The  S252W  FGFR2  did not lead to enhanced Erkl/2  activation in response to 
FGF1  stimulation in transfected osteoblasts [164]. However, when using different FGFs 
such  as  FGF9  mitogenesis  was  greatly  upregulated  in  cells  expressing  the  S252W 
FGFR2,  which  indicates  that  perhaps  the  Erkl/2  pathway  and  others  regulating 
mitogenesis are indeed upregulated in cells expressing the Apert mutant receptors [160]. 
The  lack  of studies  focusing on the  intracellular  signalling  downstream  of the  Apert 
mutant receptors is apparent. Although the Apert mutations have been classed as gain- 
of-function  mutations  [173],  no  studies  have  truly  investigated  the  effects  of  the 
mutations on early signalling events initiated by the FGFR2.  A detailed study into the 
effects  of both  the  S252W  and  the  P253R  on  intracellular  signalling  is  required  to 
understand  the  cellular  mechanisms  that  contribute  to  the  manifestation  of  Apert 
syndrome.
1.6.7.3 Effects of the Apert syndrome mutations in non-osteoblastic cells
In addition to affecting differentiation and apoptosis in osteoblasts, the Apert mutations
have been shown to result in positive selection in sperm cells [173]. The fact that mutant 
receptors portrayed this  gain-of-function effect in mature  spermatogonia prompted an
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investigation into whether they were involved in tumour formation [174]. However, out 
of 77 tumours investigated, none showed expression of the Apert mutant FGFR2. Thus 
the  gain-of-function  effect  is  not  necessarily  transferable to  all  kinds  of systems  and 
plays  specific  roles  in certain  cellular  contexts.  This  means that the  Apert  mutations 
confer very specific cellular effects, which only manifest themselves in cells in which 
FGFR2  signalling  plays  an  important  role.  More  detailed  studies  of  intracellular 
signalling  downstream  of  the  mutant  FGFR2  would  be  required  to  elucidate  how 
different cellular phenotypes arise.
1.7  The signalling adaptor protein She
1.7.1  She domain composition and structure
1. 7,1,1 She isoforms
Three different forms of the She adaptor are expressed in mammals: She A, ShcB (also 
known as Sck) and ShcC, of which ShcB and ShcC are predominantly expressed in the 
brain  ([175-177].  ShcA  (most  commonly  and  from  hereon  referred  to  as  She)  is 
ubiquitously  expressed  and  exists  as  three  isoforms,  namely  p66Shc,  p52Shc  and 
p46Shc, where the numerical values reflect their relative molecular weight.  These are 
encoded by two different transcripts generated from the same gene by use of alternative 
5’ exons [178]. The p52 and the p46 isoforms are produced from the same transcript by 
use of alternative start sites.
1.7.1.2 Domain composition
All  three  She  isoforms  contain  a  collagen  homology  domain  (CHI,  a  region  rich  in 
proline and glycine residues but with no resemblance to the collagen fold) flanked by an 
SH2 domain on the C-terminus and a PTB domain on the N-terminus. The p66 isoform 
contains an additional CH2 domain at the very N-terminus [175].
1.7.1.3 She structure
The  structure  of full-length  She  has  not  been  solved.  However,  the  structure  of the 
isolated SH2 domain has been determined [179, 180], and has been shown to essentially 
portray the same fold as other SH2 domains with some additional loops. The structure 
of the PTB domain has also been solved, which revealed a fold  similar to that of the 
pleckstrin homology (PH) domain but with the ability to bind phosphotyrosine  [181]. 
The PTB domain on its own is fairly unstructured, and only folds upon ligand binding
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[182].  Despite  its  name, the  CHI  domain does not form a collagen-like  fold,  but the 
exact structure of this domain is unknown.
1.7.2 Role of She in RTK signalling
She  was  one  of the  first  signalling  proteins  studied  in  detail  and  to  date  has  been 
implicated  in  a  large  number  of  cellular  functions  ranging  from  differentiation  to 
regulation of mitogenesis, cell adhesion and migration. When first discovered, She was 
reported to bind to and be phosphorylated by the EGFR [175]. Since this discovery, She 
has been implicated in signal transduction from an enormous variety of tyrosine kinase 
receptors,  including  the  insulin  receptor,  FGFR,  TrkA,  PDGFR,  hepatocyte  growth 
factor receptor and others [183].
She  binds to phosphotyrosine  motifs  on different tyrosine  kinase  receptors  following 
ligand activation via either its PTB or SH2 domain or a combination of both [184]. In 
addition, the similarity of the PTB domain fold to that of the PH domain allows it to 
interact with phosphatidylinositols in the plasma membrane and can be recruited to the 
sites of activated receptors in this way [185]. Once recruited to the vicinity of activated 
RTKs, She is phosphorylated on two major sites within the CHI  domain, tyrosine 317 
and the dual site consisting of tyrosines 239 and 240  [72]. Both form binding sites for 
Grb2, via which Sos can be recruited to  She and hence the respective activated RTK. 
This  leads  to  activation  of the  Ras/Raf/MEK/Erkl/2  pathway.  Despite  its  ability  to 
interact with various other proteins, the main role for She in RTK signalling seems to lie 
in  providing  additional  Grb2  binding  sites  and  the  assembly  of  larger  signalling 
complexes downstream of tyrosine kinase receptors to regulate Erkl/2 activation.
1.7.3 Role of individual She domains
1.7.3.1  The phosphotyrosine binding (PTB) domain
The  involvement  of the  She  PTB  domain  in  cell  signalling  was  first  described  by 
Blaikie  et  al.  [184].  It  has  since  been  shown  to  be  the  major  component  of  She 
mediating interaction with various growth factor receptors. The minimal motif required 
for She PTB domain interaction is the sequence NPXpY and the authors proposed that 
the motif “hydrophobic residue-(D/E)-N-X-X-pY-(W/F)” as found in the Trk and ErbB 
receptors allows the highest affinity interaction with the She PTB domain [186].
The  She  PTB  domain  has  been  shown  to  interact  with  the  EGFR  and  the  insulin 
receptor [50], HER2/neu and TrkA [184]. The NPXY motif around Y490 in the TrkA 
receptor functions as a binding site for both FRS2 and She [4], and competition between
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these two  proteins  exists  for binding  at  this  site.  In contrast,  the  FRS2  PTB  domain 
binding site on the FGFR1  does not need to be phosphorylated for FRS2 to bind and 
does not contain the NPXY motif required for interaction with the  She  PTB  domain. 
Thus a competition model for this site is unlikely.  Different modes of She  interaction 
with  various  receptors  may  regulate  specific  involvement  of this  adaptor  protein  in 
different pathways and complexes.
Since the fold of the PTB domain is similar to that of the PH domain it is able to bind to 
acidic  phospholipids  (such  as  phosphatidylinositols)  [181].  Phospholipid  and 
phosphotyrosine  binding  to  the  PTB  domain  are  independent  of each  other  and  both 
properties are required for She to be able to localise to the membrane and carry out its 
functions in RTK signalling [185]. The ability of She to be recruited to the membrane 
via  phospholipid  binding  could  also  explain  how  it  retains  the  ability  to  be 
phosphorylated and activate the Erkl/2 signalling pathway in cells that express only a 
truncated EGFR or an FGFR1  lacking all major autophosphorylation  sites  [103,  187, 
188]. Altogether the PTB domain is important for localisation of She to the membrane 
and binding to the receptor, which can then lead to its phosphorylation.
1.7.3.2  The Src homology 2 (SH2) domain
The  structure  of the  She  SH2  domain  bound to peptide  has  been  solved  [179,  180]. 
Although the overall fold was similar to that of other SH2 domains, analysis by nuclear 
magnetic  resonance  (NMR)  revealed  that  the  interaction  with  the  phosphotyrosine 
peptide was slightly different. The phosphotyrosine moiety bound the SH2 domain in a 
similar fashion to that observed for other SH2-peptide complexes. In contrast the pY+3 
residue of the peptide did not make significant contact with the protein [180].
The  SH2  domain has been shown to  interact with the EGFR,  albeit at  slightly  lower 
affinity  than  the  PTB  domain  [49].  Other  reports  have  also  implemented  the  SH2 
domain  as  an  important  factor  in  EGFR  signalling  [50,  72,  189].  Further,  the  SH2 
domain has been shown to bind the T-cell receptor ^-chain, which indicates that it plays 
a  role  in  She  recruitment  to  activated  cell  surface  receptors  in  addition  to  the  PTB 
domain [190, 191].
Although generally physiological binding partners for the She SH2 domain are not very 
well characterised, the SH2 domain has been shown to also mediate functions other than 
recruitment of She to tyrosine kinase receptors. For example, it can bind CEACAM (a 
120kDa phosphoprotein  involved  in regulating  mitogenic  activity  downstream  of the
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insulin receptor [192]), cadherin  and integrins  (which are involved in cell adhesion and 
cell-cell interactions [193-195]), the E3 ubiquitin ligase c-Cbl [196] and Gab2 [197].
1.7.3.3  The collagen homology 1 (CHI) domain
The  main role  of the  CHI  domain  is to  provide the two  phosphorylatable  motifs  for 
Grb2 binding,  Y317  and Y239/Y240.  For a long time the Y317  site was  deemed the 
only  and  most  important  site  of  Grb2  binding,  but  the  Y239/Y240  site  plays  an 
important role in mediating PC 12 cell differentiation in response to TrkA stimulation by 
NGF [72]. It was also shown that both tyrosine residues in the Y239/Y240 motif were 
necessary for functionality, although Y239 is the only residue that is part of a pYXNX 
consensus sequence for Grb2 binding [198].
Although the main role of the CHI domain is recruitment of the Grb2/Sos complex, and 
both the Y317 and the Y239/Y240 sites are important for this function, it has also been 
shown  that  the  individual  sites  carry  out  pleiotropic  and  nonredundant  roles  in  the 
regulation  of JNK  and  p38  MAPK  activation,  cell  death  and  c-myc  transcription  in 
response to T-cell receptor activation [199]. Further, a CHI-domain deletion mutant can 
suppress  ErbB2-induced  transformation  by  a  mechanism  separate  from  Erkl/2 
activation  [200].  In addition, analysis of the amino acid sequence of the CHI  domain 
reveals  the  presence  of potential  sites  for  SH3  domain  binding,  which  may  play  a 
previously unidentified role in She interaction with various binding partners.
1.8  Use of fluorescent proteins to study signal 
transduction
1.8.1 Ways to visualise proteins and signalling events intracellularly
1.8.1.1 Antibodies, protein tagging and  fluorescent proteins
To analyse the spatio-temporal changes that different signalling proteins undergo upon
stimulation  of  cells  with  a  given  growth  factor,  a  method  for  visualising  their 
localisation, and changes thereof, is essential. Methods such as membrane fractionation 
are  useful  to  analyse  protein  movement  between  different  cellular  or  membraneous 
compartments. However, more information can be gained from studies visualising such 
changes intracellularly.
Antibodies  against  specific  cellular  proteins  that  are  detected  using  a  secondary 
antibody tagged with an organic dye, a phycobiliprotein or quantum dots or are directly 
labelled  with  a  fluorophore  such  as  Cy3  or  Cy5  can  be  used  to  analyse  protein
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localisation  intracellularly  [201].  Some  of  the  problems  of  this  technique  are  the 
requirement of highly specific antibodies or the need to tag the target protein with an 
epitope  tag,  the  size  of  the  immuno-complex  that  might  interfere  with  protein 
recognition as well as its restricted use only in permeabilised cells. Enzymatic tags such 
as peroxidase, beta-galactosidase, luciferase or beta-lactamase can also be used to study 
the localisation of proteins intracellularly [202, 203].
The use of fluorescent protein (FP) tags such as the 27kDa green fluorescent protein has 
made  visualisation  of proteins  easier.  However,  their  use  has  disadvantages  such  as 
exogenous  expression  in  a  normal  background  system,  the  requirement  of 
overexpression  and  the  size  of FPs  that  may  interfere  with  protein  localisation  or 
function  [201, 203].  The use of fluorescent proteins allows the investigation of direct 
protein-protein  interactions  using  techniques  based  on  energy  transfer  between 
individual fluorophores (refer to section  1.8.4). This makes them a preferred choice to 
study spatial and temporal changes in recruitment of various adaptor proteins to RTKs 
and their multiprotein complexes despite the caveats described.
Systems  such  as  the  use  of a  tetracysteine-biarsenical  motif provide  alternatives  to 
fluorescent proteins. This 12 amino acid tag containing four cysteines is fused to target 
proteins and is able to bind biarsenical dyes such as the green ‘FlAsH’ and red ‘ReAsH’ 
with  picomolar  affinity  which  allows  intracellular  visualisation  [204].  However, 
exogenous  expression  is  still  required,  toxicity  to  endogenous  processes  cannot  be 
excluded, higher fluorescent background occur and the system does not allow the use of 
two different colours in the same cellular compartment (reviewed in [201]).
1.8.1.2  Conventional microscopy compared to confocal microscopic imaging
Imaging  of  protein  localisation  can  be  carried  out  using  conventional  microscopy
techniques  or  confocal  microscopic  imaging.  Although  conventional  microscopy  is 
straightforward to use it does have  some drawbacks.  For example,  due to the  uneven 
shape  of cells,  protein  localisation  in  membrane  invaginations  or  caveolae  may  be 
misinterpreted due to the lack of three-dimensional information [203].
The use of confocal microscopy allows an increase in resolution by a factor of up to  1.4 
[203]. Moreover, the great advantage of confocal microscopy lies in being able to view 
optical  sections through the  sample and therefore gaining more information about the 
three-dimensional  distribution of proteins.  Optical  sectioning also  avoids  out-of-focus 
signals from outside the focal plane.
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1.8.2  Fluorescent proteins
The green  fluorescent protein  (GFP,  Figure  1.1 OA)  was  first  cloned  from Aequorea 
victoria  in  1994  [205],  which  was  shortly  followed  by  its  use  to  measure  gene 
expression and to monitor protein trafficking intracellularly  [206, 207].  However, the 
early fluorescent proteins possessed some disadvantages such as reduced photostability, 
slow  folding  intracellularly  and  formation  of  multimers.  More  recently,  various 
modified  versions  of GFP  have  become  available  which  are  more  photostable,  fold 
easily  at  37°C,  are  mostly  monomeric  and  can  be  excited  at  different  wavelengths 
([208] and reviewed in [209]). Most importantly, through several mutations, a number 
of  fluorescent  proteins  were  created  that  display  very  different  excitation/emission 
spectra, such as yellow, orange and cyan varieties (Figure 1.10B). This allows the use of 
more than one FP to be employed in the same system without spectral overlap, which is 
important for studies using co-localisation or FRET (see below).
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Figure  1.10:  Structure of GFP and  emission  spectra  for commonly  used  fluorescent  proteins The
structure  of GFP  is  shown  in  form  of a  ribbon  diagram.  The  tripeptide  forming  the  fluorophore  is 
indicated (A).  Adapted  from  [210].  The  emission  spectra of four commonly  used  fluorescent proteins 
variants (cyan (CFP), yellow (YFP), enhanced green {EGFP), and monomeric red (mRFPl) fluorescent 
protein) are shown as indicated. (B) Adapted from [211].
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1.8.3 Different techniques using fluorescent proteins
1.8.3.1 Single protein labelling
The  discovery  of fluorescent  proteins  created  an  entirely  new  avenue  for  studying 
intracellular  signalling  and protein trafficking  in  response  to  various  stimuli.  On  the 
simplest level, a single protein can be tagged with a FP and its cellular localisation can 
be assessed microscopically. This approach has been used to study the trafficking and 
functions of proteins such as the EGFR and TrkA  and has revealed new insight into the 
dynamics of these receptors upon ligand stimulation [13, 212].
1.8.3.2 Protein co-localisation
Although  the  use  of  single  FP-tagged  molecules  is  useful  to  obtain  data  on  the 
intracellular  dynamics  of proteins,  more  information  can  be  gained  from  the  use  of 
different FPs fused to two proteins that are,  for example,  part of the  same  signalling 
cascade (reviewed in [213]). Co-localisation alone cannot indicate direct protein-protein 
interactions and  simply portrays whether or not two proteins are  in the  same cellular 
location. However, combined with conventional biochemical techniques, co-localisation 
studies can be a powerful tool to investigate the spatial and temporal changes in protein- 
protein interactions and recruitment to cell surface receptors.
1.8.4 Techniques using energy transfer between two fluorophores
1.8.4.1  Forster resonance energy transfer (FRET)
For an accurate  assessment of whether or not proteins  interact directly  intracellularly 
Forster resonance energy transfer (FRET) measurements can be used. FRET refers to a 
nonradiative, dipole-dipole coupling process that involves the energy transfer from an 
excited donor fluorophore to  a nearby  acceptor fluorophore  [214,  215].  FRET occurs 
when  sufficient  spectral  overlap  (30%  or  more)  is  present  between  the  emission 
spectrum  of a  fluorescent  donor  and  the  absorption  spectrum  of an  acceptor.  FRET 
efficiency  varies  with  the  inverse-sixth  power  of the  distance  between  acceptor  and 
donor.  The  Forster  radius  describes  the  distance  at  which  the  efficiency  of energy 
transfer between donor and acceptor is 50%, which typically lies between 1-1 Onm [211, 
216]. Thus FRET only occurs if the two fluorescent proteins are within this distance of 
each  other.  If the  donor  is  excited,  this  leads  to  emission  at  a particular  wavelength 
within the excitation range of the acceptor. Thus if fluorescent donor and acceptor are in 
close  enough  proximity  and  in  favourable  orientation  to  each  other,  the  transfer  of 
energy leads to emission from the acceptor which would not be observed in the absence
57of FRET. By detecting emission at the wavelength of the acceptor emission spectrum 
FRET can be measured.
Since  FRET  only  occurs  over  a very  short  distance,  it  is  an  accurate  technique  for 
measuring  direct  protein-protein  interactions  in  vivo  and  effectively  allows  these 
interactions  to  be  assessed  at  nanometer  resolution.  FRET  depends  on  favourable 
orientation of the donor and acceptor molecules (i.e. on the way in which the respective 
attached  protein  interact)  as  well  as  on  the  stoichiometry  of  donor  and  acceptor 
molecules.  Nonetheless,  it  is  far  superior  over  simple  co-localisation  techniques. 
Whereas  co-localisation  studies  are  only  able  to  indicate  whether  two  proteins  are 
located  in the  same  cellular region  or compartment,  FRET allows the  assessment  of 
complex assembly and disassembly with time inside the cell.
CFP  and  YFP  are a widely  used pair of fluorescent proteins for FRET  experiments, 
although various problems are associated with their use  [217-219].  The problem with 
using a GFP-RFP FRET pair is the oligomerisation of red fluorescent proteins such as 
DsRed,  which  might  affect  the  cellular  localisation  and  behaviour  of  the  tagged 
proteins. With the creation of mRFPl, a monomeric version of DsRed  [220], the use of 
the  GFP-RFP  pair  for FRET became  more  feasible.  These  two  FPs  have  significant 
spectral overlap and can be used for FRET analysis (Figure 1.11) [211].
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Figure 1.11: Overlap of the GFP emission and mRFP excitation spectra The respective emission and 
absorption spectra of EGFP and mRFPl  from protein extract solutions were  measured and represented 
graphically. Adapted from [211].Chapter 1
1.8.4.2  Fluorescence lifetime imaging microscopy (FLIM)
Fluorescence  lifetime  imaging  (FLIM)  makes  use  of  FRET  between  individual
fluorophores. Other than FRET, where emission from the acceptor is measured, FLIM 
relies on the changes that occur in the lifetime of the donor fluorophore as a result of an
defined as the average time spent in the excited state after light absorption. The typical
lifetime  is  a  parameter  intrinsic  to  the  fluorophore  and  is  independent  of relative 
fluorophore  concentration  or  light  path  length.  It  is  however,  highly  sensitive  to 
processes taking place at the excited state such as FRET, which results in a decrease in 
donor lifetime (Figure 1.12) [221, 222]. By measuring the differences in donor lifetime 
in the absence or presence of an acceptor fluorophore, direct interaction between two 
fluorescently tagged proteins can be assessed.
Some of the advantages of using FLIM over FRET is that the concentration of acceptor 
does not need to be controlled (as long as it is in excess) and that it is insensitive to 
spectral  bleed-through  and  fast  photobleaching  (a  property  of  RFP  that  makes 
conventional FRET difficult). In addition, FLIM provides an internally calibrated FRET 
measurement (and thereby an  internal  control),  and the differences  in lifetime  in the 
presence or absence of an acceptor can be used to measure FRET efficiency.
Figure  1.12:  Diagrammatic  representation  of  the  decrease  in  donor  fluorophore  lifetime  in  the 
presence of FRET FLIM measures the average time a fluorophore remains in the  excited stated upon
of a FRET acceptor (RFP) it emits light of a certain wavelength; its lifetime is represented by t (A). When 
an acceptor fluorophore is brought into vicinity due to protein-protein interaction of the GFP- and RFP- 
tagged proteins, FRET takes place, which leads to emission from the acceptor and shortened lifetime of 
the donor fluorophore as indicated (B). Adapted from [223].
acceptor being in its vicinity when excited. The fluorescence lifetime of a molecule is
fluorescence lifetime ranges between picoseconds and nanoseconds [221]. Fluorescence
A im
absorption of a photon of excitation light. Upon excitation of the donor fluorophore (GFP) in the absence
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1.9 Objectives
One  of  the  questions  regarding  signalling  from  receptor  tyrosine  kinases  that  still 
remains largely unanswered is how different receptors are able to maintain the integrity 
of specific  signals  that  induce  varied  and  defined  cellular responses.  Particularly  the 
way in which specific recruitment of signalling proteins to a given receptor is achieved 
and the precise role that formation of unique multiprotein complexes plays in regulating 
activation of a defined set of downstream signalling pathways remain to be elucidated. 
The work presented herein aims to address these questions by using two different model 
systems.
1.9.1 The importance of precise protein recruitment to different 
tyrosine kinase receptors to generate specific cellular responses
Although  numerous  studies  have  focused  on  the  differences  in  signals  induced  by
various  growth factors  in PC 12  cells,  comparisons  of the  early  signalling  complexes 
induced by the EGFR, FGFR and TrkA are limited. Therefore PC 12 cells were chosen 
as  a  model  system  to  investigate  the  role  of the  assembly  of different  multiprotein 
complexes  downstream  of RTKs  in  regulation of specific  cellular  responses  (namely 
differentiation or proliferation). It was chosen to focus on the recruitment of FRS2, Sos, 
Grb2  and  She  to  the  receptors,  since  all  four  proteins  play  a  role  in  signalling 
downstream of TrkA, EGFR and FGFR.  The recruitment of the Grb2/Sos complex to 
the receptor via She and/or FRS2 is an important regulator of the Ras/Raf/MEK/Erkl/2 
pathway, which in turn is a major determinant of PC 12 cell fate in response to growth 
factor stimulation. This means that the differential recruitment of these four signalling 
proteins and their involvement in defined protein complexes may be an important factor 
in determining signalling specificity.
1.9.2 Apert syndrome mutations as a model system to investigate 
the effects of altered ligand binding affinities on intracellular 
signalling
The  Apert  mutations  in  the  FGFR2  result  in  an  increased  affinity  for  various  FGF 
ligands. However, there is a lack of knowledge regarding the effects of these mutations 
on intracellular signalling events, particularly the early signalling events proximal to the 
activated  receptor.  These  aspects  make  the  Apert  mutant  receptors  an  ideal  model 
system to investigate the effects of extracellular mutations on the recruitment of adaptor 
proteins into multiprotein complexes. The fact that the mutations primarily affect ligand 
binding, but are removed from the regions of the receptor that are involved in protein 
recruitment  and  activation  of  downstream  signalling  pathways,  makes  this  system
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particularly  interesting.  It  allows  investigation  of the  importance  of ligand-receptor 
interaction in creation of specific downstream responses and additional effects of these 
mutations  in  the  extracellular  region  on  signalling  downstream  of  the  FGFR2. 
Mutations that alter the assembly of signalling complexes would be expected to change 
the ultimate signals generated.  In the case of the Apert mutant receptors, the changes 
that occur on the outside of the cell are expected to alter the signalling events that are 
induced  intracellularly  upon  ligand  binding.  The  investigation  will  focus  on  whether 
these mutations  simply  cause  increased  signalling via the  same  pathways  or whether 
they alter the way in which proteins are recruited to the receptor and the signals that are 
emanated as a result. This will further the understanding of the factors that are required 
in a receptor system to maintain highly regulated protein recruitment as well as integrity 
and  specificity  of  the  signals  induced.  Additionally,  this  investigation  will  allow 
analysis  of the  effects  that  disturbance  of the  receptor  signalling  system  has  on  the 
specificity  of  downstream  signalling  events  as  well  as  cellular  responses  to  FGF 
stimulation.
1.9.3 Investigation of the regulation of She recruitment to the FGFR2
In addition to addressing questions regarding the recruitment of multiple proteins into 
different  protein  complexes  downstream  of various  receptors  and  the  disturbance  of 
protein recruitment and signalling specificity by mutations, it was chosen to specifically 
analyse the way that recruitment of a single protein to a receptor is mediated. To date, 
She has been implemented with a role  in FGFR signalling,  but its interaction with or 
recruitment to the FGFR has not been elucidated. It was therefore chosen to analyse the 
importance of the different She domains for its recruitment to the activated FGFR2. In 
addition  to  determining  the  mode  of  She  recruitment  to  a  specific  receptor,  this 
approach also allowed further insight into how intrinsic differences in terms of protein 
recruitment to different receptors might be mediated by providing direct binding sites 
for different proteins on a receptor.
1.9.4 Experimental approach
Changes  in protein-protein  interactions  upon  stimulation of a receptor are  commonly 
assessed by immunoprecipitation and pulldown techniques. However, these approaches 
are limited to examination of the temporal changes, such as recruitment of proteins into 
a  multiprotein  complex,  and  cannot  provide  information  about  changes  in  protein 
localisation.  Spatial  changes  in  protein  localisation  intracellularly  following  receptor 
activation  may  be  an  important  regulator  of signalling  specificity.  It  was  therefore
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chosen to use fluorescently tagged proteins to analyse the spatial as well as the temporal 
changes that occur in response to activation of various receptors. Co-localisation studies 
are  useful  to  assess  changes  in  localisation  of  two  proteins  to  the  same  cellular 
compartment  such  as  the  plasma  membrane.  However,  the  resolution  achieved  by 
confocal  microscopy  is  not  high  enough  to  assess  changes  in  protein-protein 
interactions. Fluorescence lifetime imaging microscopy (FLIM) was therefore chosen to 
analyse changes in direct protein-protein interactions in addition to changes that occur 
in terms of their (co-)localisation. It was the technique of choice because the GFP-RFP 
pair was used and the rapid photobleaching of RFP makes measurements by traditional 
FRET  methods  difficult.  Since  FLIM  does  not  rely  on  acceptor  (RFP)  emission,  it 
allows  accurate  and  detailed  analysis  of  changes  in  protein  interaction  following 
recruitment to activated RTKs that may play an important role in regulating activation 
of  specific  and  diverse  signals.  Analysis  of  changes  in  protein  localisation  and 
interaction  intracellularly  can be  complemented  with  traditional  western blotting  and 
immunoprecipitation  techniques  to  generate  an  overall  picture  of the  importance  of 
regulated protein recruitment to RTKs in the generation of signalling specificity.
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Materials and Methods
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2.1 Materials
2.1.1 Chemicals
All chemical reagents used throughout were purchased from Sigma, Melford or VWR 
unless otherwise stated.
2.1.2  Restriction and modification enzymes and polymerases
Calf intestinal phosphatase (CIP) NEB
Dpnl Stratagene
Pfu Turbo DNA polymerase Stratagene
Restriction endonucleases NEB
RNAse Invitrogen
T4 DNA ligase NEB
Vent® DNA polymerase NEB
2.1.3  Growth factors and ligands
Bovine pancreatic insulin Sigma
Heparan sulphate salt Sigma
Murine natural nerve growth factor 7S Sigma
Recombinant human epidermal growth factor Peprotech
Recombinant human fibroblast growth factor 2 Peprotech
Recombinant human fibroblast growth factor 9 R&D Systems
2.1.4  Kits and other materials
Enhanced chemiluminescence substrate (ECL) Pierce Perbio
Glutathione resin Novagen
Immobilon-P PVDF membrane 0.45pm Millipore
Lipofectamine 2000 transfection reagent Invitrogen
Protease inhibitor cocktail set III Calbiochem
Protease inhibitor cocktail tablets (complete) Roche
Protein A agarose Sigma
Protein G agarose Sigma
QIAprep spin miniprep kit Qiagen
QIAquick gel extraction kit Qiagen
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Tissue culture flasks, dishes and multiwell plates Helena Biosciences
Tissue culture flasks, dishes and multiwell plates Sarstedt
Whatman filter paper 3MM Fisher Scientific
XB-200 blue X-ray film X-ograph
2.1.5  Bacterial and cell culture media and buffers
All  growth media and buffers were prepared with distilled water from an  Elga water 
purifier and autoclaved where appropriate.
2.1.5A Bacterial culture
Luria bertani (LB) broth
1.0% (w/v) tryptone
0.5% (w/v) yeast extract 
0.5% (w/v) sodium chloride
The  medium  was  autoclaved  and  appropriate  antibiotics  were  added  to  a  final 
concentration of 250pg/ml carbenicillin, 50pg/ml kanamycin, 50pg/ml tetracyclin (stock 
in 100% ethanol) or 50pg/ml chloramphenicol (stock in 100% ethanol).
NZY+ broth
For  transformation  of  the  products  of  the  mutagenised  nicked  circle  plasmids 
(Stratagene Quikchange mutagenesis kit) a richer medium than LB broth is required.
1.0% (w/v) NZ amine (casein hydrolysate)
0.5% (w/v) yeast extract 
0.5% (w/v) sodium chloride 
pH 7.5
After  autoclaving,  the  following  filter  sterilised  supplements  were  added  per  litre  of 
broth:
12.5ml of 1M magnesium chloride 
12.5ml of 1M magnesium sulphate 
20ml of 20% (w/v) glucose
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2.1.5.2 Agar plates
Agar  plates  were  created  by  the  addition  of  1.5%  (w/v)  agar  to  LB  broth  before 
autoclaving. Plates containing various antibiotics were prepared as described for the LB 
medium after the agar was cooled to 50°C.
2.7.5.3 Glycerol stocks
Glycerol stocks of all strains were created by addition of 300pl 50% glycerol in ddLLO 
to 700pl of an overnight bacterial culture. The samples were frozen, stored at -80°C and 
used to streak cultures on agar plates when required.
2.1.6  Mammalian cell culture
All  tissue  culture  media  and  supplements  were  purchased  from  Cambrex,  Gibco  or 
Invitrogen. Foetal calf serum (FCS) was supplied by Biosera and horse serum (HS) and 
plasma-derived (platelet poor) horse serum were obtained from Sigma.
HEK 293T complete growth medium
Dulbecco’s  modified  Eagle’s  Medium  (DMEM)  with  4.5g/L  glucose,  4mM  L- 
glutamine,  10%  FCS,  1%  antibiotic/antimycotic  solution  (10,000units/ml  penicillin, 
10,000pg/ml streptomycin, 25pg/ml amphotericin B) and 50pg/ml gentamycin sulphate
PC 12 complete growth medium
Dulbecco’s  modified  Eagle’s  Medium  (DMEM)  with  4.5g/L  glucose,  4mM  L- 
glutamine,  10%  HS,  5%  FCS,  1%  antibiotic/antimycotic  solution  and  50pg/ml 
gentamycin sulphate
Starvation medium
Complete growth medium without FCS  for HEK 293T, or containing 0.1% HS  in the 
case of PC 12 cells
Dulbecco’s PBS
lx PBS without calcium or magnesium, pH 7.3-7.7 
Poly-D-lysine solution
0.01% poly-D-lysine hydrobromide (MW 70,000-150,000) in ddH20
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Freezing medium
20% dimethylsulphoxide DMSO
80% FCS or HS
The freezing medium was diluted  1:1  with regular growth medium containing the cells 
to  be  frozen.  Cells  were  frozen  in  cryotubes  using  a  special  cryo  tub  at  -80°C  and 
subsequently placed in liquid nitrogen for long-term storage.
2.1.7  Stock solutions and buffers
All buffers and solutions were prepared with distilled water from an Elga water purifier 
and autoclaved where appropriate.
Coomassie stain solution
0.2% (w/v) Coomassie Brilliant Blue R
40% (v/v) methanol 
10% (v/v) acetic acid
Coomassie destain solution
10% (v/v) acetic acid
40% (v/v) methanol
6x DNA loading dye
60% glycerol
0.05% bromophenol blue 
2x HBS
42mM Hepes pH 7.05 
274mM NaCl 
lOmM KC1 
1.5mM Na2HP04 
2% (w/v) glucose
2x/6x Laemmli loading buffer
lOOmM / 300mM Trizma hydrochloride pH 6.8
4% /12% (w/v) SDS 
20% / 60% (v/v) glycerol 
0.6% bromophenol blue
lOmM / 30mM DTT (added immediately before use)
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Lysis buffer (bacterial)
lxTBS pH 8.0
0.1% Triton-XlOO
Before  use  0.1 mg  lysozyme  and  one  protease  inhibitor  cocktail  tablet  (Roche)  were 
added per 10 ml lysis buffer.
Lysis buffer (mammalian)
20mM TrisHCl pH 7.5
138mM NaCl 
ImM EGTA
20mM p-glycerophosphate 
10% (w/v) glycerol 
ImM sodium ortho  vanadate 
20mM sodium fluoride
1% (v/v) protease inhibitor cocktail III (Calbiochem) was added directly before use.
Midiprep buffer PI
25mM Trizma hydrochloride pH 7.5
lOmM EDTA 
50mM glucose
Midiprep buffer P2
200mM NaOH
1% SDS
Midiprep buffer P3
3M potassium acetate pH 4.8
lOx mounting solution (anti-fade agent)
1% (w/v) 1,4-phenylenediamine pH 9.5
lx mounting solution (anti-fade agent)
lml lOx stock solution
9ml 50% glycerol in PBS 
pH 7.5-8.0
Paraformaldehyde
10% (w/v) paraformaldehyde, pH 8.0 stock solution
4% (v/v) paraformaldehyde (10% stock diluted in PBS pH 8.0 for cell fixation)
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lx PBS
lOmM phosphate 
2.7mM KC1 
137mM NaCl 
pH 7.4
Rapid screening buffer
5mM EDTA
10% w/v sucrose 
0.25% w/v SDS 
lOOmMNaOH 
60mM KCL
0.05% Bromophenol blue
SDS-PAGE stacking gel buffer
0.5M Trizma hydrochloride pH 6.8
SDS-PAGE resolving gel buffer
3M Trizma hydrochloride pH 8.8
lOx SDS-PAGE running buffer
1.9M glycine
250mM Trizma base
10% (w/v) sodium lauryl sulphate (SDS)
0.5x TBE
45mM Trizma borate 
ImM EDTA 
pH 8.3
lOx TBS (Tris buffered saline)
500mM Trizma hydrochloride
1.5M sodium chloride 
pH 7.4
lx TBS-T
100ml lOx stock solution
ImM EDTA
0.01% (v/v) Tween-20
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lOx Transfer buffer
1.9M glycine
250mM Trizma base
lx Transfer buffer (per litre)
200ml methanol
100ml lOx stock solution 
900ml water
Western blot stripping buffer
62.5  mM Trizma hydrochloride pH 6.7
2% (w/v) SDS (200ml 10% (w/v) stock per litre after autoclaving) 
0.7% (v/v) p-mercaptoethanol (added immediately before use)
2.1.8  Bacterial strains
Bacterial strain Genotype Use
XL1 Blue recAl endAl gyrA96 thi-1 hsdR17 supE44 
relAl lac [F’ proAB lacPZAMl5 Tn 10 
(Tetr ;]
Plasmid vector 
propagation, cloning
BL21 (DE3) E.coli B F' dcm ompT hsdSix^'mB) gal Expression of 
recombinant protein
DH5a F'phi80d/acZ delta(/a  cZ YA-a  rgF)U 169 
deoKrecAl endAl hsdRll (rk-, m k+) 
phoA supE44 lambda-//?/-1  gyrA96 
elAl/E' pro  AB+ ZacIqZdeltaM 15 
TnlO(tetr)
Plasmid vector 
propagation, cloning, 
expression of 
recombinant protein
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2.1.9  Cell lines
Name Origin Stably transfected with Reference
HEK 293T Human embryonic kidney 
fibroblasts transformed 
with adenovirus and SV40 
T-antigen
ATCC:
293tsA1609neo
HEK 293T 
WT-FGFR2
Human embryonic kidney 
fibroblasts
WT-FGFR2-GFP 
monoclonal cell line
[224]
HEK 293T 
SW-FGFR2
Human embryonic kidney 
fibroblasts
S252W-FGFR2-GFP 
monoclonal cell line
[224]
HEK 293T 
PR-FGFR2
Human embryonic kidney 
fibroblasts
P253R-FGFR2-GFP 
monoclonal cell line
[224]
PC12 Rat adrenal 
phaeochromocytoma
EC  ACC: 
88022401
PC12
WT-FGFR2
Rat adrenal 
phaeochromocytoma
WT-FGFR2-GFP 
monoclonal cell line
this work
PC12
SW-FGFR2
Rat adrenal 
phaeochromocytoma
S252W-FGFR2-GFP 
monoclonal cell line
this work
PC12
PR-FGFR2
Rat adrenal 
phaeochromocytoma
P253R-FGFR2-GFP 
monoclonal cell line
this work
PC12
Grb2-GFP
Rat adrenal 
phaeochromocytoma
Grb2-GFP 
monoclonal cell line
this work
2.1.10  Antibodies
Antibody (antigen/immunogen) Host species Source
phospho-Akt (synthetic phospho-peptide 
corresponding to residues surrounding Ser473 of 
mouse Akt)
Mouse Cell Signaling 
Technology
Bek (epitope at the C-terminus of human FGFR2) Mouse Santa Cruz
Grb2 (amino acids 1-217 of rat Grb2) Mouse BD Transduction 
Laboratories
Grb2 (epitope at C-terminus of human Grb2) Rabbit Santa Cruz
Erkl/2 (synthetic peptide derived from rat p42 
MAPK)
Rabbit Cell Signaling 
Technology
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phospho-Erkl/2 (synthetic phospho-peptide 
corresponding to region surrounding 
Thr202/Tyr204 of human p44 MAPK)
Mouse Cell Signaling 
Technology
FRS2 (Peptide corresponding to residues 283-297 
of human FRS2/SNT1)
Mouse Upstate
GFP (recombinant Aequorea victoria GFP) Goat Rockland
GFP-HRP (amino acids 1-238 of Aequorea 
victoria GFP)
Mouse Santa Cruz
PDGFRP (extracellular domain of PDGRP) Mouse Sigma
pY99 (phosphotyrosine) Mouse Santa Cruz
RFP (RFP fusion protein) Rabbit Chemicon
International
She (residues 359-473 of human She) Mouse BD Transduction 
Laboratories
She (recombinant GST fusion corresponding to 
amino acids 366-473 of human She)
Rabbit Upstate
She pY317 (peptide FDDPSpYVN-C 
corresponding to amino acids 312-319 of human 
p52 She)
Rabbit Upstate
She pY239/pY240 (synthetic phosphopeptide 
correseponding to residues surrounding 
Y239/Y240)
Rabbit Cell Signaling 
Technology
Sosl (C-terminus of human Sosl, amino acids 
1057-1178)
Rabbit Santa Cruz
Anti-mouse secondary Ab, HRP conjugated Goat Sigma
Anti-rabbit secondary Ab, HRP conjugated Goat Sigma
Anti-goat secondary Ab, HRP conjugated Guinea pig Sigma
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2.1.11  Plasmids and oligonucleotides
2.1,11.1 Original plasmids
Plasmid Characteristics Source
pcDNA 3.1 Hygro (+) Mammalian expression vector, Ampr, 
Hygr, CMV promoter, SV40 poly A
Invitrogen
pcDNA 3.1 (+) Mammalian expression vector, Ampr, 
Neor, CMV promoter, SV40 poly A
Invitrogen
pEGFP(Nl/N2) Mammalian expression vector allowing 
C-terminal GFP-fusion, Kanr, Neor, 
CMV promoter, SV40 poly A
Clontech
pGEX4T-2 Bacterial expression vector allowing N- 
terminal GST fusion, Ampr
Amersham
Biosciences
pGEX2T Bacterial expression vector allowing N- 
terminal GST fusion, Ampr
Amersham
Biosciences
2.1.11.2 Modified Plasmids
Plasmid Insert Reference/Source
RFPN mREP between Nhel and Hindlll sites 
of pcDNA 3.1 (+)
Ng, T., King’s 
College London
RFPC mRFP between Notl and Xhol sites of 
pcDNA 3.1 (+)
Ng, T., King’s 
College London
WT-FGFR2-GFP Full-length wild type FGFR2 in frame 
with GFP in pEGFP(N2)
[224]
S252W-FGFR2-GFP Full-length S252W mutant FGFR2 in 
frame with GFP in pEGFP(N2)
[224]
P253R-FGFR2-GFP Full-length P253R mutant FGFR2 in 
frame with GFP in pEGFP(N2)
[224]
pc3.1 HygShc-RFPC Human She amino acid 17-472 in 
Hindlll site in frame with C-terminal 
mRFP
This work
pc3.1HygShc-RFPC-3F Human She amino acids 17-472 
containing Y239F, Y240F and Y317F 
mutations in Hindlll site in frame with 
mRFP
This work
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pc3.1 HygShc APTB- 
RFPC
Human She amino acids 208-472 in 
Hindlll site in frame with mRFP
This work
pc3.1 HygShcR401A- 
RFPC
Human She amino acids 17-472 
containing R401A mutation in frame 
with mRFP
This work
PTB(Shc)-RFPC Human She amino acids 17-207 
between EcoRI and EcoRV sites in 
frame with mRFP
This work
SH2(Shc)-RFPN Human She amino acids 369-472 
between  BamHI and EcoRI sites in 
frame with mRFP
This work
pGEX2T-Shc Human She amino acids 17-472 in 
frame with GST-tag
This work
pGEX2T-SH2(Shc) Human She amino acids 369-472 in 
frame with GST-tag
This work
pGEX4T-2-PTB(Shc) Human She amino acids 17-207 in 
frame with GST-tag
This work
Grb2-GFP(N2) Human full-length Grb2 amino acids 
1-217
This work
pGEX2T-Grb2 Human full-length Grb2 amino acids 
1-217
This work
2.1.11.3  Oligonucleotides
All oligonucleotides read 5’ to 3’.
Mutagenesis
CCA CCT GAC CAT CAG TTC TTT AAT GAC TTC CCG GGG 
Forward primer for mutagenesis of  She Y239 and Y240 to phenylalanine 
CCC CGG GAA GTC ATT AAA GAA CTG ATG GTC AGG TGG 
Reverse primer for mutagenesis of  She Y239 and Y240 to phenylalanine
GCT TTT TGA TGA TCC CTC CTT TGT CAA CGT CCA GAA CC 
Forward primer for mutagenesis of  She Y317 to phenylalanine 
GGT TCT GGC CGT TGA CAA AGG AGG GAT CAT CAA AAA GC 
Reverse primer for mutagenesis of  She Y317 to phenylalanine
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GGA CTT CCT GGT AGC GGA GAG CAC G 
Forward primer for mutagenesis of  She R401 to alanine 
GGT GCT CTC CGC TAC CAG GAA GTC C 
Reverse primer  for mutagenesis of  She R401 to alanine
Gene amplification
GCG GGC TAT CCC TAT AAG CTT CCG GAC TAT GCA GG 
Insertion of  Hindlll site N-terminal to She start codon 
CTC TAG AGT CGC GGC GGT ACC GAT CAG TTT CCG 
Insertion of  Kpnl site at She C-terminus
GCG CTT CAA ACA AAG CTT ATG GAA CCC 
Insertion of  Hindlll site at position 206 offull-length She 
CTC GGT ACC AAG CTT GAT ATC GAA TTC 
Reverse primer for amplification of  ShcAPTB
CGC TGC TCGAATTCA TAT GGG CCA GCT TGG G 
Amplification of  She PTB domain and insertion ofEcoRI site 
GGG GTC ACC AGT TTG ATA TCG TTC CTG AGG 
Amplification of  She PTB domain and insertion of  EcoRV site
GCT CCG TCG ACG AAG CTT GCG GCC GC
Forward primer to introduce reading  frame shift in Grb2 for creation of GFP-fusion 
GCG GCC GCA AGC TTC GTC GAC GGA GC
Reverse primer to introduce reading  frame shift in Grb2 for creation of GFP-fusion 
Sequencing
TAG AAG GCA CAG TCG AGG 
BGH reverse primer (pCR 3.1)
TAA TAC GAC TCA CTA TAG GG 
T7 promotor forward primer
GCC CTC GCC CTC GCC
GFP/RFP reverse primer for sequencing  junction of C-terminally tagged  fusions
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2.2 Molecular biological techniques
2.2.1  DNA preparation, analysis and manipulation
2,2, LI Preparation of DNA for manipulation
Small amounts of plasmid DNA for molecular biological manipulation were prepared 
using  the  QIAprep  spin  miniprep  kit  (Qiagen)  according  to  the  manufacturer’s 
instructions.  Approximately  10-20pg  of plasmid  DNA  were  recovered  from  a  5ml 
overnight culture in the XL1 Blue bacterial strain.
2.2.1.2 Preparation of  DNA for transfection into mammalian cells
For high efficiency transfections of DNA into mammalian cells, large amounts of highly
concentrated  DNA  were  required.  100ml  LB  with  the  appropriate  antibiotic  were 
inoculated with  1ml of an overnight starter culture of XL1  Blue containing the target 
plasmid and grown overnight at 37°C in a shaking incubator. The bacterial cells were 
pelleted by centrifugation at 4000rpm for ten minutes and resuspended in 5ml buffer PI. 
5ml  of lysis  buffer  P2  were  added.  Precipitation  of insoluble  cell  components  was 
achieved by addition of 5ml neutralisation buffer P3.
The insoluble material was removed by centrifugation of the sample at 4000 rpm for 20 
minutes, followed by transfer of the supernatant into a fresh tube. An equal volume of 
phenolchloroform isoamide alcohol was added and mixed by vortexing. The two layers 
were  separated by  centrifugation  at  4000rpm  for  five  minutes  and  the  top  layer  was 
transferred to a fresh tube. Two volumes of cold  100% ethanol (30 ml) were added to 
precipitate the DNA which was subsequently pelleted by centrifugation at 4000 rpm for 
30 minutes. The pellet was washed with 15ml cold 70% ethanol and the DNA was dried 
at room temperature.
To remove all RNA, the DNA was resuspended in 500pl TE with  lOpg/ml RNAse and 
incubated at 37°C for one hour.  Subsequently,  125pl 4M NaCl and  1ml of 13% PEG- 
800 were added.  The DNA was left to precipitate on ice for two hours,  subsequently 
pelleted by centrifugation at  13000rpm for 20 minutes and washed once with  1ml ice- 
cold 70% ethanol and once with  1ml  100% ethanol. The DNA was left to dry at room 
temperature and was resuspended in 200-400pl double distilled water.
2.2.1.3 Determination of  DNA concentration
Double  stranded  DNA  absorbs  light  at  a  wavelength  of  260nm.  To  measure  the 
concentration  of  PEG-precipitated  DNA,  the  absorbance  of  a  1:100  dilution  was
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measured  at  260nm  using  a  Quartz  cuvette.  An  OD26o=l  is  equivalent  to  a  DNA 
concentration of 50pg/ml.
For less concentrated samples such as Miniprep DNA or smaller volumes such as gel 
purified  digested  DNA,  the  DNA  concentration  was  measured  using  lpl  of sample 
directly in a Nanodrop spectrophotometer.
2.2.1.4 Restriction digests
Restriction  digests  were  set  up  according  to  the  following  standard  dilutions  and 
incubated  in  a  waterbath  at  the  appropriate  temperature  for  two  hours.  The 
manufacturer’s  buffer  and  temperature  recommendations  for  double  digests  were 
followed.
14pl DNA (plasmid DNA or PCR product)
2 pi recommended buffer 
2 pi lOx bovine serum albumin
lpl (10,000-20,OOOU/ml) of each respective enzyme used
2.2.1.5 Dephosphorylation of  DNA 5’ ends
To  prevent  re-ligation of the  vector when  cut  with  only  one  restriction  enzyme,  lpl 
(10,OOOU/ml)  of calf intestinal phosphatase  (CIP)  was  added to  the  restriction  digest 
containing  the  backbone  vector  for  the  cloning  reaction  for  one  hour  at  37°C.  The 
removal of 5’ phosphates prevents self ligation.
2.2.1.6 Separation of  DNA fragments by gel electrophoresis
Double  stranded  DNA  fragments  from  restriction  digests  were  separated  by  gel
electrophoresis  on  a  horizontal  0.8%  agarose  gel  in  0.5%  TBE  buffer  containing 
ethidium bromide. 4pl of 6x DNA loading buffer were added to the restriction digests 
and  the  entire  reaction  was  loaded  in  one  well.  A  lkb  ladder  (NEB)  was  used  as  a 
molecular  size  marker.  Electrophoresis  was  carried  out  in  0.5x  TBE  at  80V  for  one 
hour.  Separated bands were visualised on a UV transilluminator and excised from the 
gel.
2.2.1.7 DNA purification from agarose gel
The  QIAquick  gel  extraction  kit  (Qiagen)  was  employed  according  to  the 
manufacturer’s instructions to purify the DNA fragments excised from agarose gels.
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2.2.1.8 DNA ligation
Ligations to clone a restriction enzyme digested  insert into the  appropriately digested 
target vector were carried out according to a standard protocol as follows.
3 pi backbone vector DNA 
14pl insert DNA
2pl lOx T4 DNA ligase buffer (thawed on ice) 
lpl (400,OOOU/ml) T4 DNA ligase
If the concentration of either insert of vector was significantly higher than that of the 
respective other component, the ratio of 3:14 was adjusted to 2:15 or 4:16 accordingly. 
The reaction mixture was incubated at room temperature for two hours and  lOpl were 
used to transform lOOpl competent XL1 Blue bacteria as described in section 2.23.2.
2.2.1.9 Rapid screening of ligation products
To  easily  assess  whether  any  of  a  large  number  of colonies  on  the  ligation  plate 
contained a plasmid with an insert, a rapid screening method was employed in which 
bacteria are  lysed  and the  entire  DNA  and  RNA  content  is  subjected to  agarose  gel 
electrophoresis.
Individual colonies were  spotted on a fresh LB Agar plate containing the appropriate 
antibiotic  and  incubated  at  37°C  overnight.  Cells  from  these  streaks  were  picked, 
resuspended  in  25pl  rapid  screening  buffer  and  incubated  for  five  minutes  on  ice 
followed  by  five  minutes  at  37°C.  The  membranous  fraction  was  pelleted  by 
centrifugation at 13000 rpm for five minutes and 15pl of the sample were run on a 0.8% 
agarose  gel.  The  size  of the  plasmid  was  compared  to  the  original  plasmid  without 
insert.  Clones  with  lower  electrophoretic  mobility  were  chosen  and  screened  for  the 
correct insert by DNA preparation and restriction enzyme digest.
2.2.1.10 DNA sequencing
All  constructs  created  by  cloning  or  mutagenesis  were  sequenced  with  appropriate 
forward and reverse primers to ensure that reading frames of fusion proteins were intact 
and that site-directed mutagenesis gave positive results.  150fmol of pure plasmid DNA 
and 12-30fmol of each primer were delivered to the sequencing facility at the Wolfson 
Institute of Biomedical Research (University College London, UK) where  sequencing 
was carried out using a Beckman Coulter CEQ 8000 genetic analysis system.
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2.2.2  DNA amplification and mutagenesis
2.2.2.1  Polymerase chain reaction
To facilitate subcloning and to allow introduction of reading frame changes for various 
fusion tags individual cDNAs or fragments thereof were PCR amplified using primers 
that introduced new restriction sites. PCR reactions were set up as follows:
1  pi DNA template (10-25ng/pl)
5 pi lOpM forward primer
5pi lOpM reverse primer
5pl lOx ThermoPol buffer (NEB)
5pi lOmM dNTP mix (2.5mM of each dATP, dCTP, dGTP and dTTP)
28pl ddH20
lpl Vent® DNA polymerase (NEB)
One reaction was also set up containing 2mM magnesium sulphate, as this may enhance 
product yield and in certain cases was necessary for any product to be obtained. Vent® 
DNA polymerase was chosen because it contains a proofreading enzyme and therefore 
introduces fewer mutations into the amplified DNA than for example Taq polymerase. 
The reactions cycles were:
Initial melting step: 95°C 5.0 minutes
Melting step: 95°C 0.5 minutes
Annealing step: 55°C 0.5 minutes
Extension step: 72°C 1.0 minutes
Final extension step: 72°C 5.0 minutes
lOpl of a PCR reaction were subjected to agarose gel electrophoresis and the DNA band 
corresponding to  the  PCR product was  excised and purified  as described.  This  DNA 
was subsequently subcloned by restriction enzyme digestion as described.
2.2.2.2  DNA mutagenesis 
“Quikchange” mutagenesis kit
To  mutate  single  residues  and  to  remove  or  insert  Stop  codons  the  “Quikchange” 
mutagenesis kit from Stratagene was used. Pfu Turbo is a DNA polymerase with a very 
sensitive  proofreading  mechanism,  which  prevents  the  introduction  of  random 
mutations  and  allows  amplification  of  entire  plasmids  up  to  8kb.  This  allows
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introduction of mutations at any chosen point within the gene of interest and prevents 
re-cloning of PCR amplified fragments being necessary.  The manufacturer’s protocol 
provided with the kit was altered slightly and the reaction mixtures set up contained:
lpl template (10-15ng/pl)
5 pi lpM forward primer 
5pi lpM reverse primer 
5 pi lOx Pfu Turbo buffer
2pl lOmM dNTPs (2.5mM of each dATP, dCTP, dGTP and dTTP)
3lpl ddH20
lpl Pfu Turbo DNA polymerase (Stratagene)
The PCR cycles were set up as follows.
Initial melting step:  95°C  5.0 minutes
Melting step:  95°C  0.5 minutes  |
Annealing step:  55°C  0.5  minutes  | x 20 cycles
Extension step:  68°C  20 minutes  |
Removal of parental plasmid DNA
After the PCR reaction, the sample contains both the intact parental plasmid without the 
mutations  introduced  and  the  newly  created  DNA  with  the  mutations.  The  mutated 
DNA is nicked on both strands and is not methylated. This means that the parental DNA 
can be removed by Dpnl digestion since this enzyme recognises its restriction site only 
when  methylated,  which  means  that  it  will  leave  the  mutated  DNA  intact,  lpl 
(20,OOOU/ml) of Dpnl enzyme was added to the PCR mixture and incubated at 37°C for 
two hours.  lOpl of the reaction were transformed into competent XL1 Blue according to 
the  manufacturer’s  instructions using NZY+  broth  instead  of LB  during  the  recovery 
phase.
2.2.3  Competent bacterial strains
2,2.3.1  Preparation of chemically competent bacterial strains 
XL1 Blue
The XL1  Blue bacterial  strain was used to propagate plasmid DNA.  These cells were 
made competent using a rubidium chloride method.  100ml of LB containing tetracyclin 
were inoculated with  1ml of an overnight culture of the XL1  Blue strain.  The culture
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was  grown  until  an  OD595  of  0.42-0.45  was  reached.  Cells  were  collected  by 
centrifugation at 4000  rpm for five minutes  and resuspended  in 30ml  ice-cold buffer 
TFB1  (lOOmM  RbCl,  50mM  MnCb,  30mM  potassium  acetate,  50mM  CaCE,  15% 
glycerol,  pH  5.8).  After  a  90  minute  incubation  on  ice,  the  cells  were  pelleted  and 
resuspended in 4ml ice-cold buffer TFB2 (lOmM MOPS,  lOmM RbCl, 75mM CaCl2, 
15% glycerol, pH 6.8). Aliquots of 100pl were frozen at -80°C.
BL21(DE3)
To produce recombinant protein, the E.coli strain BL21(DE3) was used. The cells were 
made competent using calcium chloride. A 100ml culture of bacteria was grown as for 
the XL1  Blue strain, but after centrifugation, the pellet was resuspended in 40ml  ice- 
cold  lOOmM CaCl2 and incubated on ice for 20 minutes. This was repeated two more 
times. After the last incubation, cells were resuspended in 4ml lOOmM CaCl2 with 10% 
glycerol, aliquoted into IOOjj.1 aliquots and stored at -80°C.
2.23.2  Transformation of competent cells
DNA  was  introduced  into  bacterial  strains  by  chemical  transformation.  Competent 
bacteria were thawed on ice and plasmid DNA (0.5pl), ligation or mutagenesis products 
(lOpl) were added. The tube was tapped lightly to mix in the DNA and incubated on ice 
for 30 minutes. Bacteria were heat-shocked at 42°C for 45 seconds and placed on ice for 
a further two minutes.  900pl of warm LB  were added and samples were recovered at 
37°C for 60 minutes. In the case of ligation of mutagenesis products, cells were pelleted 
by centrifugation at 13000rpm for 30 seconds, resuspended in 100-200pl LB and spread 
on a pre-warmed LB plate containing the appropriate antibiotic for selection. When pure 
plasmid DNA was transformed, lOOpl were spread on the plate directly after recovery.
2.3  Cell biological techniques
2.3.1  General techniques
All tissue culture work was carried out aseptically in a filter flow cabinet  (HeraSafe, 
Heraeus). All cells were grown in a humidified atmosphere containing 5% CO2 at 37°C 
using special tissue culture plasticware.  Cell stocks were frozen in medium containing 
50% FCS and 10% DMSO and stored in liquid nitrogen. When bringing up stocks from 
the  frozen  state,  aliquots  were  thawed  quickly  in  a  37°C  waterbath  and  cells  were 
transferred  to  20ml  fresh,  pre-warmed  respective  growth  medium  and  allowed  to
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recover  for  2-4  days.  Stably  transfected  HEK  293T  and  PC 12  cells  were  not  used 
beyond passage 15 and 8 respectively to avoid alterations in expression levels.
2.3.2  Coating of dishes and slides
To allow adherence of loosely attaching cells such as the PC 12 cell line to the plastic 
surface  of the tissue  culture  dishes  and  glass  coverslips,  these  had to  be  coated with 
poly-D-lysine.  Poly-D-lysine  was  chosen  as  a  substratum to  avoid the  breakdown  of 
poly-L-lysine that may occur by  some  cell types  and result in their overload with L- 
lysine.  Dishes  were  covered  with  the  following  volumes  of  0.01%  poly-D-lysine 
hydrobromide (w/v), incubated for four hours at room temperature and sterilised using a 
UV lamp. Following this, the poly-D-lysine solution was removed by aspiration and the 
dishes were dried at 37°C for several hours. Dishes were always prepared the day before 
use.
Diameter of dish Surface area (mm2) Volume of poly-D-lysine
10cm 7900 5.0ml
6cm 2800 3.0ml
3.5cm 1000 1.5ml
Poly-D-lysine  slides  were  prepared  by  incubating  glass  coverslips  in  0.01%  poly-D- 
lysine  hydrobromide  solution  (w/v)  at  37°C  overnight  and  dried  at  50°C  for  several 
hours. The slides were stored at room temperature for several weeks.
2.3.3 HEK 293T cells
HEK  293T  cells  are  epithelial  cells  of human  embryonic  kidney  origin.  They  are  a 
derivative  of the  HEK  293  cell  line  that  has  been  additionally  transformed  with  the 
SV40 large T-antigen. More recently it has been reported that they may actually be of 
neuronal  origin,  as they express a number of neuronal  cell markers  [225].  They have 
been transformed with adenovirus and additionally contain the  SV40  large  T-antigen. 
HEK  293T  cells  were  grown  in  DMEM  growth  medium  and  cells  were  passaged 
approximately  1:25  every 2-3  days  by  washing the  monolayer  once  with Dulbecco’s 
PBS, then once with Versene/EDTA 1:5000 (Invitrogen), incubating cells at 37°C for 5 
minutes and resuspending them in complete growth medium.
2.3.4 PC12 cells
The PC 12 rat pheocytochroma cell line was grown in DMEM growth medium and cells 
were subcultured at a ratio of approximately 1:10 -  1:15 every 3-4 days by transferring
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part of the cells in suspension into a new tissue culture flask containing fresh medium. 
Clumps were broken up by pipetting along the  sides and bottom of the tissue culture 
flasks.
2.3.5  Transfection
2.3.5.1 Lipofection
HEK  293T  cells  were  transfected  using  Lipofectamine  2000  transfection  reagent 
(Invitrogen) according to the manufacturer’s instructions. Briefly, for a 3.5 cm dish of 
80% confluent cells,  10pl  of the transfection reagent were  diluted  in 250pl  Optimem 
serum free medium and incubated at room temperature for five minutes. 5pg of plasmid 
DNA  were  also  diluted  in  250pl  Optimem  and  mixed  with  the  Lipofectamine  2000 
reagent after the incubation time by gentle pipetting. The mixture was incubated at room 
temperature  for  a  further  20  minutes  and  added  dropwise  to  the  cells  in  complete 
medium, mixed by gentle rocking of the dish and incubated overnight.
For  stable  transfections,  transfectants  were  selected  in  400pg/ml  hygromycin 
(Invivogen)  or  800pg/ml  geneticin  (G418)  (Invivogen)  for  two  weeks  with  regular 
medium change every 3-4 days. Individual clones expressing the desired target protein 
were isolated by dilution cloning in 96-well plates.  Stable cell lines (pools and clones) 
were maintained in 200pg/ml geneticin or 1  OOpg/ml hygromycin.
2.3.5.2 Electroporation
PC 12 cells were transfected by electroporation using a Biorad Gene Pulser II.  lOxlO6 
cells were collected by centrifugation at  1100 rpm for 5 minutes, resuspended in 800pl 
Dulbecco’s PBS and mixed with 40pg purified plasmid DNA by gentle pipetting. After 
a five minute incubation period on ice, cells were transferred to a 4mm electroporation 
cuvette and pulsed at 300V and 960pF. Cells were allowed to recover for ten minutes on 
ice, followed by a wash in  10ml room temperature PBS and incubation for at least 24 
hours in pre-warmed complete growth media.
For  the  selection  of  stable  cell  lines,  antibiotics  (800pg/ml  geneticin  or  600pg/ml 
hygromycin) were added after the recovery period and the medium was changed every 
3-4 days. Clonal cell lines were established by dilution cloning in 96-well plates. Stably 
transfected cell lines were maintained in medium containing  100pg/ml hygromycin or 
200pg/ml geneticin.
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2.3.5.3 Calcium phosphate precipitation
HEK  293T  cells  were  transfected  on  a  large  scale  using  the  calcium  phosphate 
precipitation method.  For a  10cm  dish  containing  10ml  growth  medium,  15pg  DNA 
were diluted in a total volume of 438pl ddH20. 62pl 2M calcium chloride solution were 
added.  While  constantly  vortexing  at  a  low  setting,  500pl  of 2x  HBS  were  added 
dropwise to the DNA  solution.  Within two minutes  of 2x  HBS  addition, the mixture 
was  added  dropwise  to  the  cells,  taking  care  to  spread  the  reagent  well.  Cells  were 
incubated overnight and subsequently used for experiments.
2.3.5.4 Selection and clonal selection
After  selection  of  stable  clones  for  two  weeks  and  assessment  of  target  protein 
expression  by  fluorescence  and/or  western  blotting  techniques,  dilution  cloning  was 
carried out to isolate individual clones of cells expressing the desired target protein. The 
cells were diluted in growth medium containing the appropriate antibiotics. Cells were 
then plated in 96-well plates and allowed to grow for several days until colonies could 
be identified. Plates were screened for wells containing individual colonies. These were 
picked,  expanded  and  their  expression  compared  by  fluorescence  microscopy  and/or 
western blotting.
2.3.6  PC12 differentiation assay
For  the  differentiation  assay  PC 12  cells  were  resuspended  in  Versene/EDTA  and 
incubated at 37°C for 5 minutes to break up clumps and obtain single cells,  lxl05 cells 
were seeded in a 3.5cm dish previously coated with poly-D-lysine in growth medium. 
After 16-24 hours the medium was changed to differentiation medium containing 0.1% 
HS and 20ng/ml FGF9. Cells were assayed for neurite outgrowth after 4,  8, 24, 48 and 
72 hours. 400-500 cells were counted and cells with neurites greater than twice the cell 
diameter were scored as positives.  The differentiation medium was changed every 24 
hours.  Images of random fields of view at the indicated times were obtained using  a 
digital  camera  fitted to  a Zeiss Axiovert  25  microscope  and operated  using  Openlab 
4.0.1 software.
2.4 Protein manipulation and analysis
2.4.1  Stimulation and lysis of mammalian cells
For  stimulation  assays,  cells  were  plated  in  3.5,  6  or  10cm  dishes  at  appropriate 
densities and allowed to reach approximately 80% or 60-70% confluency for HEK 293T
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or  PC 12  cells  respectively.  Cells  were  serum-starved  for  18  hours  by  replacing  the 
growth medium with serum-free DMEM (HEK 293T) or DMEM containing 0.1% HS 
(PC 12). Serum-starved cells were stimulated with various growth factors (reconstituted 
from  lyophilised  powder  according  to  the  manufacturer’s  instructions  and  diluted 
appropriately in Dulbecco’s PBS). After addition of growth factor, dishes were placed 
in the incubator for various stimulation periods. Subsequently all medium was removed 
and  cells  were  washed  once  in  ice-cold  PBS  (l-3ml  depending  on  dish  diameter). 
Dishes were placed on ice and the cells were lysed in ice-cold lysis buffer by scraping 
with a rubber policeman.
Dish diameter 3.5cm 6cm 10cm
Volume lysis buffer 150pJ 300pl lOOOpl
Lysates  were  collected  and  the  insoluble  fraction  was  removed  by  centrifugation  at 
13000rpm for 20 minutes. The supernatant was collected in fresh Eppendorf tubes and 
either  directly  subjected  to  SDS-PAGE  as  whole  cell  lysate  or  used  in 
immunoprecipitation or pull-down experiments.
2.4.2 Determination of protein concentration using the Bradford 
assay
To ensure that the same amount of protein was subjected to immunoprecipitation, pull­
down  or  SDS-PAGE  electrophoresis,  the  total  protein  concentration  of lysates  was 
determined with the Bradford protein assay.  This assay works on the  principle  of an 
absorbance shift when the Coomassie Brilliant Blue G-250 dye binds to arginine and to 
a lesser extent histidine, lysine, tyrosine, tryptophan, and phenylalanine contained in the 
proteins of a sample.  The bound,  anionic  form portays an absorbance  shift to  595nm 
compared  to  470nm  for  the  unbound,  cationic  form.  The  protein  concentration  was 
calculated according to the  formula y=0.0496x+0.005,  where y  is  OD595  and x  is the 
concentration  in  mg/ml.  This  was  determined  by  creation  of a  standard  curve  using 
bovine serum albumin at various concentrations.
2.4.3 Gel electrophoresis
Proteins  were  separated  by  SDS-polyacrylamide  gel  electrophoresis  (SDS-PAGE) 
according  to  Laemmli  [226].  The  addition  of sodium-dodecyl-sulphate  (SDS)  to  the 
protein  sample  denatures  the  protein  and  causes  all  proteins  to  acquire  an  overall 
negative charge that is related to the number, but not the composition of amino acids in
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the protein.  This means that proteins can be  separated on the basis of their molecular 
weight alone.
The protein gels used had dimensions of 6cm x  10cm and a thickness of 1.5mm. They 
were made up as follows to achieve separation of proteins of different sizes. Depending 
on the size of the proteins to be analysed,  8% or  10% acrylamide gels were used. The 
resolving  gel  was  overlaid  with  a 4%  stacking  gel  into  which  the  well  combs  were 
inserted.
Component 8% resolving gel 
Volume (ml)
10% resolving gel 
Volume (ml)
4% stacking gel 
Volume (ml)
3M Tris-HCl pH 8.8 1.875 1.875 -
0.5M Tris-HCl pH 6.8 - - 1.500
30% acrylamide/ 
0.8% bisacrylamide
3.975 4.970 0.750
10% SDS 0.150 0.150 0.060
ddH20 8.775 7.780 3.000
10% ammonium 
persulphate
0.113 0.113 0.150
TEMED 0.015 0.015 0.003
Equal  amounts  of whole  cell  lysate  for  each  sample  were  mixed  with  6x  Laemmli 
loading dye and boiled for five minutes in a heating block.  Samples were subjected to 
electrophoresis at 200V and a maximum of 60mAmp per gel for one hour.  Gels were 
either Coomassie stained or subjected to transfer onto PVDF membrane as described.
To determine the molecular weight of proteins on the gel or the subsequent western blot 
membrane  a pre-stained protein marker (Biorad)  was run alongside the  samples.  The 
marker  contained  pre-stained  proteins  of 250,  150,  100,  75,  50,  37,  25,  20,  15  and 
lOkDa.
2.4.4  Coomassie staining of gels
Coomassie  staining  is  a  relatively  low  sensitivity  method  (detection  range  of  100- 
lOOOng  of protein)  to  visualise  proteins  on  an  SDS-PAGE  gel,  that  is  based  on  the 
Comassie Brilliant Blue R dye that binds non-specifically to  all proteins.  For protein 
staining,  SDS-PAGE gels were incubated in stain solution for 4-5  hours or overnight 
with gentle agitation. To remove non-specifically bound dye from the gel, it was placed
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in  destain  solution  with  gentle  agitation  until  individual  bands  could  be  clearly 
visualised.
2.4.5  Western blotting
2.4.5.1 Transfer of  proteins onto PVDF membrane
Western blotting refers to a procedure by which proteins are transferred from an SDS- 
PAGE  gel  onto  a  PVDF  membrane.  The  positioning  of individual  protein  bands  is 
retained and the membrane can be probed with various primary antibodies to detect the 
presence, positioning and modification state of proteins.
Before  use,  the  PVDF  membrane  was  moistened  in  methanol,  to  allow  efficient 
attachment of proteins to the membrane  during transfer,  and  subsequently washed  in 
transfer buffer. A blotting ‘sandwich’ containing the gel and membrane was assembled 
using a Biorad blotting module for the Mini Protean gel apparatus according to standard 
procedures. Transfer of proteins was carried out at 250mAmp for two hours in transfer 
buffer.
2.4.5.2 Protein staining after transfer using Ponceau stain
To  detect  whether  even  transfer  of proteins  onto  the  membrane  has  occurred,  the 
membrane was stained using 0.1% (w/v) Ponceau S in 5% acetic acid. The excess stain 
was  removed  from  the  membrane  by  quick  successive  washes  in  ddFkO.  Once  the 
protein  bands  were  visualised,  the  dye  was  removed  by  quick  successive  washes  in 
ddH20 and a ten minute wash in TBS-T.
2.4.5.3 Immunoblotting
After protein transfer, the membrane was treated with blocking buffer (5% non-fat dried 
milk  in  TBS-T  or  3%  bovine  serum  albumin  (BSA)  in  TBS-T  depending  on  the 
antibody  manufacturer’s  recommendation)  for  one  hour.  This  ensures  that  all  empty 
space  between  the  proteins  transferred  from  the  gel  are  occupied  by  non-specific 
protein, to prevent antibodies attaching to the membrane non-specifically.
Membranes were generally incubated with 1  pg of primary antibody overnight at 4°C in 
5ml  blocking  buffer,  with  the  exception  of the  pY99  anti-phosphotyrosine  antibody, 
which was  added  for two  hours  at room temperature.  Membranes  were  subsequently 
washed three to four times for ten minutes in 50-100ml TBS-T on a horizontal shaking 
platform.  Following  the  washes,  the  appropriate  horseradish-peroxidase-tagged 
antibody (anti-goat,  anti-rabbit or anti-mouse) was added  in a  1:1000  dilution in  5ml 
blocking  buffer  and  incubated  for two  hours  at room temperature.  Membranes  were
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washed three to  four times  for ten minutes  and bands  were  detected using  enhanced 
chemiluminescence.
2.4.S.4  Detection of  protein bands by enhanced chemiluminescence (ECL)
The secondary antibodies used to detect the bands on the western blot were tagged with
horseradish-peroxidase.  This  enzyme  is  able  to  carry  out  a  reaction  that  creates 
chemiluminescence when the two substrates of the enhanced chemiluminescence (ECL) 
kit (Pierce) are mixed and added to the membrane. The membrane was incubated with 
the  ECL  substrate  for  one  minute  according  to  the  manufacturer’s  instructions. 
Detection was carried out using X-ray film in a dark room (exposure time between ten 
seconds and ten minutes depending on intensity of bands for various antibodies) or a 
Fujifilm Las-1000 phosphoimager operated by Image Reader Las 1000 software.
2.4.6 Immunoprecipitation
Whole  cell  lysates  were  subjected  to  immunoprecipitation  with  selected  primary 
antibodies  to  investigate  the  presence  and  changes  in  protein  complexes  upon 
stimulation of cells with growth factors. Depending on the type of cells used, the whole 
cell  lysates  from  a  10cm  tissue  culture  dish  contained  various  amounts  of protein. 
Generally, 1.5-3.5mg of total protein in 1ml were used for immunprecipitation.  l-2pg of 
the chosen primary antibody was added, followed by incubation overnight at 4°C on a 
rotating wheel  to  allow formation  of immuno-complexes.  After  16  hours,  50pl  50% 
Protein A or Protein G agarose slurry in PBS were added for an additional four hours. 
Subsequently, the beads were washed four times with 1ml lysis buffer by removing the 
supernatant after centrifugation at 13000rpm for 30 seconds and replacing it with fresh 
lysis buffer. After the last wash, the beads were dried completely by careful removal of 
all  supernatant  using  a  thin  pipette  tip  and  were  resuspended  in  45 pi  2x  Laemmli 
loading buffer. The samples were boiled and subjected to SDS-PAGE as described.
2.4.7 GST-tagged protein expression
GST-tagged Grb2  and pl3™ c'7 were expressed in the DH5a bacterial  strain.  500ml of 
LB  were  inoculated  with  5ml  of  overnight  starter  culture  in  the  presence  of  the 
appropriate antibiotics and grown until they reached mid-log phase (OD595=0.5).  Cells 
were induced by addition of 0.5mM isopropyl P-D-1  -thiogalactopyranoside (IPTG) for 
four hours  and  subsequently pelleted  by  centrifugation  at  5000  rpm  for  15  minutes. 
Pellets were lysed in bacterial lysis buffer by sonication (three bursts of 20 seconds). 
The insoluble material was removed by centrifugation at 13000 rpm for 20 minutes. The
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cell lysate was incubated with glutathione beads (provided in 20% ethanol and washed 
extensively in PBS and once in bacterial lysis buffer) overnight on a rotating wheel. The 
beads were washed four times with bacterial lysis buffer and stored at -20°C after the 
addition of an equal volume of glycerol.
GST-tagged  full-length  She  and  the  She  SH2  and  PTB  domains  respectively  were 
expressed in the BL21(DE3) bacterial strain and provided by Dr. R. George. The SH2 
and the PTB domains were stable for storage at -20°C in glycerol, but full-length She 
was made directly before use to avoid protein degradation.
2.4.8  GST-tagged protein pulldown experiments
The volumes of beads with attached Grb2-GST or pl3suc'7 required for a pulldown assay 
was  assessed  by  SDS-PAGE.  If only  a  small  volume  was  required,  the  beads  were 
mixed  with  additional  glutathione  beads  to  enable  visualisation.  1.5-3.5mg  of total 
protein in  1ml were added to the beads and incubated overnight at 4°C  on a rotating 
wheel to allow complex formation.  The beads were washed four times with  1ml lysis 
buffer by removing the supernatant after centrifugation at 13000rpm for 30 seconds and 
replacing it with fresh lysis buffer. After the last wash, the beads were dried completely 
and were resuspended in 45pi 2x Laemmli loading buffer. The samples were boiled and 
subjected to SDS-PAGE as described.
2.5 Confocal microscopy analysis
2.5.1 Cell seeding and stimulation
HEK 293T cells were  seeded on glass coverslips and allowed to  attach/spread for 24 
hours.  PC 12  cells were resuspended after centrifugation for 5  minutes  at  lOOOrpm to 
break up clumps and obtain as many single cells as possible. They were seeded on poly- 
D-lysine coated slides and allowed to attach for 24 hours. Cells were serum-starved and 
stimulated as described previously.
2.5.2 Cell fixation and slide preparation
2.5.2.1  Fixation
After stimulation, the coverslips were washed once in ice-cold PBS and cells were fixed 
by the  addition  of 4%  (w/v)  paraformaldehyde  for  20  minutes.  The  coverslips  were 
washed five times in 1.5ml PBS pH 8.0 to remove all traces of paraformaldehyde.
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2.5,2.2  Preparation of slides
After extensive washing, the coverslips were submerged in 0.5x mounting solution in 
PBS for a few seconds and subsequently placed upside down on a glass slide on a drop 
of lx mounting solution. The excess liquid was removed by blotting with tissue paper 
and the slides were sealed using clear nail varnish. Slides were stored at 4°C for up to 
two days or at -20°C for longer storage, although this usually impaired fluorescence and 
was avoided where possible.
2.5.3 Confocal microscopy
Slides were analysed using a Leica TCS SP2 system with a 63x oil immersion objective. 
GFP was excited at 488nm using an argon visible light laser, RFP was excited at 568nm 
using a krypton laser. Their emission was detected using 514/10nm and 595/1 Onm band 
selection  respectively.  Mid-sections  of  the  cells  imaged  were  chosen  to  avoid 
interference from the attachment of the cell to glass. Fluorescence images (image size 
512x512  pixels)  were  collected  using  a  photomultiplier  tube  interfaced  to  an  Intel 
Pentium II  system running the  Leica TCS NT control  software.  The images obtained 
were  analysed  using  the  Leica  LCS  lite  software  and  co-localisation  fluorescence 
intensity  graphs  were  generated  using  the  quantification  function  of  the  software. 
Approximately 10 cells were analysed for each image presented; the images shown are 
representative of the overall trend observed.
2.5.4 Fluorescence lifetime imaging microscopy (FLIM)
FLIM analysis was carried out using a Leica TCS SP2 inverted microscope set-up with
a  63x  water  immersion  objective,  which  was  adapted  for  Time-Correlated  Single- 
Photon Counting (TCSPC) FLIM with a Becker & Hickl SPC 830 card using 64 or 256 
time channels in a 3 GHz, Pentium IV, 1GB RAM computer. The samples were excited 
using a femtosecond Titanium Sapphire  laser (Coherent Mira, repetition rate  76MHz) 
that was pumped by  a 6.5W  solid  state  laser (Coherent Verdi  V6).  Images  (512x512 
pixels, reduced to 256x256 on the FLIM system) were obtained with a line scan speed 
of 200Hz.  Two-photon  excitation  was  carried  out  with  a  wavelength  of 900nm  and 
fluorescence  was  detected  through  a  525+/-25nm  interference  filter  using  a  cooled 
PMC 100-01  detector  (Becker  &  Hickl,  based  on  a  Hamamatsu  H5772P-01 
photomultiplier).  The  fluorescence  decays  obtained  were  fitted  using  a  single 
exponential  decay  model  with  Becker  &  Hickl  SPCImage  software  v2.8.3.  GFP
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fluorescence lifetimes were portrayed in false  colour maps.  The images presented are 
representative of at least five independent fields of view analysed.
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Chapter 3
Differences in protein recruitment 
to the EGFR, FGFR and TrkA 
regulate signal specificity
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3.1 Introduction
Signalling  pathways  are  often  represented  and  viewed  in  a  linear  fashion.  However, 
several factors have been identified that raise the question of how specificity in tyrosine 
kinase  receptor-mediated  signalling  is  achieved:  (i)  individual  protein-protein 
interactions do not confer sufficient specificity to allow signalling to take place in the 
form  of  linear  pathways,  (ii)  many  RTKs  recruit  and  activate  the  same  signalling 
proteins  and  (iii)  the  same  downstream  targets  such  as  Erkl/2,  PLCy  or  PI3K  and 
various transcription factors are activated. These points indicate that linearity causes a 
number of problems in terms of achieving biological specificity and highlight the need 
to elucidate how signal  crossover can be  avoided and how specific responses can be 
achieved. The formation of multiprotein complexes downstream of activated RTKs has 
been implicated as an important mechanism for regulating specificity in RTK signalling 
[126,  135].  The  work  presented  in  this  chapter  will  focus  on  the  regulation  of 
downstream responses to  stimulation with  different  growth  factors  by  recruitment  of 
adaptor proteins into unique signalling complexes.
PC 12 cells are a model system commonly used to compare signalling pathways initiated 
by different RTKs (for example  [16, 67, 227, 228]). Previous work has indicated that 
the assembly of different multiprotein complexes is important for regulation of whether 
cells undergo proliferation or differentiation. Proliferation is primarily characterised by 
the transient activation of the Erkl/2 pathway in response to EGF or insulin stimulation. 
In  contrast,  differentiation  requires  prolonged  activation  of this  kinase  initiated  by 
stimuli  such  as  NGF  or  FGF  [16].  Thus  although  these  different  tyrosine  kinase 
receptors  share  many  components  on  the  qualitative  level,  quantitative  differences 
between the signalling pathways are important in the regulation of cellular responses. 
More  recently  it  has  been  shown  that  although  both  physiological  processes  rely  on 
activation of Erkl/2, differential activation of the Raf/MEK/Erkl/2 pathway via Ras or 
Rapl due to recruitment of different complexes to the plasma membrane upon EGFR or 
TrkA activation respectively is an important regulator of specific downstream responses 
[67, 228].
As  a  result  of the  clear  physiological  differences  in  response  to  stimulation  with 
different  growth factors,  PC 12  cells are  an excellent model  system to  investigate  the 
way  in  which  cells  regulate  specific  outcomes  in  response  to  activation  of various
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tyrosine  kinase  receptors.  Although  several  independent  studies  have  shown  the 
importance  in transient versus  sustained Erkl/2  activation  in the  decision to  undergo 
proliferation or differentiation,  there  is  a  lack  of studies  comparing the  formation  of 
early signalling events induced by the activation of the FGFR, EGFR and TrkA. Many 
studies have focused on events distal to the activated receptor, namely Erkl/2 activation 
and  the  role  of the  two  different  small  GTPases  Ras  and  Rapl  in  this  process  in 
response to growth factor stimulation [67, 228-230]. However, the proximal signalling 
events initiated by the various receptors have not been fully elucidated. Altogether, the 
PC 12  cell  line  provides  an  interesting  model  system  to  investigate  the  assembly  of 
different early signalling complexes downstream of the three different receptors (EGFR, 
FGFR and TrkA) and their importance in regulating specific cellular outcomes.
To investigate the differences in early signalling complex formation downstream of the 
EGFR, FGFR and TrkA, this work focused on the signalling proteins  She,  Sos,  Grb2 
and FRS2. All four proteins have been reported to play a role downstream of each of the 
three  receptors.  However,  the  contribution  of each  component  to  the  activation  of 
Erkl/2  signalling  varies  depending  on  which  receptor  is  activated.  This  provides  an 
interesting basis to investigate the role that differences  in protein recruitment play  in 
activating specific downstream responses.
Techniques that involve isolation of protein complexes from cells mainly focus on the 
temporal  regulation  of signalling  by  complex  assembly,  since  no  information  on  the 
localisation of proteins and their binding partners can be obtained. However, the spatial 
distribution  of signalling  complexes  provides  another  important  point  of regulation, 
because cellular localisation may affect the  signal that emanates from various protein 
complexes.  Indeed,  cellular  compartmentalisation  of  signalling  molecules  is  an 
important factor in generating specific signals and avoiding signal crosstalk (reviewed 
in [145]). Changes in cellular localisation of adaptor proteins such as She, FRS2, Grb2 
and  Sos  in  response  to  PC 12  stimulation  with  EGF,  FGF  or  NGF  have  not  been 
investigated previously. However, the identification of differences in spatial distribution 
of these proteins and interactions with each other in response to activation of different 
receptors  would  provide  further  insight  into  the  way  in  which  specific  downstream 
responses  are  initiated,  controlled  and  downregulated.  The  work  presented  in  this 
chapter  highlights  temporal  differences  in  protein  recruitment  to  unique  signalling 
complexes downstream of the EGFR, FGFR and TrkA. Further it presents the basis for
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investigation of spatial differences in terms of protein localisation and interactions using 
fluorescently tagged signalling proteins.
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3.2  Results
3.2.1  Different patterns of Erk1/2 activation by EGF, NGF and FGF2
It is a widely accepted dogma that NGF and FGF lead to sustained Erkl/2 activation,
whereas EGF leads to a more transient stimulation of this downstream kinase. However, 
most  published  studies  only  compared  two  of  these  growth  factors.  Additionally, 
variations in the concentrations of growth factors used and different ways of measuring 
Erkl/2 activation make comparison between studies difficult. Consequently the effect of 
stimulation with equal amounts of all three growth factors on Erkl/2 phosphorylation 
was  assessed  over  the  time  course  of two  hours  (Figure  3.1).  A  concentration  of 
20ng/ml  of  each  growth  factor  was  found  to  induce  comparable  levels  of  Erkl/2 
phosphorylation after stimulation of all three receptors for ten minutes and was chosen 
for  subsequent experiments  (data not  shown).  The  results  obtained  from time  course 
stimulation of PC 12 cells with all three growth factors were in agreement with previous 
reports.  Both  NGF  and  FGF2  led  to  sustained  phosphorylation  of Erkl/2,  which  is 
representative of its prolonged activation (Figure 3.1). Even though the phosphorylation 
declined slightly around 30 minutes after stimulation, the return to near-basal levels of 
Erkl/2  phosphorylation  that  was  observed  after  prolonged  EGF  stimulation  did  not 
occur  (Figure  3.IB).  EGF  stimulation  on  the  contrary  led  to  more  transient  Erkl/2 
activation. After 30 minutes of stimulation, the levels of phosphorylated Erkl/2 returned 
to a low level and by 60-120 minutes had nearly returned to basal levels.
More subtle differences in Erkl/2 phosphorylation downstream of the activated TrkA, 
EGF and FGF receptors were also observed.  The onset of Erkl/2 activation following 
EGF stimulation was much faster (i.e.  a large amount of phospho-Erkl/2 was already 
present  after  2  minutes  of stimulation)  than  after NGF  or  FGF2  stimulation  (Figure 
3.IB:  inset  graph).  Thus  overall,  EGF-stimulated  Erkl/2  activation  was  quicker  and 
more  transient.  NGF-  and  FGF2-stimulated  Erkl/2  activation  portrayed  a  slightly 
slower onset but was sustained over several hours.
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Figure 3.1: Erkl/2 phosphorylation in response to PC12 stimulation with NGF, EGF or FGF2 PC12 
cells were serum-starved overnight and stimulated with 20ng/ml of each growth factor for various time 
periods. Cells were lysed and 200pg of whole cell lysate were subjected to SDS-PAGE. The Western blot 
was probed with an anti-phospho-Erkl/2 antibody, stripped and re-probed with an anti-Erkl/2 antibody as 
loading control (A). The intensity of the phospho-Erkl/2 bands were quantified using densitometry and 
the data represented graphically.  The  inset graph  shows the early time points  of the  same graph  in an 
expanded fashion (B). The results are representative of three independent experiments.
3.2.2  She is differentially phosphorylated following NGF, EGF and 
FGF2 stimulation
Full-length  She  contains  two  Grb2-binding  sites  around  phosphorylated  tyrosine 
residues 239/240 and 317  in the collagen-homology  1   (CHI) domain.  Both positions 
form docking sites for the Grb2 SH2 domain when tyrosine phosphorylated but are also 
involved in activation of divergent, non-redundant signalling pathways [72,  198,  199]. 
Since  Sos  recruitment  via  Grb2  is  an  important  step  in  Ras  (and  hence  Erkl/2) 
activation,  the  effects  of  stimulation  with  different  growth  factors  on  She 
phosphorylation  was  investigated  using  specific  antibodies  raised  against  the  two 
different tyrosine phosphorylated motifs.
97pY239/      _ _
S t M f
p66
i-p52
-p46
EGF
She
pY239/ 
pY240-Shc
p66
-p52
-f>46
She
FGF2
pY317-S hc^| 
She
p66
EGF
pY317-Shc
She
-
P66
FGF2
Figure  3.2:  Differences  in  She  phosphorylation  in  response  to  NGF,  EGF  or  FGF2  stimulation
Lysates (200pg) from PC 12 cells stimulated with 20ng/ml of each NGF, EGF or FGF2 for various time 
periods after overnight serum-starvation were subjected to SDS-PAGE. All gels were run under the same 
conditions at the same time.  Western blots were probed with an anti-phospho(Y239/Y240)Shc antibody 
(A) or and anti phospho(Y317)Shc antibody (B). The blots were stripped and re-probed with an anti-Shc 
antibody to control for equal loading. The western blots in (A) were exposed for the same amount of time. 
The western blots in (B) were exposed for different periods of time to highlight the temporal changes for 
each  growth  factor  rather  than  the  direct  comparison  between  the  growth  factors.  The  results  are 
representative of two independent experiments in each case.
Both  Grb2  binding  sites  on  all  three  She  isoforms  are  highly  phosphorylated  after 
stimulation of PC 12 cells with EGF.  Interestingly, phosphorylation of the p46 and the 
p66  isoforms  was  downregulated  faster  than  that  of the  p52  isoform  (Figure  3.2). 
Phosphorylation of both the  Y317 and the  Y239/Y240 sites was downregulated after 
120 minutes of stimulation, which is in accordance with the more transient nature of the 
Erkl/2 signal in EGF-stimulated cells. Y317 was dephosphorylated more quickly than 
Y239/Y240.  Y317  has  been  reported  to  be  the  main  Grb2  binding  site,  and  its 
downregulation by 30 minutes of EGF stimulation is in agreement with the decrease in 
Erkl/2  phosphorylation  around  this  time  (Figure  3.1).  The  Y239/240  site  may  have 
functions  other  than  Grb2  recruitment,  which  may  be  regulated  by  differential 
phosphorylation. This could explain the fact that this site remained phosphorylated for 
longer despite Erkl/2 phosphorylation being downregulated following prolonged EGF 
stimulation. In any case, mechanisms such as Sos phosphorylation will prevent further 
activation of Ras despite the possibility that Grb2 can remain bound to this site on She 
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NGF  stimulation of PC 12  cells  led to  a much  lower level  of She phosphorylation on 
tyrosines  239/240  than  EGF  stimulation (Figure  3.2A upper and  middle  panels).  The 
p52  isoform was the predominant tyrosine phosphorylated isoform in cells exposed to 
NGF, but upon longer exposure of the X-ray film, phosphorylation of the p66 (between 
ten  and  60  minutes)  and  the  p46  (all  stimulated  time  points)  isoforms  could  also  be 
detected  (data not  shown).  The  onset of phosphorylation  is  slightly  slower than  after 
EGF  stimulation and the maximum is reached after ten minutes exposure of cells.  By 
120 minutes the levels had decreased slightly, but were still comparable with that of ten 
minutes,  which  indicates  that  the  phosphorylation  of  She  is  not  downregulated 
following prolonged exposure to NGF. Y317 was also phosphorylated in cells exposed 
to NGF (Figure 3.2B). The levels of pY317 did not seem to change throughout the time 
course,  or if anything,  increase  slightly,  which again is in accordance  with prolonged 
Erkl/2  activation.  The  levels  of pY317  in  Figure  3.3B  cannot  be  directly  compared 
between NGF, EGF and FGF2 stimulation, as a longer exposure of the western blot was 
required  to  observe  phosphorylation  in  response  to  NGF  and  FGF2  stimulation. 
Interestingly,  p66  She  was  not  phosphorylated  on  Y317  following  NGF  stimulation, 
which is in agreement with its involvement in other cellular functions such as apoptosis, 
that are not necessarily activated by RTKs [231, 232].
Exposure of PC 12 cells to FGF2 resulted in yet another pattern of She phosphorylation. 
Whereas TrkA recruits both She and FRS2 and these two docking proteins compete for 
the  same  binding  site  on  the  receptor  [70],  the  FGFR  recruits  mainly  FRS2.  The 
function of She in FGFR signalling has not been clearly elucidated, although it has been 
shown to be phosphorylated in response to FGF2 stimulation [100, 103, 104]. Following 
exposure to FGF2,  She was slightly more phosphorylated on Y239/Y240 compared to 
unstimulated cells (Figure 3.2A). However the amount of pY239/pY240 She in FGF2- 
stimulated cells was significantly less than in EGF and NGF stimulated cells, which is 
in agreement with its minor role as a Grb2 recruiting adaptor in FGFR signalling [47]. 
Y317  was  only  phosphorylated  to  very  low  levels,  if  at  all,  in  response  to  FGF2 
stimulation.  Only  a  longer exposure  of the  X-ray  film  revealed  any bands  for pY317 
She, and the levels were not significantly  greater than basal  levels (Figure  3.2B).  The 
p46  isoform  seems  to  slightly  more  phosphorylated  on  Y317  in  stimulated  than  in 
unstimulated  cells.  However,  the  levels  of  phosphorylation  are  also  low  and  the 
importance of this observation is unclear.
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Clear differences in the tyrosine phosphorylation pattern of the two She Grb2-binding 
sites after exposure of PC 12 cells to NGF, EGF or FGF2 were observed, and these were 
in agreement with the differential  levels of Erkl/2  phosphorylation patterns observed 
(Figure 3.IB). Thus although all three receptors recruit the same proteins, there is a high 
level of specificity in terms of phosphorylation threshold and duration. These factors are 
likely to contribute to the generation of highly controlled downstream signals.
3.2.3  Differences in FRS2 phosphorylation downstream of all three 
growth factor receptors
FRS2  exhibits  decreased  electrophoretic  mobility  upon  cell  stimulation  with  EGF  or 
FGF. This characteristic is due to serine/threonine phosphorylation of FRS2, and Erkl/2 
and MEK have been show to play a role in this process  [55]. A similar gel shift was 
detectable  in  PC 12  cells  stimulated  with  the  three  different  growth  factors  (Figure 
3.3A). In unstimulated cells, FRS2 appeared as a single band of approximately 65kDa, 
whereas  stimulation  with  EGF,  NGF  or  FGF  resulted  in  a  gel  shift.  This  reduced 
electrophoretic mobility is due to serine/threonine phosphorylation as described by Wu 
et  al.  [55]  and  results  in  FRS2  appearing  as  a  band  of approximately  90kDa  on  a 
western blot (Figure 3.3.A).  There was no detectable difference in the FRS2 mobility 
shift induced by NGF compared to EGF stimulation. In both cases the majority of FRS2 
showed  retarded  electrophoretic  mobility  and  appeared  as  the  higher  band  of 
approximately  90kDa  in  all  stimulated  time  points.  In  unstimulated  cells,  FRS2 
appeared as a band of approximately 65kDa which is indicative of its unmodified state. 
Only a small amount of FRS2 remained as the 65kDa form in EGF and NGF stimulated 
cells. The gel shift does not indicate changes in tyrosine phosphorylation, which needs 
to  be  addressed  separately  to  assess  the  involvement  of FRS2  in  Grb2  recruitment 
downstream of the different receptors (Figure 3.3B).
In contrast a larger amount of FRS2 still appeared as the lower molecular weight form 
in FGF2  stimulated  cells,  indicating that this had not yet undergone  serine/threonine 
phosphorylation.  This  observation  may  indicate  a  greater  involvement  of  FRS2  in 
signalling from the FGFR at all time points, since downregulation via negative feedback 
does  not  occur  to  the  same  extent  observed  following  NGF  or  EGF  stimulation. 
Additionally, the  shift to the higher molecular weight band occurs  slightly  later than 
after EGF or NGF stimulation (Figure 3.3A: two versus five minutes). The differences
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in FRS2 gel shift certainly indicate a different temporal regulation of the involvement of 
this  docking  protein  downstream  of the  different receptors.  Altogether,  the  gel  shift 
occured immediately after Erkl/2  activation and is independent of the level  of FRS2 
tyrosine phosphorylation (Figure 3.3B).  Thus the gel shift may not necessarily reflect 
the  involvement  of  FRS2  in  signalling  complex  formation  and  positive  receptor 
signalling.  The  serine/threonine  phosphorylation  may  simply  act  as  a  mechanism  to 
prevent excessive tyrosine phosphorylation and is important in regulating the type and 
intensity of signals initiated from various RTKs [55, 110].
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Figure 3.3: Gel shift and tyrosine phosphorylation of FRS2 in reponse to exposure of cells to NGF, 
EGF or FGF2 PC12 cells were serum-starved overnight and stimulated with 20ng/ml of NGF, EGF or 
FGF2. 200pg of whole cell lysate were subjected to SDS-PAGE and immunoblotting using an anti-FRS2 
antibody (A). 3mg of whole cell lysate were incubated with GST-pl3™c'; on glutathione beads overnight 
and  precipitants  were  subjected  to  SDS-PAGE  and  immunoblotting  with  an  anti-phosphotyrosine 
antibody (B). The results are representative of two independent experiments.
The  serine/threonine  phosphorylation  of  FRS2  did  not  directly  affect  its  tyrosine 
phosphorylation  (Figure  3.3B).  Precipitation  of  FRS2  using  a  GST-pB5"0'7  fusion 
protein revealed  that despite  its  gel  shift,  FRS2  (only  the  90kDa  form)  was  heavily 
tyrosine phosphorylated following FGF2 stimulation (Figure 3.3B). Although the level 
of tyrosine phosphorylation declined slightly by 60 minutes of exposure to FGF2, the 
level remained high, even throughout this prolonged stimulation period. EGF stimulation
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did not result in tyrosine phosphorylation, whereas NGF only resulted in a fairly low 
level of FRS2 tyrosine phosphorylation that declined by 30 minutes (Figure 3.3B: lane 
3).  Following  60  minutes  of NGF  stimulation,  FRS2  tyrosine  phosphorylation  had 
virtually disappeared, which seems to be in contrast with the prolonged activation of the 
Erkl/2 pathway. Even if FRS2 does not recruit Grb2 during later time points of TrkA 
activation, it would be expected to remain tyrosine phosphorylated to retain the ability 
to recruit other signalling proteins such as Shp2 and Crk.
3.2.4  Differences in Sos phosphorylation downstream of the three 
tyrosine kinase receptors
The  differences  observed  in  She  and  FRS2  phosphorylation  led  to  the  question 
regarding the effect that the recruitment of Sos to different proteins (She, FRS2, EGFR) 
may  have  on  its  involvement  in  signal  transduction  from  the  three  receptors.  Sos 
becomes phosphorylated on serine and threonine residues as part of a negative feedback 
mechanism  of signalling  from  RTKs.  This  modification  results  in  dissociation  from 
Grb2,  which  thereby  prevents  further  stimulation  of  Erkl/2  via  the  Ras/Raf/MEK 
pathway [233, 234]. Phosphorylation on serine and threonine residues results in retarded 
mobility on SDS-PAGE gels. A previous report indicated that there was no difference in 
the  phosphorylation  of Sos  (as  assessed  by  retarded  electrophoretic  mobility  during 
SDS-PAGE)  between  EGF  and  NGF  stimulation  of  PC 12  cells  [67].  The  authors 
concluded on the basis of these data that TrkA and the EGFR both stimulate the Grb2- 
Sos-Ras  pathway  transiently,  and  that  Ras  does  not  play  a  role  in  sustained  Erkl/2 
phosphorylation.  The  report  indicated that  sustained Erkl/2  activation  in response  to 
NGF  stimulation was  due  to prolonged  Rapl  activation via Crk  and  C3G.  Since  the 
study  did  not  include  the  effect  of  FGF  stimulation  on  Sos  serine/threonine 
phosphorylation, it was chosen to partially repeat the experiment. The effect of all three 
growth  factors  on  Sos  electrophoretic  mobility  (i.e.  gel  shift)  as  a  result  of  this 
phosphorylation was assessed.
Subtle differences in the gel shift of Sos were observed when comparing stimulation of 
PC 12  cells  with  all  three  growth  factors  (Figure  3.4).  Upon  EGF  stimulation,  Sos 
portrays retarded mobility on the gel between five and 30 minutes, which indicates that 
within a short period, a large proportion of Sos became serine/threonine phosphorylated 
and therefore unavailable for recruitment to the plasma membrane via Grb2. This would
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provide a mechanism to ensure transient Erkl/2 activation. Interestingly, a decrease in 
total  cellular  level  of Sos  was  observed  upon  prolonged  exposure  of cells  to  EGF 
(Figure 3.4: middle panel, levels of Sos compared to PLCy loading control). This may 
provide  an  additional  mechanism  to  avoid  prolonged  activation  of  Erkl/2  during 
continuous exposure to EGF.
In NGF stimulated cells, a mobility shift of Sos was observed only after ten minutes, 
which is in agreement with the slightly delayed onset of Erkl/2 phosphorylation (Figure 
3.1). However, degradation of Sos was only observed after prolonged exposure of cells 
to NGF  and this occurred at a later time point and to  a lesser extent than after EGF 
stimulation (Figure 3.4: 60-120 minutes upper and lower panel versus 20-120 minutes 
middle panel). This indicates that although the overall pattern of Sos phosphorylation is 
fairly similar to that of EGF, the association with Grb2 does not need to be prevented by 
degradation  of  Sos.  Other  mechanisms  may  regulate  the  association  of  these  two 
proteins in cells stimulated with different growth factors.
It  was  further  interesting  to  note  differences  in  the  electrophoretic  mobility  of  Sos 
between  NGF  and  FGF2  stimulated  cells.  Both  of  these  growth  factors  induce 
prolonged Erkl/2  activation.  However,  the  gel  shift observed  after FGF2  stimulation 
was  less  compared  to  NGF  (or  EGF)  stimulation  and  was  only  observed  after  ten 
minutes. NGF stimulation leads to prolonged activation of Erkl/2 by recruitment of the 
guanine nucleotide exchange factor C3G, which results in Rapl  activation. This makes 
activation of Ras via Sos redundant. The data presented here indicate the possibility that 
Grb2  and  Sos  remain  associated  for  prolonged  periods  of  time  following  FGF2 
stimulation  due  to  a  lower  level  of  Sos  phosphorylation  via  negative  feedback. 
Subsequently, FGF2 stimulation of PC 12 cells might result in prolonged activation of 
Ras via the recruitment of the Grb2/Sos complex to the activated receptor.
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Figure 3.4:  Sos gel shift in  response to stimulation with NGF, EGF or FGF2 Lysates (200pg) from 
PC 12 cells stimulated with 20ng/ml of each NGF, EGF or FGF2 for various time periods after overnight 
serum-starvation were subjected to SDS-PAGE. All gels were run under the same conditions at the same 
time.  Western  blots  were  probed  with  an  anti-Sos  antibody  and  an  anti-PLCy  antibody  as  a  loading 
control. The results are representative of three independent experiments.
3.2.5  Immunoprecipitation and pulldown experiments confirm the 
recruitment of adaptor proteins into different early signalling 
complexes
To assess whether the adaptor proteins She, FRS2, Grb2 and Sos were not only post- 
translationally modified differentially upon stimulation of PC 12 cells with NGF, EGF 
or FGF2 but were also found in distinct early signalling complexes downstream of each 
growth factor receptor, immunoprecipitation and pulldown experiments were carried out 
(Figure 3.5).
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Figure 3.5:  Formation  of different  multiprotein  complexes  in  response  to  stimulation  with  NGF, 
EGF or FGF2 PC 12 cells were stimulated with 20ng/ml of the respective growth factors for ten, 30 or 60 
minutes and lysed. Whole cell lysates were subjected to immunoprecipitation with an anti-Shc antibody 
(A), an anti-Sos 1   antibody (C) or a pulldown using Grb2-GST (B).  Western blots were initially probed 
with an anti-phosphotyrosine antibody, stripped and re-probed with various antibodies against Sos, She, 
Grb2, or FRS2.  Longer exposures of the western blot are shown on the right.  The  label for the EGFR 
applies to EGF-stimulated lanes only. * phosphoprotein likely to be Gabl, “ non-specific band recognized 
by anti-FRS2 antibody
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3.2.5.1  She is primarily involved in EGFR signalling, but also plays a role in 
TrkA and FGFR signalling
Based on the observations made regarding She phosphorylation, this protein seems to be 
primarily  involved  in  EGF  signalling  (Figure  3.2).  Nonetheless,  tyrosine 
phosphorylation of both sites following NGF and FGF stimulation of PC 12 cells raised 
the question of whether there are differences in recruitment to signalling complexes. In 
parallel with the dephosphorylation of She, its association with Grb2 declined by 30-60 
minutes  of EGF  stimulation  (Figure  3.5A  and  B:  lanes  6  and  7),  which  implicates 
downregulation  of  this  association  as  another  means  to  prevent  further  Erkl/2 
stimulation.  Grb2  was  found  to  associate  with  all  three  She  isoforms  after  EGF 
stimulation.  However,  the  levels  of  Shc/Grb2  association  were  still  higher  in  cells 
stimulated with EGF for 60 minutes than they were at any time point in cells stimulated 
with NGF or FGF2. This indicates that other mechanisms such as dissociation of Sos 
from Grb2 must take place to allow downregulation of Erkl/2 following prolonged EGF 
stimulation.  This  observation  also  indicates  that  She  is  not  the  only/main  Grb2 
recruiting adaptor protein downstream of the FGFR and TrkA.
She phosphorylation was lower in response to TrkA compared to EGFR activation and 
hence portrayed less association with Grb2 (Figure 3.5A and B). In agreement with the 
prolonged  She  phosphorylation  in  response  to  NGF  compared  to  EGF  stimulation 
(Figure  3.2),  the  association  between  She  and  Grb2  did  not  change  throughout  60 
minutes  of  stimulation  (Figure  3.5B  and  C:  lanes  2-4,  anti-Shc  and  anti-Grb2 
immunoblots respectively).  Although less Grb2 was associated with She  compared to 
EGF stimulation, this observation indicates a potential role for She in prolonged Erkl/2 
activation via the Grb2/Sos/Ras pathway in response to TrkA activation. However, the 
dissociation of Grb2 and Sos by 60 minutes of NGF stimulation (Figure 3.5C:  lane 4) 
prevents such signalling. It is not clear what the role of the persistent Shc/Grb2 complex 
is  following  prolonged  exposure to  NGF,  since  Ras  is  not  activated  for a prolonged 
period of time [67]. The Shc/Grb2 complex may be involved in recruiting other proteins 
such  as  Gabl  to  the  TrkA  receptor  that  are  important  in  activation  of  additional 
downstream pathways.
In response to FGF2, She was not heavily phosphorylated (Figures 3.2 and 3.5A), but it 
bound to Grb2 throughout the 60 minute stimulation period (Figure 3.5A and B: lanes 
8-10  and  longer  exposures).  Neither  She  phosphorylation  nor  the  amount  of Grb2
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associated with it changed throughout the 60 minutes of stimulation, although both were 
elevated compared to unstimulated cells (Figure 3.5A and B: lanes 8-10 versus lane  1). 
This indicates a lack of downregulation of this interaction and confirms that indeed the 
recruitment  of Grb2  via  She  may  play  a  minor  role  in  prolonged  Erkl/2  activation 
downstream of the FGFR.  More She  seemed to be precipitated by GST-Grb2  (Figure 
3.5B) than Grb2 was co-precipitated with She (Figure 3.5A). This observation may be 
explained by the fact that an excess of GST-Grb2 was added to the cell lysates, which 
can  interact  with  a  greater  pool  of  phosphorylated  She  than  would  be  the  case 
intracellulary.
3.2.5.2  The Grb2-Sos complex is regulated differentially by all three receptors
Grb2 has been shown to be constitutively associated with Sos, although this interaction
can be enhanced upon activation of certain tyrosine kinase receptors and association of 
Grb2  with  She  [235].  The  recruitment  of Sos  to  the  membrane  via  Grb2  leads  to 
activation of the Ras-Raf-MEK pathway. Since subtle differences in Sos gel shift were 
observed  (Figure  3.4),  the  changes  in  its  interaction  with  Grb2  were  analysed  using 
immunoprecipitation and pulldown techniques (Figure 3.5B and C).  Although the  Sos 
gel shift occurred within a short period of stimulation (five to ten minutes) of all three 
growth factors, the association pattern with Grb2 did not change remarkably throughout 
60 minutes. This is surprising in light of the fact that it has been previously reported that 
the gel shift is due to serine/threonine phosphorylation which then leads to dissociation 
of Grb2  [233].  Perhaps  a  large  enough  pool  of Sos  remains  unphosphorylated  and 
therefore  able  to  bind  Grb2,  or  additional  mechanisms  are  important  in  regulating 
dissociation of these two proteins.
Grb2 and Sos were indeed constitutively associated in PC 12 cells (Figure 3.5B and C: 
lane  1). Interestingly only EGF stimulation resulted in a true increase in the amount of 
Grb2 associated with Sos (Figure 3.5A). Unfortunately in the Grb2-GST pulldown, the 
actual amount of Sos precipitated with Grb2 could not be determined, because Sos runs 
at the same molecular weight as the EGF receptor, and the large amount of EGFR co­
precipitated  with  Grb2  masked  the  Sos  antibody  recognition  site  and  hampered  its 
detection  (Figure  3.5B:  lanes  5-7).  However,  immunoprecipitation  using  an  anti-Sos 
antibody  revealed  that the  amount  of Grb2  associated  with  Sos  did  not  significantly 
decrease  even  after  30  minutes  of EGF  stimulation  (Figure  3.5C:  lanes  5-7),  which 
indicates that this interaction can persist despite serine/threonine phosphorylation of Sos
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(Figure 3.4). It is likely that the decreased interaction of Grb2 with She and the EGFR 
after 60 minutes of stimulation (Figure 3.5 A and B) results in relocation of the Grb2/Sos 
complexes away from the membrane,  which means that Ras activation can no  longer 
take  place.  This  is  in  agreement  with  previous  findings,  which  indicated  that  Sos 
phosphorylation in response to EGF stimulation resulted in dissociation of the Grb2/Sos 
complex from She and the EGFR rather than Sos dissociation from Grb2 [236-238]. Co­
localisation analysis of these two proteins in complex would be important to elucidate 
more  clearly  how  downregulation  occurs  and  whether  re-localisation  to  a  different 
compartment (i.e. removal of Sos from the plasma membrane and hence the membrane- 
anchored Ras) plays a role in this process.
In comparison to EGF  stimulation,  the  amount of Grb2  associated with  Sos  declined 
with prolonged NGF stimulation (Figure 3.5C), which may be consistent with a switch 
from the Sos/Ras/Raf pathway for Erkl/2  activation to the C3G/Rapl/Raf pathway as 
previously reported [67]. Whereas Sos immunoprecipitation indicated loss of Grb2/Sos 
interaction by 30 minutes of NGF stimulation, the Grb2 pulldown suggested prolonged 
association until 60 minutes (Figure 3.5B and C). However, the latter is likely an effect 
caused by the presence of excess GST-Grb2 that is able to bind the maximum amount of 
Sos present and therefore  does not necessarily represent the true  level  of association 
between these two  proteins.  This  is  further  supported by the  fact that no  increase  in 
Sos/Grb2 association was observed from basal in the Grb2 pulldown experiment (Figure 
3.5B: lane  1   versus lanes 2-10). It is not clear why dissociation occurs after prolonged 
NGF  stimulation but not  after prolonged  EGF  stimulation,  although  similar  gel  shift 
patterns of Sos were observed.  However, this indicates that the existence  of different 
signalling  complexes  is  able  to  promote  the  correct,  desired  signals  in  response  to 
different growth factors and is able to control downregulation of the signal in different 
ways.  It  has  been  proposed  previously  that  the  recruitment  of different  kinases  to 
signalling  complexes  downstream  of various  receptors  and  their  phosphorylation  of 
specific  sites  on  Sos  may  affect  the  stability  of Grb2/Sos  complexes  [238].  Further 
studies would need to be undertaken to assess whether differences in the sites on which 
Sos becomes phosphorylated by different kinases are important in mediating differential 
dissociation from Grb2.
Perhaps  the  most  striking  observation  was,  that  in  contrast  to  NGF  stimulation,  the 
Grb2/Sos interaction was  slightly increased with prolonged  exposure  of cells to  FGF
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(Figure  3.5B  and  C:  lanes  8-9  versus  lane  10).  This  is  in  agreement  with  the  less 
prominent Sos gel shift observed in FGF-stimulated cells (Figure 3.4). Since both NGF 
and FGF  initiate very  similar cellular responses  (i.e.  prolonged Erkl/2  activation and 
subsequent differentiation),  one  might  have  expected  the  FGFR and  TrkA  to  initiate 
activation of similar  signalling pathways.  However,  the  differential  regulation  of the 
dissociation  of the  Grb2/Sos  complex  indicates  that  this  is  not  the  case.  Prolonged 
activation  of  TrkA  leads  to  Erkl/2  phosphorylation  via  activation  of  Rapl  by 
recruitment  of  Crk  and  C3G  while  the  Grb2/Sos/Ras  signalling  pathway  is  only 
important  for  transient  Erkl/2  activation  [67].  The  data  presented  in  this  chapter 
indicate that sustained FGFR activation does not cause downregulation of the Grb2/Sos 
signalling pathway and continues to signal via these proteins for a prolonged period of 
time.
3.2.5.3  FRS2 is the major component recruiting the Grb2/Sos complex 
downstream of the FGFR
FRS2  has  been  described  as  the  main  component  recruiting  Grb2  to  the  FGFR.  As 
described in section 3.2.5.1, She may play a minor role in Grb2 recruitment downstream 
of the  activated  FGFR.  However,  She  phosphorylation  (and  hence  association  with 
Grb2) is much lower than that following activation of the EGFR, which indicates that 
She does not carry out a major role in Erkl/2 activation by the FGFR. FRS2 was found 
to be the major tyrosine phosphorylated protein in FGF stimulated cells (Figures 3.3B 
and 3.5B and C). Its association with Grb2 and Sos decreased slightly by 60 minutes of 
FGF stimulation (Figure 3.5B and C:  lane  10 versus lanes 8-9), which is concomitant 
with  its  slight  dephosphorylation  (Figure  3.3B:  lane  10).  This  dephosphorylation  of 
FRS2 is in contrast with the persistent or even somewhat increased association between 
Grb2 and Sos (section 3.2.6.2) observed at later time points of FGF exposure. However, 
FRS2  remains  highly  phosphorylated  throughout prolonged  FGF  stimulation,  so  that 
sufficient  bindings  sites  for  Grb2  are  retained,  which  would  allow  Grb2  and  Sos  to 
remain associated near the plasma membrane and lead to Ras activation.  The level of 
FRS2 phosphorylation at later time points may therefore be sufficient for recruitment of 
enough  Grb2/Sos  complexes  to  maintain  Erkl/2  phosphorylation.  Altogether,  FRS2 
remained phosphorylated more  strongly  and for a longer period of time than in cells 
stimulated with NGF and the interaction with Grb2 and  Sos was more pronounced in 
FGF2 stimulated cells. This indicates that although both of these growth factors cause 
differentiation  by  inducing  prolonged  Erkl/2  phosphorylation,  the  formation  of
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signalling  complexes  differs  downstream  of  TrkA  and  FGFR.  The  differential 
recruitment  of adaptor  proteins  to  the  activated  receptors  regulates  the  activation  of 
downstream targets by diverse but convergent signalling pathways.
Virtually no FRS2 co-precipitated with Grb2 and Sos in EGF stimulated cells (Figure 
3.5B and C: lanes 5>6), which is in accordance with previous findings that FRS2 does 
not associate with Grb2 following EGF stimulation [55]. FRS2 is not a major docking 
protein downstream of the activated EGFR, since Grb2 can be recruited to the receptor 
directly or via She. FRS2 has been shown to be part of a mechanism for downregulation 
of signalling from the EGFR [55], which would explain its presence in EGFR signalling 
complexes at later time points (Figure 3.5B: lane 7). Nonetheless, precipitation of FRS2 
with p n 5^'7 (Figure 3.4B) revealed no significant phosphorylation of FRS2, which is in 
agreement with the fact that FRS2 is not a major component of EGFR signalling. Even 
if FRS2 was  involved in signal  downregulation,  it would not be  expected to  interact 
with Grb2  and  Sos in any case,  which further explains the  absence of this  signalling 
protein from the EGFR-induced signalling complexes analysed in this study.
Surprisingly, FRS2 was only minimally phosphorylated in response to TrkA compared 
to  FGFR  activation  (Figure  3.4B).  FRS2  seems  to  only  be  involved  in  Grb2/Sos 
recruitment in the earlier stages of TrkA signalling,  since it only co-precipitated with 
Sos five minutes after NGF  stimulation (Figure  3.5C) but was not found  in complex 
with Grb2 at any of the time points used for the pulldown assay (i.e. ten to 60 minutes, 
Figure 3.5B: lanes 2-4). The GST-pl35w c‘7 pulldown revealed that FRS2 was maximally 
phosphorylated  around  ten  minutes  of NGF  stimulation  and  that  it  was  completely 
dephosphorylated by 60 minutes (Figure 3.4B).  In contrast to FGF  stimulation, where 
phosphorylation  and  association  with  Grb2  occurred  up  until  60  minutes,  NGF 
stimulation did not cause prolonged recruitment of Grb2 and Sos to the activated TrkA 
receptor  via  FRS2.  This  observation  seems  to  indicate  that  in  response  to  NGF 
stimulation,  She  is  the  main  Grb2/Sos  recruiting  adaptor,  whereas  FRS2  plays  an 
important  role  in  recruitment  of other  proteins  such  as  Crk  into  larger  multimeric 
complexes. Recruitment of such proteins may be required to initiate differentiation.  It 
was  interesting  to  note  that  FRS2  phosphorylation was  not  maintained  throughout  a 
longer time period, and it must therefore be able to carry out some of its roles in the 
absence  of major  tyrosine  phosphorylation.  It  could  be  a  possibility  that  the  Grb2 
binding sites on FRS2 are dephosphorylated, but that the remaining tyrosine residues
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(Y436 or Y471, which are Shp2 binding sites) remain phosphorylated to a small extent. 
Phosphorylation of tyrosine residue Y436 would allow Crk interaction with FRS2 to be 
retained [67], but may not be sufficient to allow high levels of FRS2 to be detected by 
an anti-phosphotyrosine antibody. Since the Grb2/Sos and the Shc/Sos association was 
also downregulated in cells exposed to NGF for prolonged periods of time (Figure 3.5 A 
and  C),  other  pathways  must  be  activated  to  results  in  prolonged  Erkl/2  activation. 
These are likely to act via Rapl rather than Ras. Altogether, the phosphorylation of Sos, 
and the signalling complexes it is involved in, differed between all three receptors. This 
indicates  that  differential  recruitment  of  proteins  like  FRS2  may  be  an  important 
regulatory mechanism of growth factor-specific signalling intracellularly.
3.2.6  Grb2 on its own does not display discrete localisation patterns 
after NGF, EGF or FGF2 stimulation
To  analyse  possible changes  in the protein recruitment to the  different receptors  and 
changes in co-localisation of proteins following NGF, EGF or FGF stimulation, PC 12 
cells  were  stably  transfected  with  C-terminally  GFP-tagged  Grb2.  Individual  clones 
expressing  different  amounts  of the  construct  were  isolated  using  dilution  cloning 
(Figure 3.6A). The cells expressing the lowest amount of Grb2-GFP (clone C2) were 
selected  for  confocal  imaging,  as  they  were  bright  enough  for  confocal  microscopic 
analysis  and did not  show any breakdown products  due to  extensive  overexpression. 
The  cells  were  stimulated  with  NGF,  EGF  or  FGF  for  various  time  periods  and 
midsection  confocal  images  of  cells  were  analysed.  No  clear  differences  in  Grb2 
localisation were observed between unstimulated and stimulated cells or between cells 
stimulated with different growth factors (Figure 3.6B). Most of the Grb2-GFP resided in 
the  cytoplasm,  with  some  localisation  to  the  membrane  as  well  as  the  nucleus.  The 
ubiquitous expression meant that there was no detectable change in the localisation of 
Grb2  upon  stimulation.  Membrane  localisation  was  perhaps  somewhat  more 
pronounced in NGF and FGF  stimulated cells throughout the later time points (30-60 
minutes), but the differences observed were minimal.  Consequently co-localisation or 
ideally FRET/FLIM  analysis  of Grb2-GFP  and  its  RFP-tagged binding  partners  She, 
Sos  and FRS2  is  required  to  obtain meaningful  information  regarding  differences  in 
spatio-temporal  protein  recruitment  and  interaction  following  EGF,  NGF  or  FGF 
stimulation.  Although  this  approach  was  attempted,  various  experimental  problems 
were encountered.  Firstly,  analysis by confocal imaging was hampered by fairly high
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levels of autofluorescence of PC 12 cells in the RFP emission range, which required high 
levels of expression of the tagged constructs. Secondly, high expression levels could not 
be achieved, so that co-localisation and FLIM studies could not be carried out.  These 
will need to be addressed in a separate study.
75kDa C2  C5  C12  C14  C16  C20  C23
—  Grb2-GFP
Blot: anti-GFP
B
5 min  15 min  30 min  60 min
Basal
NGF
HI EGF
FGF2
Figure 3.6: Grb2 localisation in response to NGF, EGF or FGF2 stimulation Stable cells expressing 
Grb2-GFP were created and individual clones were analysed by western blotting (A).  The cells (clone 
C2) were seeded on glass coverslips coated with poly-D-lysine and serum-starved overnight. They were 
subsequently stimulated with 20ng/ml of each respective growth factor for different periods of time, fixed 
in  4%  paraformaldehyde  and  mounted  on  glass  slides.  Cells  stimulated  with  FGF2  are  represented  at 
lower magnification. Images were obtained using a Leica SP2 confocal system and Leica TCS NT control 
software and are representative of at least ten cells imaged (B).
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3.2.7  The threshold of Erk1/2 activation as well as its duration is 
important for initiation of correct cellular responses to growth factor 
stimulation
The effects of Apert syndrome mutations on FGFR2 signalling will be the main focus of 
Chapters 4 and 5. However, it was chosen to use the Apert syndrome mutations as an 
additional  model  system  whilst  investigating  the  role  of  differential  Erkl/2 
phosphorylation in determining whether cells undergo proliferation or differentiation. 
The Apert mutant receptors portray increased ligand binding affinity compared to the 
wild type FGFR2 [7, 161]. This property made these mutations an interesting system to 
investigate  the  effects  that  altered  receptor/ligand  interactions  have  on  downstream 
signalling  in  general  (refer to  Chapter  4  and  5)  and  on  PC 12  cell  differentiation  in 
particular.
To  be  able to directly compare  the  effects that the  mutant receptors  have  on  Erkl/2 
phosphorylation  and  differentiation  compared  to  the  wild  type  FGFR2,  cell  lines 
expressing equal amounts  of each respective  receptor were  created.  PC 12  cells  were 
transfected with constructs encoding GFP-tagged wild type, S252W and P253R FGFR2. 
The GFP-tag did not interfere with functionality of the receptor (refer to  Chapter 4). 
Although the tag was not necessary for the studies carried out in PC 12 cells presented in 
this chapter the same GFP-tagged receptors were used for their availability and ease of 
selection of stable transfectants.  Individual clones stably expressing each of the GFP- 
tagged receptors  were  isolated  by dilution-cloning  in  96-well  plates  and  analysed  by 
western blotting and fluorescence microscopy. Clones WT C6, S252W C2 and P253R 
C3 were chosen for further experiments since they expressed comparable levels of each 
of the three receptors (Figure  3.7A).  Clonal variation was excluded by assessment of 
different  clones  for  the  same  downstream  signalling  responses  to  FGF  stimulation. 
Confocal microscopy revealed that the receptors were targeted to the plasma membrane, 
which  indicates  that  GFP-tagging  does  not  interfere  with  correct  receptor  folding  or 
post-translational modification (Figure 3.7B).
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Figure 3.7: Creation of stable PC12 cell lines expressing the wild type, S252W and P253R FGFR2 
respectively  PC 12  cells  were  stably  transfected  with  constructs  encoding  the  wild  type,  S252W  and 
P253R FGFR2-GFP and individual clones were obtained by dilution cloning and subsequently analysed 
by western blotting with an anti-GFP-antibody (A) and by confocal microscopy (B).
To  assess  the  effects  of  the  Apert  syndrome  mutations  on  signalling  pathways 
downstream of the FGFR2, cells expressing the wild type,  S252W or P253R FGFR2 
were  stimulated  with  FGF9  for  various  periods  of time  and  the  levels  of  Erkl/2 
phosphorylation  were  assessed  by  western  blotting  (Figure  3.8A  and  B).  Erkl/2 
activation in response to  FGF9  stimulation was  greatly enhanced  in  cells expressing 
either the S252W or the P253R compared to the wild type receptor. PI3K signalling has 
been implicated with a role in neurite  outgrowth,  but is primarily  important for cell 
survival  in  response  to  NGF  stimulation  [239,  240].  Nonetheless,  changes  in  the 
activation of this kinase  might contribute to  changes  in the  differentiation pattern of 
PC 12 cells expressing the Apert mutant receptors compared to the wild type FGFR2. To 
investigate whether the Apert mutations affect the activation of PI3K, the levels of Akt 
phosphorylation were assessed by western blotting, as a read-out of PI3K activity. No 
changes  in  the  levels  of Akt  phosphorylation  were  observed,  which  indicates  that 
differential activation of this pathway does not contribute to any alterations in formation 
or stability of neurites in cells expressing either of the mutant receptors (Figure 3.8A). 
Untransfected PC 12 cells did not portray Erkl/2 activation since they do not express 
any FGFR2  (Figure  3.8A)  [100], which indicates that all effects observed are due to 
activation  of the  exogenously  expressed  receptors  and  not  activation  of endogenous 
FGFRs.
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Figure 3.8:  Effect of Apert syndrome mutations on  Erkl/2  phosphorylation  and differentiation  in 
PC12  cells  PC12  cells  stably  transfected  with  constructs  encoding the  wild type,  S252W  and  P253R 
FGFR2-GFP were plated on poly-D-lysine  coated dishes,  serum-starved overnight and  stimulated with 
20ng/ml FGF9 for various periods of time. Western blots were probed with antibodies against phospho- 
Erkl/2,  phospho-Akt (a prolonged exposure  of the blot is presented),  GFP and  stripped and re-probed 
with  an  anti-Erkl/2  antibody  (A).  The  amount  of  phosphorylated  Erkl/2  was  quantified  using 
densitometry  and  represented  graphically  (B).  For  differentiation  assays  cells  were  plated  on  poly-D- 
lysine coated coverslips and incubated with 20ng/ml FGF9 or  lOOng/ml NGF for 72 hours.  Cells (400- 
500 per sample) in random fields of view were photographed and scored for neurites greater than twice 
the cell body diameter at the times  indicated (C  and D, page  116).  The  data are representative  of two 
independent experiments with the exception of NGF stimulation of untransfected PC 12 cells.
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PC 12 cells are an ideal model  system to  investigate the cellular effects of changes in 
Erkl/2  phosphorylation,  since  differences  in  the  duration  of  Erkl/2  activation  are 
important  in  determining  cell  fate.  Although  the  duration  of  Erkl/2  activation  in 
response to  stimulation  of the  mutant  receptors  was  not  altered  compared to  normal 
FGFR signalling, it was greatly enhanced (Figure 3.8A and B). It was proposed that this 
enhanced Erkl/2 activation in cells expressing the Apert mutant receptors would lead to 
enhanced neurite  formation.  This  might  have  been revealed  in the  form  of (i)  faster 
differentiation (i.e. within a shorter time period after addition of FGF), (ii) formation of 
more neurites or (iii) elongated neurites in cells expressing the Apert mutant receptors. 
Surprisingly,  cells  expressing  the  Apert  mutant  receptors  showed  diminished 
differentiation (Figure  3.8C  and D).  Whereas the  P253R receptor was able to  induce 
formation  of  some  neurites,  barely  any  neurite  outgrowth  was  evident  in  S252W- 
expressing cells even after 72 hours of FGF9 stimulation (Figure 3.8D).  Furthermore, 
despite the enhanced Erkl/2 activation caused by the P253R receptor, cells expressing 
this receptor were not able to reach neurite maturation stages. By 48-72 hours of FGF9 
stimulation,  many cells  were  in the  early  stages  of differentiation  (i.e.  flattened,  less 
round and with  some  membrane  protrusions),  but  could not progress  to  form  proper 
extended neurites even after 120 hours of FGF9 stimulation (Figure 3.8C). Activation of 
the S252W receptor did not even induce flattening of the cells, which remained round 
and loosely attached to the surface (Figure 3.8C). The ability of the wild type FGFR2 to 
induce  neurites  was  comparable  to  the  response  of  untransfected  cells  to  NGF 
stimulation.  However,  the  neurites  induced  by  stimulation  of the  FGFR2  were  less 
stable and retracted with prolonged FGF9 stimulation (beginning at 72 hours but more 
pronounced at  120 hours).  The cells  detached from the poly-D-lysine  coated  surface, 
which  is  why  no  cell  counts  could  be  undertaken  at  120  hours  (Figure  3.8D).  It  is 
unclear  why  this  occurred,  but  is  in  accordance  with  a  previous  report  indicating 
decreased prolonged stability of FGF-induced compared to NGF-induced neurites [241].
Additionally, it was observed that the proliferation rate of cells expressing either of the 
two  mutant receptors  seemed to  increase  in the  presence  of FGF9  (in  differentiation 
medium).  Quantitative  assessment  was  not possible  because  the  cells  did  not  adhere 
well  to  glass-bottom  gridded  tissue  culture  dishes  despite  poly-D-lysine  coating. 
However, regular PC 12 cells did not differentiate in response to FGF9 stimulation since 
this FGF did not induce Erkl/2 phosphorylation (Figure 3.8A and D), and subsequently 
most cells died in the differentiation medium (which lacks serum for cell growth) by 72
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hours. On the contrary, cells expressing the S252W or the P253R receptors did not die 
or  detach  and  displayed  increased  numbers  in  differentiation  medium.  The  fact  that 
these cells seemed to proliferate in medium that was lacking serum but contained FGF9 
indicated that  somehow the  enhanced Erkl/2  activation caused the  opposite response 
normally expected to take place in response to prolonged activation of this pathway.
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3.3 Discussion
3.3.1  Duration and magnitude of signals have to be regulated to 
achieve specific cellular responses
Previous findings indicated that prolonged Erkl/2 activation downstream of the FGFR 
and TrkA  leads  to  differentiation,  whereas  EGFR-induced transient Erkl/2  activation 
leads to proliferation. Comparison of the signal duration in response to NGF, EGF and 
FGF confirmed and enhanced these results. Interestingly, it was found using the Apert 
syndrome FGFR2 that precise quantitative regulation of Erkl/2 activation is required to 
achieve  specificity in the  cellular outcome.  The activation of either of the two  Apert 
syndrome mutant FGFR2s resulted in prolonged but also enhanced Erkl/2 activation in 
comparison to the wild type receptor.  Surprisingly, this did not induce differentiation. 
This is interesting in light of the fact that the duration of Erkl/2 activation is believed to 
be  the  most  important  regulator  of the  proliferation/differentiation  decision  in  PC 12 
cells. The observation that the threshold and not only the duration of Erkl/2 activation 
is  important to  achieve  the  correct  cellular  response  sheds  new  light  on  the  way  in 
which the regulation of cell signalling is viewed. The fact that the Apert mutations can 
alter cell fate by changing the level of activation of this kinase rather than the length of 
time  for which  it  is  activated,  indicates  that  cell  regulation  is  highly  controlled  and 
several  aspects  have  to  be  tightly  controlled  to  achieve  the  correct  downstream 
response.
As described in later chapters (refer to Chapters 4 and 5), the Apert syndrome mutations 
not only affect Erkl/2 signalling, but also result in other effects on both the receptor and 
downstream signalling events. Hence the possibility that the changes in differentiation 
pattern observed in PC 12 cells expressing the mutant receptors are not solely due to the 
increased activation of the Erkl/2 kinase cannot strictly be excluded. Interestingly, the 
Apert syndrome mutations did not result in any changes in the phosphorylation of Akt 
(Figure  3.7B),  which  is  an  indication  that  alteration  of  the  PI3K  pathway  is  not 
responsible for the changes in differentiation. Expression of constitutively active MEK1 
or  Ras  is  sufficient  for  induction  of neurite  outgrowth  and  PI3K  signalling  is  more 
important for cell survival than neurite outgrowth [240, 242, 243]. This supports the fact 
that the PI3K pathway does not play a role in causing the altered differentiation pattern 
observed in the presence of the Apert syndrome mutations. Nonetheless,  further work 
investigating  the  changes  that  cause  enhanced  Erkl/2  activation  (such  as  altered
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assembly  of signalling  complexes  involving  Grb2,  Sos,  FRS2,  She  and  other adaptor 
proteins)  would  be  extremely  interesting  and  valuable  in  gaining  insight  into  the 
mechanism by  which differentiation  is  prevented by the  S252W and P253R receptors 
despite  prolonged  Erkl/2  activation.  Although  activation  of the  Erkl/2  pathway  was 
deemed  sufficient for PC 12  cell  differentiation  [243],  other studies have  indicated the 
requirement  for  the  activation  of additional  pathways  involving  for  example  Src  or 
PLCy  for this  process  [244].  Analysis  of the  effects  of the  Apert  mutations  on  these 
pathways has to be undertaken to exclude the possibility that it is not the altered Erkl/2 
signal strength but the changes in other pathways that result in lack of differentiation in 
cells expressing the Apert syndrome FGFR2.
The  observation  that  both  the  duration  and  the  magnitude  of activation  of a  certain 
pathway are important for specific downstream responses adds further complexity to the 
regulation  of  signal  transduction.  Tight  control  of  the  strength/magnitude  (i.e.  the 
number of downstream proteins such as Erkl/2 that are activated) or the duration of a 
signal can be achieved by the formation of signalling complexes. Multiprotein complex 
formation is important for modification of signal duration, since downregulation may be 
prevented  or  enhanced,  by  for  example  sheltering  from  dephosphorylation  or  by 
specifically recruiting proteins involved in signal downregulation such as phosphatases 
or ubiquitin ligases, respectively. At the same time, assembly of proteins into a complex 
may  also  provide  a  means  to  specifically  regulate  the  magnitude  (e.g.  level  of 
phosphorylation or activation) of a signal generated. Such regulation could be achieved 
by  recruitment  of proteins  into  slightly  different  complexes  downstream  of various 
receptors. Depending on the complex formed, both the duration and the magnitude of a 
signal could be precisely regulated. This is important for allowing activation of specific 
cellular  responses,  such  as  differentiation  or  proliferation,  by  the  same  signalling 
pathways  (in this  case  Erkl/2).  If quantitative differences  such as  signal  duration  and 
magnitude were not present and could not be tightly controlled, all receptors in a given 
cell type might lead to the same cellular response, because they often employ the same 
proteins  and  activated  the  same  downstream  pathways  (refer to  Figures  1.2,  1.3  and 
1.4).
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3.3.2  Recruitment of unique signalling complexes to different RTKs 
regulates downstream signal transduction
3.3.2.1  Receptor-specific differences regulate protein recruitment
Since  the  discovery  that  various  cellular  responses  to  different  growth  factors  are
regulated  by  activation  of very  similar  intracellular  pathways  including  the  Erkl/2, 
PLCy and PI3K pathways, it has been shown that spatio-temporal regulation of factors 
such  as  protein  (re)location and  signal  duration are  important  mediators  of biological 
specificity  (reviewed  in  [145]).  The  work  presented  in  this  chapter  has  shown  that 
differential regulation of the same downstream pathway can be regulated by assembly 
of the same proteins into unique signalling complexes downstream of different RTKs.
The recruitment of the proteins She, FRS2, Grb2 and Sos into multiprotein complexes 
was found to be intrinsically different between the EGFR, FGFR and TrkA. Regulation 
of the  assembly  of different  complexes  is  mediated  by  various  factors  such  as  the 
availability of binding  sites  for adaptor proteins  on the receptor,  differential  levels  of 
phosphorylation  and  exclusion  of certain  proteins  from  complexes  by  occupation  of 
binding sites by other interacting partners. Firstly, each of the three receptors possesses 
different  binding  sites  for  various  adaptor  proteins,  which  affects  the  recruitment  of 
proteins into multimolecular assemblies (Figure 3.9).  Secondly, the stoichiometry with 
which individual  sites on the receptors are phosphorylated also affects the recruitment 
of adaptor  proteins  and  whether  or  not  certain  protein-protein  interactions  can  take 
place. Highly regulated and very precise phosphorylation of the FGFR1  has been shown 
to occur [15]. Undoubtedly this plays an important role in regulating the recruitment of 
specific proteins to the receptor at different times, not only by providing binding sites 
for  selected  proteins,  but  by  also  adding  temporal  control  over  which  pathways  are 
activated and in which order. Thirdly, it has been shown that the cytoplasmic region of 
the EGFR undergoes various structural changes upon stimulation by EGF, since certain 
antibody  epitopes  are  only  unmasked  in  the  phosphorylated  but  not  the 
unphosphorylated EGFR  [245].  Such mechanisms may add additional control  over the 
availability of binding sites on receptors. Altogether the availability of binding sites for 
different adaptor proteins on the individual receptors is an important determinant of the 
type of signalling complex that will be assembled.
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Figure 3.9 Diagrammatic  representation  of the  known  binding sites  for signalling  proteins  on  the 
EGFR,  FGFR  and  TrkA  The  known  phosphorylation  sites  in  the  intracellular  regions  of the  three 
different  receptors  as  well  as  the  signalling  proteins  that  have  been  shown  to  bind  to  these  sites  are 
indicated. Y683 and Y684 on TrkA and Y653 and Y654 on FGFR are activation loop tyrosines. She has 
been suggested to bind to Y730 and Y766 of the FGFR1, but it is unclear whether this interaction occurs 
in  vivo.  FRS2  binds  to  the  FGFR1  in  a  phosphotyrosine-independent  fashion  in  the juxtamembrane 
region.  Only the main binding partners of TrkA  are  shown.  She  and FRS2  compete for the  same  PTB 
domain binding site surrounding phosphorylated Y490 of TrkA. FRS2 has been suggested to bind to the 
EGFR  in  a  single  report,  but  no  site  has  been  identified  and  this  finding  is  unconfirmed  by  other 
investigations. The binding sites for the FGFR are for a generalised model and do not represent a specific 
FGFR isoform.  Adapted from [33,48, 68-70, 246-250].
3.3.2.2 Differential recruitment of FRS2 and She to the EGFR, FGFR and 
TrkA is an important regulator of transient versus prolonged Erkl/2 activation
The differential recruitment and involvement of FRS2 presents a clear example of how
the presence of different binding sites on the receptor intrinsically regulates formation 
of receptor-specific complexes (refer to Figure 3.10 for diagrammatic representation). 
TrkA  possesses  a  shared  recognition  and  binding  site  for  the  She  and  FRS2  PTB 
domains  (Figure  3.9),  which  was  reflected  in the  fact that  both  She  and  FRS2  were 
phosphorylated and  involved in Grb2/Sos recruitment (Figure  3.5).  Whereas  She was 
able to bind to Grb2 for prolonged periods of time with a slight decline in association 
with prolonged exposure to NGF (Figure 3.5A and B), FRS2 was hardly detectable in 
complex with Grb2 at all, and only at the earliest time points (Figure 3.5B and C). The 
amount  of  FRS2  in  complex  with  Sos  declined  faster  compared  to  the  amounts
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associated  with  She  (Figure  3.5C:  lanes  2-4).  This  indicates  that  both  proteins  are 
recruited  to  the  receptor where  they  compete  for the  same  site,  but  She  seems  to  be 
more important for the recruitment of Grb2 and  Sos.  The dissociation of this complex 
leads  to  the  downregulation  of the  Ras  pathway  with  prolonged  NGF  stimulation  as 
previously  described  by  Kao  et  al.  [67],  FRS2,  on the  contrary,  only  associates  with 
Grb2  very  transiently.  However,  it  is  also  able  to  interact  with  Crk,  a protein  that  is 
important  in  mediating  sustained  Erkl/2  activation  via  binding  C3G,  a  guanine 
nucleotide exchange factor for Rapl  [251]. She could not carry out this function since it 
does not possess the same binding sites as FRS2. This shows that simply the presence of 
a  binding  site  to  which  both  proteins  can  bind  allows  additional  recruitment  and 
activation of different proteins (refer to  Figure  3.9  for diagrammatic representation of 
the binding sites on different receptors).  Particularly the dual binding site for She and 
FRS2 on TrkA means that a certain proportion of receptors can activate  Shc-mediated 
pathways, whereas the other TrkA receptors can recruit complexes surrounding FRS2 or 
differences in binding of each protein after various periods of stimulation may tightly 
regulate the transient and prolonged activation of different pathways.
Although interaction of the PTB domain of FRS2 with the EGFR has been documented 
in a single report [55], no specific FRS2 binding site on the EGFR has been described to 
date.  The lack of FRS2  tyrosine phosphorylation in response to  EGFR activation also 
indicates that FRS2 does not seem to play a major role  in terms of Grb2  recruitment. 
The multitude of proteins that are recruited to TrkA compared to the EGFR may form 
the basis for initiation of differentiation rather than proliferation. Since the EGFR lacks 
the  ability  to  activate  for  example  FRS2-mediated  pathways,  it  may  not  be  able  to 
induce prolonged  Erkl/2  activation nor other pathways that are required  for sustained 
neurite outgrowth (refer to Figures 3.9 and 3.10). Thus indeed the presence of different 
binding  sites  is  important  for  regulation  of  protein  recruitment  and  activation 
downstream of different RTKs.
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Figure 3.10:  Diagrammatic representation of the signalling complexes assembled around each RTK 
and the changes they undergo with  prolonged  receptor activation The role of She (light blue), Grb2 
(yellow), Sos (green), FRS2 (grey), Ras (red), Rapl (pink) in EGFR, TrkA and FGFR signalling based on 
the results presented in this chapter and previous studies is represented diagrammatically. Other proteins 
that  are  also  recruited  to  these  receptors  and  play  a  role  in  generation  of specific  signals  have  been 
omitted for simplicity.
(A) Transient activation of the EGFR leads to recruitment of the Grb2/Sos complex directly and indirectly 
via She, FRS2 is not involved in Grb2 recruitment to this receptor. Recruitment of Sos leads to activation 
of Erkl/2 via Ras. Prolonged exposure to EGF results in EGFR signal downregulation by dissociation of 
the  Grb2/Sos  complex  from  the  EGFR  and  She,  as  well  as  dissociation  of Sos  from  Grb2  and  the 
Shc/Grb2 complex. This would prevent sustained activation of Erkl/2 [233].
(B) The Grb2/Sos complex is recruited to TrkA via She and FRS2  following transient activation of this 
receptor.  Following prolonged TrkA activation by NGF results  in pronounced dissociation of Sos from 
Grb2  as  well  as dissociation  of the  FRS2/Grb2  and  Shc/Grb2  complexes.  Prolonged  Erkl/2  activation 
must therefore be achieved via activation of Rapl via recruitment of Crk and C3G to FRS2 [67].
(C) Transient activation of the  FGFR leads primarily to recruitment of the Grb2/Sos complex to FRS2. 
She  may  play  a  minor role  in  Grb2/Sos  recruitment,  and  is  itself recruited to the  FGFR  via unknown 
mechanisms  such  as  interaction  with  one  or  more  unidentified  proteins  (as  indicated  by  the  question 
mark).  Prolonged exposure to  FGF does not result in downregulation of the Grb2/Sos/Ras pathway  as 
seen following prolonged NGF stimulation, but the FRS2/Grb2/Sos and Shc/Grb2/Sos complexes persist 
and would be expected to be able to induce prolonged Erkl/2 activation via Ras [17].
124Chapter 3
Moreover, it was interesting to note that activation of the FGFR leads to the formation 
of yet a different protein complex  compared to  TrkA.  The  constitutive  association of 
FRS2 with the FGFR1  means that it is highly phosphorylated upon stimulation of this 
receptor.  The  phosphorylation  is  prolonged,  compared  with  the  transient  FRS2 
phosphorylation following NGF stimulation. On the basis of both NGF and FGF leading 
to prolonged Erkl/2 activation, it could have been proposed that activation of the FGFR 
and TrkA leads to formation of similar complexes. However, the FRS2 binding site on 
the FGFR is unable to bind She since it does not contain a consensus NPXY motif [4]. 
This means that the assembly of protein complexes may be affected differently by the 
presence  of different  interaction  sites.  Indeed,  although the  interaction  between  Grb2 
and  FRS2  was  also  somewhat  downregulated  by  60  minutes  of FGF  stimulation,  the 
FRS2/Grb2/Sos  complex  persisted  for  longer  periods  of  time  than  following  NGF 
stimulation (Figure 3.5).  This observation indicates the possibility that,  in response to 
FGFR stimulation, the prolonged existence and/or recruitment of the Grb2/Sos complex 
to the membrane is important for sustained Erkl/2 activation. Crk can bind to the FGFR 
directly  [122], and could therefore lead to recruitment of C3G and activation of Rapl. 
Nonetheless,  the  data  presented  in  this  work  clearly  indicate  a  role  of  the 
FRS2/Grb2/Sos  complex  in  prolonged  Erkl/2  activation  in  response  to  FGF2 
stimulation.  The hypothesis that differences in the formation of the Grb2/Sos complex 
and  prolonged  interaction  with  FRS2  is  largely  responsible  for the  prolonged  Erkl/2 
activation in response to FGF stimulation was further supported by both Sos and FRS2 
being  less  serine/threonine  phosphorylated  than  following  EGF  or  NGF  stimulation 
(Figures  3.3  and  3.4).  This  is  indicative  of a  lesser  degree  of downregulation  of this 
pathway  following  FGFR  activation,  which  contributes  to  the  prolonged 
phosphorylation  of the  Erkl/2  pathway.  Hence  the  presence  or  absence  of  specific 
binding  sites  for  FRS2  on  the  various  receptors  is  an  important  regulator  of  the 
assembly  of very precise  yet different  multiprotein  complexes as  well  as the  ultimate 
downstream signal initiated.
In addition to the differences in FRS2 recruitment to and involvement in signalling from 
the different receptors, She was also found to be differentially involved downstream of 
all three receptors (refer to Figure 3.10 for diagrammatic representation).  She can bind 
the EGFR via both its PTB and its SH2 domain, whereas it interacts with TrkA via the 
PTB domain only [49, 50, 69,  184]. Direct association between the FGFR and She has 
not been reported to date, although co-precipitation of She with the FGFR3 and FGFR1
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has been shown [105,  106].  However, She can be phosphorylated in response to EGF 
and FGF even in the absence of any phosphorylation sites on their receptors  [51,  103], 
which indicates that interaction with the receptor is not required for phosphorylation and 
therefore its involvement in signalling pathways. This means that regulation of the way 
in  which  She  is  involved  in  signalling  from  a  certain  RTK  has  to  be  achieved  in  a 
different way than simply by availability of binding sites on a receptor.  If She can be 
phosphorylated  in  the  absence  of  binding  to  a  receptor  directly  (i.e.  membrane 
recruitment is sufficient for it to be phosphorylated as long as a receptor tyrosine kinase 
is active), theoretically all three receptors should be able to phosphorylate She equally. 
It is therefore remarkable to note that clear differences in She phosphorylation by each 
receptor existed (Figure  3.5).  Whereas  She was strongly phosphorylated  on both sites 
(Y239/Y240 and Y317) in response to EGF stimulation, both NGF and FGF stimulation 
only  caused  mild  phosphorylation  (with  that  induced  by  NGF  being  somewhat 
stronger). This observation portrays the differences in the relative involvement of She in 
Grb2 recruitment in response to the different growth factors.  It is not clear how these 
differences are achieved and certainly the availability of binding sites on the receptors 
enhances  She  phosphorylation (i.e.  it can bind to the EGFR,  but has to  compete with 
FRS2  for the binding site on TrkA and most likely does not interact with the FGFR). 
Nonetheless other factors such as varied access to the vicinity of the receptor kinase due 
to  assembly  of different  signalling  complexes  or  different  abilities  of the  individual 
kinases to phosphorylate the tyrosine residues on She might also play an important role 
in differential She phosphorylation and subsequent involvement in signal transduction.
33.2.3  Temporal regulation of the formation and dissociation of different 
complexes by the EGFR, FGFR and TrkA
The  finding  that  FGFR  signalling  seems  to  lead  to  sustained  Erkl/2  activation  by 
prolonged  Ras  activation  via  Grb2/Sos  recruitment  is  interesting  in  light  of  recent 
studies  highlighting  the  ‘switch’  from  Ras  to  Rapl  signalling  in  transient  versus 
sustained Erkl/2 activation following NGF stimulation [67, 228]. In these studies it was 
proposed that both transient activation of Ras and Rapl  was similar in response to EGF 
or NGF stimulation, but that prolonged Erkl/2 activation in response to NGF occurred 
primarily  via  the  activation  of  Rapl  via  C3G  instead  of  Ras  activation  via  Sos. 
Recruitment of C3G via Crk was shown to be mediated via FRS2  [67].  Although the 
data  presented  in  this  chapter  indicate  that  different  mechanisms  lead  to  prolonged 
Erkl/2 activation in response to FGF stimulation, further investigation of the activation
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of Ras and Rapl  in response to this growth factor would be required.  It would be very 
interesting, if differences in the way in which NGF and FGF lead to prolonged Erkl/2 
activation would be confirmed. Differences in how these two growth factors achieve the 
same cellular outcome  indicate that  intrinsic  differences  in  signalling  pathways  occur 
and  that  even  the  same  cellular  outcome  (i.e.  sustained  Erkl/2  activation)  can  be 
achieved via different mechanisms. Based on the results presented in this study, it seems 
possible  that  the  FGFR  leads  to  prolonged  phosphorylation  of  Erkl/2  purely  by 
activation of Ras,  since the  FRS2/Grb2/Sos complex existed  for prolonged periods of 
FGF  stimulation.  However,  since  Crk  has  been  shown  to  associate  with  the  FGFR 
directly  [122],  the  possibility  that  Rapl  is  activated  in  addition  to  prolonged  Ras 
activation via FRS2/Grb2/Sos cannot be excluded.  Since slight differences exist in the 
stability of neurites induced by FGF and NGF [241], it would be particularly interesting 
to investigate whether these are the result of differences in signalling complexes formed 
upon NGF or FGF stimulation, which lead to differences in Ras and Rapl  activation as 
well as variations in activation of secondary signalling pathways.
33.2.4  Importance of complex formation in the activation of diverse secondary 
pathways
In addition to leading to differences in Erkl/2 activation, the importance of assembling 
different protein complexes downstream of various receptors  lies  in the  fact that they 
may  differentially  activate  signalling  pathways  other  than  Erkl/2.  The  activation  of 
other,  secondary pathways  from  different  signalling complexes  is required to  activate 
those  cellular  responses  that  are  not  shared  between  different  RTKs.  Differential 
involvement of She and FRS2 is not only important in activation of the Erkl/2 pathway. 
Their  presence  in  different  signalling  complexes  in  response  to  EGF,  NGF  or  FGF 
stimulation is also a key regulator of the activation of secondary pathways, which may 
be important in regulation of the overall cellular response.
For example, recruitment of Gabl  to the FRS2/Grb2 complex is an important regulator 
of activation  of the  PI3K  pathway.  This  means  that  depending  on the  level  of FRS2 
phosphorylation  and the type  of complex  it forms  with other proteins  downstream  of 
different receptors numerous convergent as well as diverse signalling pathways can be 
activated.  The  assembly  of protein  complexes  is  important  in  this  process,  because 
linear pathways would not be able to result in such fine-tuned differences.
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In addition to different pathways activated by the differential recruitment of FRS2, She 
may also be  involved in the activation of secondary pathways beyond Erkl/2.  Recent 
studies have implicated She with roles other than Grb2 recruitment. This property may 
be  important  when  considering  the  role  of  She  in  TrkA  and  FGFR  signalling. 
Downstream  of these  receptors  it  may  play  a  minor  role  in  Erkl/2  activation  when 
compared  to  EGFR  signalling  but  may  be  important  in  assembly  of  a  signalling 
complex  that  activates  secondary  pathways  important  for  differentiation.  The 
differential  phosphorylation  of the  two  major  sites  on  She  may  be  important  for this 
process.  Phosphorylation  of  the  Y239/Y240  site  was  more  stimulation-dependent 
downstream of TrkA and the FGFR than Y317, although Y317 has been reported to be 
the  main  Grb2  binding  site  [198].  Since  NGF  and  FGF  both  do  not  cause  a  great 
increase in phosphorylation of the Y317 site, this may indicate differences in She roles 
compared to  EGF  stimulation,  which causes both sites to be  strongly phosphorylated. 
The  importance  of the  various  sites  in  terms  of Erkl/2  activation  and  recruitment  of 
proteins  such  as  Grb2  to  the  activated  receptors  would  have  to  be  investigated 
separately to  quantitatively  assess the  different  contribution they  may  make to  signal 
transduction downstream of the different receptors.
3.3.3  Intrinsic differences in RTK signalling versus cell-specific 
interpretation of the same general signal
This  work  has  shown  that  both  quantitative  (different  duration  of  activation)  and 
qualitative  (different  protein  recruitment  patterns  and  complex  formation)  traits  are 
intrinsic properties to each receptor system analysed. Generally such intrinsic diversity 
forms the  basis  for the  precise regulation required to  achieve  signalling  specificity  in 
response to different growth factors. Disturbance of these intrinsic properties may result 
in the wrong downstream response, as demonstrated by the Apert syndrome mutations 
in  the  FGFR2.  The  observation  that  both  the  duration  and  strength  of  Erkl/2 
phosphorylation  are  essential  for  generating  the  correct  cellular  signal  (namely 
differentiation  instead  of  proliferation)  indicates  that  the  signal  initiated  by  each 
receptor is not  simply a  ‘go’  signal  that  is  interpreted differently by cells of different 
origin (as proposed  Simon  in  [252]).  It  is  important for the regulation of downstream 
responses  such  as  differentiation,  which  receptor  activates  the  signal  (in  this  case 
Erkl/2).  Although  each  receptor  can  activate  similar  pathways,  assembly  of unique
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signalling  complexes  allows  the  generation  of  individual  signals  from  different 
receptors.
The  model  in  which  basically  all  RTKs  just  provide  a  single  signal  that  activates 
specific  responses  has  been  supported  by  findings  that  the  PDGFR  and  FGFR  both 
induce  transcription  of  very  similar  early  genes  in  NIH  3T3  cells  [253].  Such  a 
mechanism  may  be  important  in  the  context  of the  whole  organism.  Nonethless,  in 
contrast the data presented herein based on the  PC 12  model  system provide evidence 
that  intrinsic  differences  in  signals  from  various  RTKs  are  present.  This  diversity  is 
important  for  precise  cellular  regulation  of  signal  transduction  and  is  mediated  by 
assembly of different complexes downstream of each receptor. Nonetheless, PC 12 cells 
are a tissue culture model system, which may not necessarily represent the events taking 
place inside a whole organism.  Although some intrinsic differences  in signalling from 
various  RTKs  exist,  the  alteration  of  receptor  and  ligand  expression  levels  during 
development of an organism may also play a very important role in signal regulation. In 
the organismal context, the availability of ligand may also play a great role in regulation 
of specific  signals.  In such a context where receptor and  ligand expression are tightly 
regulated, the different receptors may indeed primarily create a ‘go’  or ‘on’  signal  for 
mainly the same signalling pathways  [252].  In the cell culture model, such differences 
are difficult to control and may therefore be overlooked in terms of their importance in 
regulation of signal specificity. Nonetheless, the results presented highlight the fact that 
precise  regulation of downstream  signalling pathways can be achieved  by  assembling 
precise, unique multiprotein complexes downstream of different RTKs.
In  conclusion,  the  data  presented  in  this  chapter  provided  further  evidence  for  the 
existence  of  intrinsic  differences  in  RTK  signalling  and  the  regulation  of these  by 
recruitment  of the  same  proteins  into  different  protein  complexes.  The  formation  of 
specific complexes is important for the regulation of downstream signalling pathways. 
However,  it  was  also  shown  that  tight  control  of the  ‘normal'  signalling  pathways  is 
required,  because changes in the duration and strength/magnitude (as observed  for the 
Apert syndrome mutant FGFR2s) of the signal initiated can affect the cellular responses 
to  receptor  stimulation.  Thus  altogether,  the  highly  fine-tuned  differences  in  protein 
recruitment downstream of various RTKs provides a means to initiate  specific  signals 
without the  need to  utilise  a completely  different  set of proteins downstream of each 
receptor.
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Chapter 4
Effects of the Apert syndrome 
mutations on the FGFR2
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4.1  Introduction
To  date  the  majority  of  studies  regarding  intracellular  signal  transduction  from  the 
fibroblast growth factor receptor (FGFR) have been carried out using the FGFR1  as a 
model  system.  Implications  that  FGFR2,  3  and  4  initiate  similar  signalling  pathways 
have been made, although differences have been shown to exist between the different 
FGFR  subfamilies  [100-102,  254].  In  addition,  all  families  of this  receptor  subclass 
show very different tissue expression, which indicates the physiological necessity to be 
able  to  initiate  similar  yet  distinct  signalling  pathways  in  various  tissues  at  different 
times.  Although  some  studies  have  indicated  subtle  differences  between  the  various 
FGFR isoforms, no detailed investigations of the FGFR2 and the intracellular signalling 
pathways initiated from it have been undertaken to date.
More importantly, in addition to a lack of in-depth studies of signal transduction from 
the FGFR2, the effects of the Apert syndrome mutations on early intracellular signalling 
from  this  receptor  have  not  been  investigated.  The  effect  of the  two  main  mutations 
(S252W and P253R) on interaction of the extracellular domain of FGFR2 with various 
FGF ligands in vitro and in vivo have been analysed [160,  161,  163]. Additionally, data 
have  been  published  highlighting  the  effects  on  physiologically  relevant  cellular 
outcomes  such  as  differentiation,  apoptosis  and  calcification  of bone  precursor  cell 
lines,  which  have  given  a  certain  level  of  insight  into  the  events  that  lead  to 
manifestation of Apert syndrome [164,  165,  167, 168, 170]. However, depending on the 
level  of  maturation  of  the  osteoblasts  used,  conflicting  results  were  obtained  (as 
described  in  [164]).  Moreover,  these  findings  were  not  able  to  provide  any  detailed 
information on the  effect that the Apert  mutations have on the  FGFR2  itself or early 
signalling  events  emanating  from  it.  Altogether,  this  makes  the  Apert  syndrome 
mutations  an  attractive  model  system  to  investigate  the  effects  that  mutations  in  the 
extracellular  region  of  a  receptor  may  have  on  spatial  and  temporal  regulation  of 
downstream signalling and the recruitment of adaptor proteins to the activated receptor.
In light of the need for studies focussing on the intracellular signalling events from the 
FGFR2  and  mutants thereof,  it was  chosen to  investigate the  effects  of the two  main 
Apert  syndrome  mutations,  S252W  and  P253R,  on  the  FGFR2  itself as  well  as  the 
recruitment  of proteins  to  its  early  signalling  complexes.  The  data  presented  in  this 
chapter highlight the vast number of effects incurred on the FGFR2 by the two Apert
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syndrome  mutations.  The  effects  of  the  Apert  syndrome  mutations  on  receptor 
phosphorylation, glycosylation, and ligand binding were analysed. Altogether the results 
presented  demonstrate  that the  Apert  syndrome  mutations  give  rise  to  more  complex 
effects on the FGFR2 than the previously reported increased ligand binding and altered 
ligand binding specificity. These various effects may act in conjunction to contribute to 
altered intracellular signalling from the FGFR2 and hence may play an important role in 
the manifestation of Apert syndrome.
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4.2  Results
4.2.1  Creation of stable cell lines expressing GFP-tagged wild type, 
S252W or P253R FGFR2
To study the effects of the two main Apert syndrome mutations on FGFR2 signalling, 
HEK 293T cells were transfected with constructs encoding each of the three receptor 
forms tagged with enhanced GFP (WT-FGFR2-GFP, S252W-FGFR2-GFP and P253R- 
FGFR2-GFP, ffom hereon referred to as the wild type, S252W and P253R receptors). 
To investigate the effects of the Apert syndrome mutations on the FGFR2 and signal 
transduction ffom this receptor a cellular model system that is completely unresponsive 
to  FGF  stimulation  would  by  ideal.  Fairly  widely  used  systems  to  study  FGFR 
signalling without any background signalling are the L6 myoblast and BaF3 cell lines, 
which do not express any endogenous FGFRs  [255,  256].  However,  the  difficulty of 
achieving high transfection efficiencies and the possible lack of components of FGFR 
signalling as a result of complete absence of FGFRs made these cells experimentally 
unfavourable  systems.  Instead,  HEK  293T  cells  were  chosen  for  their  ease  of 
transfection and ability to express exogenous proteins to a high level.
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Figure 4.1:  Creation of stable  HEK 293T cell  lines expressing GFP-tagged  wild  type, S252W  and 
P253R  FGFR2  HEK 293T were  stably transfected with each of the three  FGFR2-GFP constructs  and 
individual clones were isolated by dilution cloning. Equal amounts of whole cell lysate were subjected to 
SDS-PAGE  and  immunoblotting with an anti-GFP antibody to probe for similar expression  levels (A). 
Individual clones were analysed by confocal microscopy to assess cellular targeting of the GFP-tagged 
receptor after seeding on glass slides in growth medium and fixation in 4% paraformaldehyde (B).
WT1  SW1  PR1  WT2 SW2 PR2
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To ensure that any differences observed between the three different receptors are solely 
due to the mutation in the  extracellular domain and not different expression  levels  in 
pools  of stable  cells,  individual  clones  expressing  each  respective  receptor  construct 
were  created.  This  was  achieved  by  dilution  cloning  in  96-well  plates  after  initial 
selection of stable  cell  pools.  Several  clones  expressing  each receptor construct were 
isolated  and  preliminary  FGF  stimulation  experiments  confirmed  that  differences 
observed between wild type and mutant receptors were not due to clonal variation. Cell 
lines  expressing  comparable  levels  of each  receptor  were  chosen  for  all  subsequent 
experiments (Figure 4.1 A). Western blotting of two independent sets of lysates with an 
anti-GFP  antibody  (Figure  4.1 A)  and  visual  analysis  by  fluorescent  microscopy 
revealed that the expression levels of all three clonal cell lines were similar.
Confocal  microscopy  was  carried  out to  confirm  that the  GFP-tagged  receptors  were 
targeted  to  the  correct  cellular  compartment,  namely  the  plasma  membrane  (Figure 
4.IB).  The  GFP-tagged  receptors  were  found  to  localise  mainly  at  the  plasma 
membrane, with some presence in the perinuclear region. The latter regions most likely 
represent the endoplasmic  reticulum  and the  Golgi  apparatus  in which the receptor is 
synthesised and which therefore contain a lot of GFP-tagged protein (Figure 4.IB). The 
presence  of  the  receptor  on  the  cell  surface  is  indicative  of  its  posttranslational 
modification being similar to that of the endogenous receptor. Incorrect folding or lack 
of glycosylation would prevent the receptor ffom being targeted to this cellular location 
[257-259].  These  observations  confirm that the  GFP-tag does  not  interfere  with  such 
processes and allows the receptor to be targeted to the correct cellular location.
4.2.2  Lower doses of FGF are required to cause maximal Erk1/2 
activation by the mutant FGFR2
To  date  several  studies  have  indicated  an  increased  affinity  of  the  Apert  mutant 
receptors for FGF ligand  [7,  161].  However, these studies have been carried out using 
the  isolated extracellular domain or parts thereof.  To  assess qualitatively whether this 
increased affinity could be observed in vivo, cells expressing the wild type or either of 
the two Apert mutant receptors were stimulated with increasing concentrations of FGF2 
and  FGF9  and  the  effect  on  the  phosphorylation  of Erkl/2  (a  major target  activated 
downstream  of  the  FGFR)  was  assessed  (Figure  4.2).  An  increased  downstream 
response  following  activation  of  the  mutant  receptors  compared  to  the  wild  type
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receptor could be indicative of the increased receptor affinity for ligand, since it would 
lead  to  engagement  of more  receptors  at  any  given  ligand  concentration  and  hence 
increased  downstream  signalling.  It  has  previously  been  demonstrated  that  increased 
affinity of the mutant receptors for a particular FGF ligand correlates with an enhanced 
mitogenic activity of cells expressing these receptors upon exposure to this ligand [160], 
which means that changes in the magnitude of Erkl/2 activation may be indicative of 
changes in receptor affinity for ligand.
The  wild  type  receptor  only  activated  Erkl/2  in  the  presence  of more  than  5ng/ml 
FGF9, and maximal Erkl/2 activation was achieved in the presence of lOng/ml FGF9 
(Figure 4.2A).  In contrast, the S252W mutant receptor led to almost the same level of 
Erkl/2  stimulation induced by the wild type FGFR2  in the presence of lOng/ml when 
only  0.5ng/ml  FGF9  were  added.  This  finding  correlates  with  previous  reports  of 
increased  affinity  of the  S252W  mutant  FGFR2  for  ligand,  since  significantly  lower 
amounts of ligand were required to  induce the  same  level  of Erkl/2  phosphorylation. 
The enhanced Erkl/2 response to FGF9 stimulation was observed throughout the dose 
response curve, with an increase in FGF9 dose corresponding to an increase in Erkl/2 
phosphorylation. Interestingly, the level of Erkl/2 activation in cells expressing the wild 
type FGFR2 never reached the level of Erkl/2 activation achieved by engagement of the 
mutant receptors, even when significantly more than lOng/ml FGF9 were used (data not 
shown). This indicates that the two mutations must introduce other changes in terms of 
receptor  functionality  and  signal  transduction  that  cannot  be  explained  by  a  simple 
increase in receptor affinity for FGF ligand.
The  P253R  mutant  has  also  been  reported  to  have  a  higher  affinity  for  FGF  ligand. 
However  it  was  difficult  to  compare  the  dose  response  curve  obtained  after  FGF9 
stimulation  with  that  obtained  for  the  wild  type  FGFR2  because  expression  of the 
P253R  receptor  resulted  in  some  Erkl/2  phosphorylation  in  unstimulated  cells.  In 
comparison,  the  other  two  receptors  did  not  cause  any  such  effect  (Figure  4.2).  It  is 
unclear whether this is a result of the increased basal P253R receptor phosphorylation 
(refer to section 4.2.5), but it meant that no direct comparison in terms of activation by 
lower  doses  could  be  made  in  this  case.  When  deducting  the  basal  Erkl/2 
phosphorylation  level,  the  pattern  observed  in  cells  expressing the  P253R  receptor  is 
similar to that of the wild type receptor.
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Figure  4.2:  Effects  of different  FGF  doses  on  Erkl/2  activation  in  cells  expressing  wild  type  or 
Apert  mutant  receptors  HEK  293T  cells  were  serum-starved  overnight  and  stimulated  with  various 
concentrations of FGF9 (A) or FGF2  (B) for ten minutes. 200pg of cell  lysate were subjected to  SDS- 
PAGE  and  immunoblotting with an  anti-phospho-Erkl/2  antibody.  To assess equal  loading,  blots were 
stripped and re-probed with an anti-Erkl/2 antibody. The amounts of phospho-Erkl/2 were assessed by 
densitometry and represented graphically  for each  experiment.  The results shown  are  representative of 
three independent experiments.
Because the activation of the wild type receptor and its ability to activate Erkl/2  are 
quite low, the same experiment was carried out using FGF2 instead of FGF9. A very 
similar trend was observed upon stimulation of cells with FGF2 as with FGF9 (Figure 
4.2B). The higher level of phosphorylation in cells expressing the wildtype receptor is 
likely due to the activation of endogenous FGFRs as well as the over-expressed FGFR2 
or may reflect the increased affinity of the FGFR2  for FGF2  compared to FGF9  [7]. 
Despite  the  higher  level  of  Erkl/2  phosphorylation  following  wild  type  FGFR2 
activation,  both  mutant  receptors  still  portrayed  an  enhanced  level  of  Erkl/2 
phosphorylation at lower doses of FGF2. This is consistent with the increased affinity of 
the Apert mutant receptors for ligand. The effect was more pronounced for the S252W 
receptor  compared  to  the  P253R  receptor,  which  seems  to  indicate  that  the  S252W 
mutation results in a greater affinity increase in binding of the FGFR2 to both FGF2 and 
FGF9.  This  observation  is  also  in  agreement  with  previously  published  affinity
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measurements  made  in  vitro  [7].  Overall,  the  results  obtained  for  the  qualitative 
assessment of receptor affinity, in terms of activation of a major downstream signaling 
pathways  of the  FGFR2,  are  in  agreement  with  the  previously  described  increased 
affinity of the FGFR2 for ligand in the presence of either of the Apert mutations.
4.2.3  Changes in heparan sulphate dependency in the presence of 
the Apert syndrome mutations
Glycosaminoglycans (GAGs) are cell  surface molecules  such as heparan  sulphate and 
chondroitin  sulphate  that  act  as  co-receptors  for  FGF  and  are  required  for  FGFR 
activation and signalling [86, 260]. Different hypotheses exist about the exact mode of 
binding,  but  it  has  been  shown  that  this  auxiliary  molecule  interacts  with  both  the 
receptor and the ligand and thereby facilitates binding and subsequent activation of the 
receptor (reviewed in [87, 260]).
As described, the Apert syndrome mutations affect the interaction between the FGFR2 
and FGF ligand.  Since a complex between FGF, GAGs and the FGFR is required for 
efficient activation of the receptor,  it was  of interest to  investigate whether the  Apert 
syndrome mutations also affect the  interaction of the  FGFR2 with GAGs.  Changes  in 
this interaction would have further effects on activation of the mutant FGFR2 and might 
contribute to the development of the Apert phenotype.  It was proposed that the Apert 
mutations might not only affect affinity of the receptor for FGF but also its dependency 
on GAGs for activation. An investigation of the requirement for heparan sulphate (HS) 
for  activation  of  the  Erkl/2  pathway  by  the  wild  type  and  the  two  Apert  mutant 
receptors was undertaken. The stimulation of Erkl/2 by FGF2 was not dependent on the 
presence of HS and the amount of phosphorylated Erkl/2 changed little over the range 
of doses of HS from Opg/ml to 5pg/ml (Figure 4.3 A). This is likely due to the presence 
of high levels of HSPG on the cell surface or in the cell medium  [261], which may be 
sufficient  to  allow  interaction  of  FGF2  with  either  endogenous  FGFRs  or  the 
exogenously expressed WT-FGFR2-GFP. Since FGF2 is not specific for the FGFR2, it 
is likely that the high level of Erkl/2 activation observed is also, at least partially, due to 
binding of FGF2 to and subsequent activation of other FGFRs expressed in HEK 293T 
cells.
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Interestingly the stimulation of WT-FGFR2-GFP by FGF9 was strongly dependent on 
HS being present.  Without HS, Erkl/2 was minimally phosphorylated, and only in the 
presence of 0.5-1 pg/ml HS was FGF9 able to invoke Erkl/2 activation. This stands in 
contrast to the activation by FGF2. This observation may be explained by the fact that 
the amount of HSPG normally present on the cell surface is not great enough to allow 
sufficient FGF9 to complex with the exogenously expressed WT FGFR2, or that FGF9 
has a greater requirement for HS to allow efficient complex formation with the receptor. 
FGF9 has a slightly lower affinity for FGFR2 than FGF2  [7], which may also explain 
the greater requirement for HS to facilitate FGF9:FGFR2 complex formation.
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Figure 4.3:  The  role of heparan  sulphate  in  Erkl/2  activation  HEK 293T cells expressing the wild 
type FGFR2 were serum-starved overnight and stimulated with lOng/ml FGF2 or FGF9 for ten minutes in 
the  presence  of  various  amounts  of  heparan  sulphate  (HS)  as  indicated.  200pg  of cell  lysate  were 
subjected  to  SDS-PAGE  and  immunoblotting with  an  anti-phospho-Erkl/2  antibody  and  an  anti-Grb2 
antibody  to  assess  equal  loading  (A).  HEK  293T  cells  expressing  the  wild  type,  S252W  or  P253R 
receptors were exposed to FGF9 (ten minutes), HS (five minutes) or HS followed by FGF9 (five minutes 
followed by ten minutes). The amount of phospho-Erkl/2 present was assessed by western blotting (B). 
An anti-Grb2 antibody was used to show equal loading.
To investigate whether HS was also required for Erkl/2 activation following stimulation 
of the Apert mutant receptors with FGF9,  all three  HEK 293T clonal  cell  lines were 
exposed  to  FGF9  in  the  absence  or  presence  of additional  heparan  sulphate  (Figure 
4.3B).  Interestingly,  the  activation  of S252W  and  P253R  FGFR2  by  FGF9  was  not 
dependent on the presence of additional HS (Figure 4.3B:  S252W and P253R,  lane 2
138Chapter 4
versus  lane  4).  The  level  of Erkl/2  phosphorylation  achieved  in  the  presence  of HS 
(Figure 4.3B  lane 4  S252W and P253R) was comparable to the levels achieved when 
only FGF9 was used to stimulate the cells (Figure 4.3B lane 2 S252W and P253R). This 
is in contrast to the wild type receptor, which required addition of HS before significant 
Erkl/2 phosphorylation could be detected. Thus the Apert mutations not only result in 
increased affinity for FGF, but also affect the dependency of the FGFR2 on HS for its 
activation.
4.2.4  Changes in receptor glycosylation as a result of Apert 
syndrome mutations
One  effect  of the  Apert  syndrome  mutations  on  the  FGFR2  itself became  obvious 
during  routine  western  blot  analysis  of the  receptor.  All  three  variants  of the  GFP- 
tagged FGFR2 appeared as three bands when whole cell lysates ffom HEK 293T cells 
were subjected to  SDS-PAGE (Figure 4.1 A).  The uppermost bands of the  S252W and 
P253R receptors portrayed slightly reduced electrophoretic mobility, whereas the other 
two bands appeared to be of the same relative molecular weight as the equivalent bands 
of the wild type receptor.  Interestingly, the two bands of lower molecular weight were 
less  apparent  in  the  case  of  the  Apert  mutant  receptors,  particularly  the  FGFR2 
containing  the  S252W  mutation.  A  similar  trend  was  also  observed  in  PC 12  cells, 
although the two lower bands were not always apparent (refer to Figure 3.7A). Various 
RTKs run as smears or several bands on SDS-PAGE gels, as a result of the presence of 
differentially glycosylated forms [262, 263]. In addition to FGFR selectivity for specific 
FGFs and glycosaminoglycans as well as the assembly of FGFRiligand complexes with 
different  signalling  potential,  N-glycosylation  of the  FGFR  has  been  proposed  as  an 
additional regulatory factor of FGFR signaling [162]. Changes in receptor glycosylation 
in the presence of the Apert mutations may therefore be an important factor resulting in 
alterations in signal transduction ffom the mutant receptors. To investigate whether the 
altered electrophoretic mobility of the S252W and P253R receptors was due to changes 
in N-glycosylation, cells were grown in the presence of tunicamycin (an antibiotic that 
acts as a specific inhibitor of N-glycosylation).  This revealed that indeed the lowest of 
the three bands corresponds to the unglycosylated form of the receptor (Figure 4.4A), 
which  identifies  the  middle  band  as  an  intermediately  glycosylated  form  (under­
glycosylated) and the highest band as the fully glycosylated receptor. It also confirmed
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that the differences observed between the wild type and mutant receptors were due to 
additional glycosylation.
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Figure 4.4:  Altered  receptor glycosylation  in  the  presence of the  Apert syndrome  mutations HEK
293T cells were  incubated  with 3  or  lOpg/ml tunicamycin overnight.  200pg of whole  cell  lysate  were 
subjected to immunoblotting with an anti-GFP antibody to assess changes in electrophoretic mobility of 
the receptors (A). Cells grown in the presence of lOpg/ml tunicamycin overnight were also assessed by 
confocal  microscopy  for  the  changes  in  cellular  distribution  in  the  absence  of the  glycosylation  after 
overnight treatment with lOpg/m tunicamycin and fixation in 4% paraformaldehyde (B).
Confocal microscopy of cells treated with tunicamycin revealed that the unglycosylated 
receptor  did  not  localise  to  the  plasma  membrane  and  was  instead  located  diffusely 
throughout  the  cytoplasm  (Figure  4.4B).  It  has  been  shown previously  that only  the 
fully glycosylated form of the FGFR is localised at the plasma membrane [262, 263].
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Accordingly,  only the  fully and perhaps the  under-glycosylated  forms of the  receptor 
are  targeted  to  the  correct  cellular  localisation.  The  unglycosylated  FGFR2  is  most 
likely the form found in the ER/Golgi in growing cells. In the presence of tunicamycin, 
not all  receptor can be contained within these cellular compartments but  seems to  be 
released into the cytoplasm to result in the diffuse localisation observed (Figure 4.4B).
Although  these  findings  confirmed  that  the  reason  for  the  retarded  electrophoretic 
mobility of the S252W and P253R receptors is due to additional  glycosylation,  it was 
beyond the scope of this investigation to determine what the exact change was. It could 
either be a changed glycosylation at a normally glycosylated site, or could result ffom 
use of an additional, normally unglycosylated site.  It is also interesting to note that the 
S252W receptor repeatedly showed the greater shift in molecular weight than the P253R 
receptor.  This indicates that differences in glycosylation may even be present between 
the two  mutant receptors.  It  would  be  of interest to  elucidate whether this  difference 
plays  a  role  in  the  divergent  effects  of  the  two  mutations  on  specific  phenotypic 
outcomes such as syndactyly and cleft palate formation [264].
4.2.5  All three receptors can be phosphorylated and portray 
differences in phosphorylation pattern
Having  observed  the  alterations  in  ligand  binding  and  glycosylation  of the  FGFR2 
introduced  by  the  Apert  syndrome  mutations  it  was  chosen  to  investigate  the  effect 
these properties have on receptor dimerisation, activation and autophosphorylation. The 
stably expressed wild type and mutant  receptors were  immunoprecipitated  ffom  HEK 
293T cell  lysates before and after stimulation with FGF9 using an anti-GFP antibody 
(Figure  4.5).  All  three  receptors  were  able  to  undergo  dimerisation  and  trans- 
autophosphorylation,  as  indicated  by  the  increased  receptor  phosphorylation  upon 
exposure  to  FGF9  (Figure  4.5B).  Since the  GFP-tag  was  present  on  all  receptors  the 
differences  observed  were  not  due  to  addition  of the  tag  but  must  represent  intrinsic 
differences in the receptors due to the presence of the Apert syndrome mutations. The 
ability  of all  three  receptors  to  undergo  autophosphorylation  upon  addition  of ligand 
indicates that the GFP-tag does not interfere with receptor functionality.
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Figure  4.5:  Phosphorylation  of GFP-tagged  wild  type  and  mutant  receptors  (A)  HEK  293T  cells 
expressing the three respective receptors were serum starved overnight,  stimulated with  lOng/ml FGF9 
and  lysed.  2mg of cell  lysate  were  subjected  to  immunoprecipitation  with  an  anti-GFP  antibody.  The 
western blot was probed with an anti-phosphotyrosine antibody, stripped and re-probed with an anti-GFP 
antibody.  The  levels  of receptor  phosphorylation  were  quantified  using  densitometry  and  represented 
graphically  (B)  or  as  a  percentage  increase  from  each  respective  ‘Basal’  level  (C).  The  results  are 
representative of two independent experiments.
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Interestingly,  it  was  evident that  both the  wild type  and the  P253R mutant  receptors 
were  highly  phosphorylated  in  the  serum-starved,  unstimulated  state,  whereas  the 
S252W receptor displayed  a  lower basal  level  of phosphorylation.  Upon  exposure to 
FGF9  all  receptors  showed an increase  in phosphorylation (represented  graphically in 
Figure  4.5B  and  as  percentage  increase  ffom  basal  in  Figure  4.5C).  Even  though  in 
S252W cells the total  level of phosphorylation was lower than in wild type or P253R 
cells, the increase ffom basal upon stimulation was found to be the greatest amongst all 
three  cell  lines  (Figure  4.5C).  In  contrast,  whereas  the  P253R  FGFR2  showed  the 
greatest overall phosphorylation level, its increase in response to FGF9 stimulation was 
small and comparable to that of the wild type receptor. The basal phosphorylation of the 
wild type receptor is exclusively due to phosphorylation of tyrosine residues located in 
the  C-terminal  region  of the  FGFR2  that  is  not  conserved  between  members  of the 
FGFR family (Z. Ahmed, unpublished results). This indicates that it is not likely to be a 
result  of receptor  activation  by  FGFs  expressed  in  HEK  293T  cells  but  an  intrinsic 
difference  of  this  receptor  compared  to,  for  example,  the  FGFR1.  Similar  ligand- 
independent  wild  type  FGFR2  phosphorylation  was  reported  by  Hatch  et  al.  [263]. 
Altogether,  it  was  interesting  to  note  that  the  level  and  pattern  of overall  tyrosine 
phosphorylation of the  wild type  and  the  P253R mutant  receptors  were  very  similar, 
which  indicates that changes  in receptor phosphorylation are not necessarily the only 
cellular basis for the cause of Apert syndrome, because the two mutant receptors portray 
different  phosphorylation  patterns  yet  ultimately  result  in  very  similar  disease 
phenotypes.
It was further interesting to note that the basal phosphorylation of the wild type receptor 
was  mostly  found on the  un-  and  under-glycosylated  forms of the receptors,  whereas 
ligand stimulation resulted in phosphorylation of the fully glycosylated form (top band) 
(Figure 4.5A:  lanes  1-3). In case of the P253R receptor both the fully glycosylated and 
the under-glycosylated forms were phosphorylated in unstimulated and stimulated cells 
(Figure 4.5:  lanes 4-6).  In contrast,  ligand  stimulation of the  S252W receptor resulted 
mostly in phosphorylation of the  fully  glycosylated  form  (Figure 4.5:  lanes  7-9).  The 
unglycosylated form of the receptor is not found at the plasma membrane (Figure 4.4B), 
and its phosphorylation may be due to increased dimerisation as a result of the lack of 
glycosylation [263]. Primarily the fully glycosylated FGFR1 was found to be targeted to 
the plasma membrane in BaF3 cells [262], but it is not clear whether the intermediately 
glycosylated  FGFR2  is  located  at  the  plasma  membrane  in  HEK  293T  cells  or  not.
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Since phosphorylation of this form of the FGFR2 did not significantly change following 
FGF9  stimulation  and  is therefore  likely to  only  consist of phosphorylation of the  C- 
terminal residues described, it may not contribute largely to signal transduction ffom the 
FGFR2.  Altogether,  the  data  presented  indicate  that  the  changes  in  receptor 
glycosylation  may  affect  the  receptor  phosphorylation  patterns.  Such  changes  would 
then be expected to result in altered intracellular signalling downstream of the mutant 
receptors compared to the wild type FGFR2.
4.2.6  The unglycosylated FGFR2 can still be phosphorylated but 
does not activate Erk1/2
After having observed the differences in phosphorylation of the differently glycosylated 
forms of the receptor, the question arose of whether this effect was due to the mutations 
alone or whether they were the result of the additional glycosylation of the S252W and 
P253R receptors. To address this question, cells expressing each of the receptors were 
incubated with tunicamycin and the phosphorylation pattern of receptors was assessed 
by  immunoblotting  with  an  anti-phosphotyrosine  antibody.  The  unglycosylated 
receptors could still be phosphorylated, but differences between the three receptor types 
were observed. Hatch et al.  recently reported that the unglycosylated FGFR2 was more 
strongly  phosphorylated  in  the  absence  of ligand than the  fully  glycosylated  receptor 
[263]. This effect was mirrored by the wild type FGFR2-GFP expressed in HEK 293T 
cells  in  this  study  (Figure  4.6),  which  may  explain  the  high  level  of  basal 
phosphorylation observed (Figure 4.5A). In contrast, both of the unglycosylated mutant 
receptors were not phosphorylated as strongly as the unglycosylated wild type receptor. 
The P253R mutant portrayed a similar level of phosphorylation in its fully glycosylated 
and  the  unglycosylated  state.  The  S252W  mutant  receptor  seemed  to  be  less 
phosphorylated in tunicamycin-treated than in untreated cells. This is in agreement with 
the low basal phosphorylation of this receptor and the fact that the S252W receptor was 
only found to be phosphorylated in its fully glycosylated state as described previously 
(Figure  4.5A).  The  under-glycosylated  receptor  was  strongly  phosphorylated  to 
comparable  levels  in  all  three  cell  lines  and  was  still  detected  in tunicamycin treated 
cells  by  the  anti-phosphotyrosine  antibody  (middle  band  as  indicated).  However,  it 
could  not  be  detected  using  the  anti-GFP-antibody.  This  indicates  that  only  a  small 
amount  of  the  under-glycosylated  receptor  is  present,  which  is,  however,  highly 
phosphorylated.  The  level  of phosphorylation  of this  form  of the  receptor  decreased
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upon tunicamycin treatment in accordance with the decrease in its amount present as a 
result of the inhibition of N-glycosylation.
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Figure  4.6:  Lack  of  FGFR2  glycosylation  inhibits  Erkl/2  activation  but  not  receptor 
phosphorylation  HEK 293T  expressing  the  wild  type,  S252W  or  P253R  FGFR2  were  treated  with 
lOpg/ml tunicamycin for 24 hours or left untreated, serum-starved overnight and stimulated with lOng/ml 
FGF9. Cells were lysed and 200pg cell lysate were subjected to SDS-PAGE and immunoblotting with an 
anti-phosphotyrosine  and  anti-phospho-Erkl/2  antibody.  The  western  blot  was  stripped  and  re-probed 
with  anti-GFP  and  anti-Erkl/2  antibodies  to  assess  receptor  expression  levels  and  equal  loading 
respectively.
An increase in FGFR2 dimerisation and tyrosine phosphorylation in the absence of N- 
glycosylation has been described previously [263]. It seems that the Apert mutations not 
only  affect  the  receptor  glycosylation,  but  also  affect  this  ligand-independent 
dimerisation in the absence of N-glycosylation described by Hatch et al.  [263]. Neither 
the  S252W  nor  the  P253R  receptors  were  as  strongly  phosphorylated  in  the 
unglycosylated state as the wild type receptor (Figure 4.6). However, this effect seems 
to be reversed in the presence of the additional glycosylation in the fully glycosylated 
receptor,  since  this  form  was  more  strongly  phosphorylated  in  the  Apert  mutant 
receptors compared to the wild type FGFR2 (Figure 4.5).
The unglycosylated wild type FGFR2 has been reported to portray increased association 
with PLCy and FRS2  [263]. In light of this finding as well as the observation that the 
unglycosylated  receptors  were  differentially  phosphorylated,  their  ability  to  activate 
Erkl/2  in  the  absence  and  presence  of FGF9  was  analysed.  Whereas  the  untreated 
receptors  portrayed  a  stimulation-dependent  increase  in  Erkl/2  phosphorylation,  this 
was  absent  in  the  tunicamycin-treated  cells,  which  is  in  agreement  with  the  lack  of
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membrane localisation of the unglycosylated receptors (Figure 4.4). This lack of Erkl/2 
phosphorylation is interesting in light of the increased association of PLCy and FRS2 
with the unglycosylated receptor described previously  [263].  The  association of these 
proteins with the receptor does not seem to cause functional activation of downstream 
signalling  pathways  in  either  cell  line  investigated  in  this  study.  The  residues 
phosphorylated  on  the  unglycosylated  FGFR2  may  be  the  same  ones  that  are  also 
phosphorylated in serum-starved, unstimulated cells (Figure 4.2) and are not sufficient 
to cause Erkl/2 activation. Further analysis would be required to investigate the effects 
of the mutations and changes in glycosylation on phosphorylation of these residues and 
their importance in FGFR2 signal transduction.
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4.3 Discussion
The  work  presented  in  this  chapter  demonstrates  the  vast  number  of effects  that  the 
Apert syndrome mutations have on various properties of the FGFR2 such as activation 
by FGF and heparan sulphate, receptor phosphorylation and glycosylation. All of these 
properties  are  important  in  regulating  receptor  activation  and  function,  and  their 
disruption as a result of a single point mutation (S252W or P253R) may form the basis 
of the manifestation of Apert syndrome.
4.3.1  Effects of the Apert syndrome mutations on activation of the 
FGFR2 by FGF ligand
It has been reported previously that the Apert syndrome mutations in FGFR2 result in 
increased affinity for FGF ligand [7, 161]. The data presented in Figure 4.2 indicate that 
the effect observed in vitro is partially mirrored in vivo. The S252W mutation causes a 
greater affinity increase than the P253R receptor in vitro, an effect that was mirrored by 
an increase in the level of activation of Erkl/2 in vivo. The S252W receptor was able to 
induce stronger Erkl/2  phosphorylation at  lower doses of both FGF9 and FGF2.  This 
seems to be in agreement with the relative affinity for these ligands, since the higher the 
affinity the more receptor:ligand complexes can be formed even at relatively low ligand 
concentrations. The increased number of active receptors would then result in increased 
activation of the Erkl/2 pathway downstream of the FGFR2. However, the addition of 
excess amounts of FGF9 to cells expressing the wild type FGFR2 was not able to result 
in the same level of Erkl/2 phosphorylation that could be reached upon stimulation of 
the  S252W or P253R receptors.  This  indicates that the  increased  activation of Erkl/2 
downstream  of the  mutant  receptors  is  not  simply  due  to  an  increased  affinity  of the 
receptors for ligand,  but that additional  changes  in the receptor and  signalling from  it 
also contribute to the greatly enhanced activation of this downstream kinase observed.
The main study of the effects of the Apert mutations on FGFR2 affinity for various FGF 
ligands has  been undertaken  using only  part  of the  extracellular domain  expressed  in 
bacteria.  The  lack  of the  first  Ig-like  domain  (Dl),  glycosylation  and  the  absence  of 
GAGs means that this system lacks many of the factors that are important in regulating 
ligand binding. The comparison of the interaction of the wild type and mutant FGFR2 
with ligand using only parts of the extracellular domain expressed in bacteria means that 
both glycosylation and the requirement for GAGs were not taken into account [7,  163].
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Nonetheless,  the  results  presented  in  this  chapter  indicate  that  the  general  trend  of 
increased affinity for FGF  ligand  seems to be mirrored by the activation of Erkl/2  at 
lower  doses  and  generally  enhanced  Erkl/2  phosphorylation  in  cells  expressing  the 
Apert mutant receptors compared to the wild type FGFR2. This is an interesting trend in 
light of recent reports indicating that lower affinity ligands for the EGFR such as E4T 
and TGFa result in greater mitogenic signals compared to the high affinity ligand EGF. 
This  dimished  EGFR-induced  signalling  upon  stimulation  with  a  high  affinity  ligand 
was found to be due to relatively greater levels of receptor ubiquitination, internalisation 
and degradation  [265-267].  These observations  further indicate that  in the case  of the 
Apert  syndrome mutations,  which result  in  increased  affinity of the  receptor for FGF 
ligand and enhanced activation of downstream signalling, other factors must contribute 
to this phenomenon.
4.3.2  The Apert syndrome mutations alter the heparan sulphate 
dependency of the FGFR2
In addition to the increased affinity of the Apert mutant receptors for FGF ligand, it was 
interesting to note that the wild type receptor portrayed HS dependence for activation by 
FGF9  in  HEK  293T  cells,  although  this  cell  type  is  likely  to  express  various  GAGs 
[261]. The two mutant receptors did not require the presence of additional HS to cause 
activation of Erkl/2  and the addition of HS did not enhance its phosphorylation.  This 
was  in  agreement  with  a  previous  report  indicating  that  the  S252W  receptor  is  less 
selective for different GAGs (i.e. does not require a specific type of GAG for receptor 
activation) and requires lower doses of GAGs for activation [261]. The data presented in 
Figure  4.5  indicate  that  the  activation  of  the  mutant  receptors  by  FGF9  is  HS 
independent. Although McDowell et al.  [261] reported a slight increase in mitogenesis 
upon  the  addition  of various  GAGs  to  the  S252W  receptor  and  FGF9,  this  increase 
(especially by HS) was minimal and the mitogenic response in the absence of any GAG 
was already almost as great as the highest level reached by the wild type receptor in the 
presence  of  large  amounts  of  HS.  This  observation  supports  the  HS-independent 
activation  of the  mutant  receptors  observed  in  HEK  293T  cells  in  this  study.  Some 
enhancement of receptor activation by FGF9 may take place by endogenous molecules, 
but the dependence on additional  HS that was observed for the wild type FGFR2  was 
not mirrored by either the S252W or the P253R receptor.  It is also interesting to note, 
that stimulation of the wild type receptor with FGF2 was not affected by the addition of
148Chapter 4
external  HS.  FGF2  has  a  higher  affinity  for  both  the  FGFR2  and  other  FGFRs  that 
might be expressed in HEK 293T cells  [5]  and has been shown to require  less GAGs 
and  show  less  specificity  for  individual  GAGs  for  activation  of mitogenesis  [261], 
which may explain the results observed.
The  data  presented  support  the  previously  described  enhanced  affinity  of the  Apert 
mutant receptors for ligands such as FGF9. In addition, both the S252W and the P253R 
mutations were observed to affect the requirement for HS  for receptor activation.  It is 
possible that this effect is a result of full receptor glycosylation in contrast to bacterially 
expressed  extracellular  domains.  It  seems  that  the  mutations  alter  the  selectivity  for 
specific GAGs, and therefore those molecules normally present on HEK 293T cells are 
sufficient to allow maximum activation of Erkl/2 by FGF9 in the absence of additional 
HS.  Previous  studies  have  indicated  that  the  protein  composition  of the  extracellular 
matrix  surrounding  cells  with  the  Apert  syndrome  mutations  is  altered  [268].  Such 
changes  could  further  enhance  the  increased  activation  of  the  mutant  receptors 
compared  to  the  wild  type  receptor  and  form  an  additional  factor  that  contributes 
towards development of Apert syndrome in the whole organism. Expression of different 
proteoglycans on, or surrounding, specific cells may enhance and/or affect the change in 
affinity for FGF observed in Apert mutant receptors and may therefore affect the signal 
created intracellularly. Especially if the mutant receptors do not rely on the presence of 
a specific  GAG  for activation,  this could  lead to a greater signal  enhancement effect. 
The  lesser  requirement/selectivity  for  certain  GAGs  would  allow  activation  of  the 
mutant  receptors  in  a  cellular  context  in  which  perhaps  activation  was  normally 
prevented because the specific GAG for FGF:FGFR complex formation is not expressed 
on the surface of these cells. This would mean that in the context of the whole organism 
a major component controlling when and where a certain receptor is activated is lost and 
incorrect signalling may ensue as a result.
It would be interesting to investigate the GAG dependence of the wild type and mutant 
receptors in the presence of various other FGFs to determine whether this adds further 
complexity  to  the  way  in  which  Apert  syndrome  develops  on  the  organismal  level. 
Additionally,  experiments  such  as  isolating  the  glycosylated  extracellular domains  of 
the FGFR2 and the S252W and P253R mutants as described by Duchesne et al.  for the 
FGFR1  [162] and measuring their affinity for heparin, HS or other GAGs are required 
to  determine  whether  the  altered  glycosylation  of  the  mutant  receptors  affects  the
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dependency on various GAGs of these receptors or whether this property is a result of 
the amino acid substitutions and subsequent conformational changes alone.  The amino 
acid  substitutions  have  been  shown  not  to  affect  the  structure  of  the  FGFR2 
extracellular  domain  greatly  [163].  However,  one  could  propose  that  the  additional 
glycosylation  of  the  S252W  and  P253R  receptors  results  in  a  more  favourable 
conformation of this region and thereby alleviates the requirement for GAGs for FGF 
ligand binding.
4.3.3  The Apert mutations result in altered, not simply enhanced, 
receptor autophosphorylation patterns
A logical proposition based on the increased affinity for FGF and the observed changes 
in Erkl/2  activation by the Apert mutant receptors would be that the phosphorylation 
levels of these receptors were simply enhanced. Contrary to this hypothesis, the overall 
phosphorylation  pattern  of  the  mutant  receptors,  in  particular  that  of  the  S252W 
receptor,  was  significantly  different  from  the  wild  type  FGFR2  and  did  not  reflect  a 
simple  increase concomitant with the  changes  in receptor/ligand  interaction.  Thus the 
Apert mutations introduce changes in the FGFR2 other than just enhanced affinity for 
FGFs. If only the affinity for ligand was altered, then one would expect that more of the 
higher affinity receptors were occupied by ligand within a given period of time than of 
the  lower  affinity  (i.e.  wild  type)  receptor.  This  would  ultimately  result  in  a  greater 
number of receptors being phosphorylated,  which would be represented  by an overall 
increase in receptor phosphorylation in an immunoprecipitation experiment.  However, 
this  was  not  the  case,  and  the  Apert  mutations  altered  the  overall  phosphorylation 
pattern  in  both  the  ligand-independent  and  ligand-stimulated  states.  Particularly  the 
lower basal  phosphorylation  of the  S252W  receptor  indicates  that  the  changes  in  the 
extracellular  region,  namely  the  point  mutation  and  the  altered  glycosylation,  are 
somehow transmitted  to  the  intracellular  region  where  they  affect  phosphorylation  of 
tyrosine residues possibly by changing the accessibility of certain residues by the kinase 
domain.  The  high  basal  phosphorylation  of the  wild  type  receptor  is  the  result  of 
phosphorylation of two tyrosine residues at the distal C-terminus that are not conserved 
amongst the other members of the FGFR family (Z. Ahmed, unpublished results). This 
indicates that some structural changes must occur in the intracellular region to prevent 
phosphorylation of these residues when the  S252W mutation is present.  Similarly, the 
increased basal phosphorylation observed in the case of the P253R receptor must be the
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result  of structural  changes  that  allow  greater  phosphorylation  of these  and  possibly 
additional  residues.  A  large  amount  of the  basal  phosphorylation  of the  wild  type 
receptor  was  due  to  phosphorylation  of the  unglycosylated  and  under-glycosylated 
receptor.  In contrast, this was completely absent in the S252W receptor.  In case of the 
P253R receptor, both fully glycosylated and under-glycosylated receptors were highly 
phosphorylated in the unstimulated state.  It would be interesting to elucidate the exact 
difference in glycosylation between the wild type and the S252W receptor and whether 
once this additional/altered glycosylation (rather than total glycosylation in the presence 
of  tunicamycin)  is  abolished,  the  phosphorylation  pattern  of  the  mutant  receptors 
resembles  that  of  the  wild  type  receptor  or  whether  the  mutations  themselves  are 
responsible  for the  observed  differences.  Although the  altered  glycosylation  seems to 
play an important role  in the changes  in receptor phosphorylation, the  unglycosylated 
mutant  receptors  were  both  phosphorylated  to  a  lesser  extent  than  the  wild  type 
receptor.  This indicates that the mutations themselves also play a role in the observed 
changes in receptor tyrosine phosphorylation.
It was beyond the scope of this work to analyse whether specific tyrosine residues are 
differentially  phosphorylated  in  the  wild  type  and  the  mutant  receptors  after  FGF 
stimulation,  and  further experiments  are  required to  find out whether this  is the  case. 
Only the tyrosines in the activation loop (Y653  and Y654) and  Y766 have truly been 
implicated  with  a  function  in  FGFR1  signalling,  and  somewhat  minor  functions  for 
other residues have been proposed  [15,  103,  122]. It would be extremely interesting to 
elucidate  any  specific  differences  in the  stoichiometry  of phosphorylation  of specific 
tyrosine residues as a result of the Apert syndrome mutations and whether residues that 
remain  unphosphorylated  in  the  wild  type  receptor  are  phosphorylated  in  receptors 
containing either of the two Apert syndrome mutations. Such differences might result in 
different recruitment of signalling proteins to the receptor. Point mutations of individual 
tyrosine  residues  or  several  residues  in  combination  might  reveal  the  basis  for  such 
altered  protein  recruitment  that  may  lead  to  enhanced  Erkl/2  activation.  The  FGFR2 
contains several tyrosine residues in its C-terminal tail that are not conserved between 
the different members of the FGFR family, which may not only form the basis of the 
high level of basal phosphorylation observed but may also have functional roles in the 
differential  activation of downstream  signalling pathways in cells expressing the wild 
type and mutant receptors.
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4.3.4  Changes in receptor phosphorylation may affect other receptor 
properties such as its downregulation by endocytosis
Clear  differences  in  the  basal  and  ligand-stimulated  receptor  phosphorylation  of all
three receptors were observed, which did not correlate with the relative affinities of the 
different receptors for FGF ligand. It therefore seems that mechanisms other than simple 
enhancement  of the  ‘regular’  signalling  pathways  play  an  important  role  in  causing 
enhanced  Erkl/2  activation  and  possibly  affecting  other  signalling  pathways.  The 
P253R  mutation  is  of  particular  interest  since  it  caused  increased  basal  receptor 
phosphorylation, but the percentage increase in phosphorylation from basal upon FGF9 
stimulation was of a similar magnitude as that  of the wild type receptor (Figure 4.5). 
This means that the overall increased phosphorylation is only due to the changes that are 
already  present  in  the  receptor  in  the  absence  of  ligand  (i.e.  higher  basal  receptor 
phosphorylation).  In  addition,  the  activation  of  Erkl/2  with  varying  doses  of  FGF 
portrayed a similar pattern (Figure 4.1). This indicates that increased affinity and hence 
increased  receptor  phosphorylation  are  not  the  only  effects  of the  Apert  syndrome 
mutations  on  the  P253R  receptor.  Similarly,  the  S252W  receptor  portrayed  greatly 
decreased basal tyrosine phosphorylation, which indicates that other factors must affect 
this  receptor  and  subsequently  its  signalling  ability.  The  relatively  lower 
phosphorylation of this receptor following FGF9 stimulation also shows that increased 
receptor affinity for FGF  ligand is not mirrored by increased phosphorylation and that 
other mechanisms must contribute to the enhanced activation of pathways such as the 
Erkl/2 pathway at lower doses of FGF ligand.
Indeed,  work  in  our  laboratory  has  shown  that  the  localisation  pattern  of both  the 
S252W and the P253R was altered in response to FGF9 stimulation in HEK 293T cells 
([224], in submission). Both mutant receptors portrayed reduced levels of endocytosis, 
which  would  be  expected  to  play  an  important  role  in  downstream  signalling,  since 
enhanced  presence  at  the  membrane  or  altered  internalization  of  receptor/adaptor 
protein  complexes  would  change  the  signal  initiated  from  a  receptor.  This  would 
explain how the activation of the Erkl/2 pathway could mirror increased affinity of the 
receptor for ligand despite receptor phosphorylation not following the same trend. It has 
been proposed that higher affinity ligands for the EGFR result in increased endocytosis 
and downregulation of this receptor [265, 267]. It is interesting to note that in the case 
of the Apert mutations this trend was not observed, and that indeed the opposite took 
place.  Despite the increased affinity for FGF  ligand, the  S252W and P253R receptors
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were retained at the membrane to  a greater extent than the wild type  FGFR2.  This is 
likely to have an effect on the activation of downstream signalling pathways such as the 
Erkl/2 pathway. The reduced endocytosis may therefore play a role in resulting in the 
Erkl/2  activation pattern that mirrored the relative affinities of the three receptors  for 
FGF9 (Figure 4.2).
It  is unclear what mechanism  mediates the altered  internalisation pattern of the  Apert 
mutant receptors, but the changes in phosphorylation pattern may play a significant role. 
Recent  studies have  implicated  a kinase-regulated targeting  signal  in the  cytoplasmic 
region  of  FGFR4  as  an  important  mediator  of whether  the  receptor  is  recycled  or 
transported to the lysosome for degradation [269]. Additionally, activating mutations in 
the  FGFR2  and  FGFR3  have  been  shown  (although  somewhat  conflictingly)  to  alter 
ubiquitination  and  receptor  trafficking  in  various  cell  systems  [171,  263,  270,  271]. 
These  reports  indicate  that  receptor  trafficking  could  be  affected  by  the  altered 
phosphorylation patterns of the Apert mutant FGFR2 as well as changes in recruitment 
of proteins such as c-Cbl that are involved in receptor internalisation [114]. The removal 
of  Y766  in  the  FGFR1,  which  is  the  binding  site  for  PLCy,  inhibits  receptor 
internalisation  [272].  Hence  it  would  be  interesting  to  determine  whether  either 
phosphorylation  of this  residue  is  reduced/absent  in  the  P253R  receptor  or  whether 
PLCy  and/or  c-Cbl  recruitment  to  the  P253R  and/or  S252W  receptors  is  altered  and 
thereby  cause  the  changes  in  receptor  localisation  observed.  However,  alterations  in 
receptor internalisation may not necessarily be the only determinant of Apert syndrome, 
since all three receptors did not portray high levels of internalisation in PC 12 cells (data 
not  shown).  In PC 12  cells,  prolonged  FGF  stimulation results  in differentiation into a 
neuronal type. To maintain responsiveness to FGF, downregulation of the FGFR would 
not be desired, which may explain why endocytosis of none of the receptors (including 
the  wild  type  FGFR2)  is  observed  in  this  cell  line.  Despite  such  cell-specific 
differences,  it  is  clear  that  the  Apert  syndrome  mutations  affect  various  cellular 
properties in addition to the changes in ligand binding described previously and in this 
study.  In  combination,  all  of these  effects  may  be  important  in  causing  changes  in 
intracellular  signalling  from  the  FGFR2  that  ultimately  result  in  the  manifestation  of 
Apert syndrome.
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4.3.5  The altered glycosylation pattern of the Apert mutant receptors 
may be an important regulator of the observed effects on the FGFR2
Although the mechanism by which the Apert syndrome mutations result in the changes 
in  receptor  phosphorylation,  localisation  and  interaction  with  its  two  ligands  is  not 
entirely understood,  it seems  likely that the altered glycosylation of the receptor plays 
an  important role  in regulation  of these  properties.  Glycosylation of proteins  is  often 
found at  sites of change  in the  structure of proteins  [273].  Thus  it is possible that the 
substitution  of  residues  252  or  253  results  in  minor  structural  changes  in  the 
extracellular domain that lead to additional or different receptor glycosylation. This may 
then enhance and support a structural change, which would not have been observed in 
the  crystal  structure  that  was  determined  in  the  absence  of  glycosylation  and  that 
subsequently  may  affect  various  receptor properties.  N-glycosylation  sites  on  FGFRs 
are positioned such that they may affect interaction of the receptor with FGF or GAGs 
and  receptor  dimer  and/or  multimer  formation  [162].  The  crystal  structures  of the 
extracellular domains of all three receptors was solved in the absence of glycosylation, 
which may explain why no  significant structural  differences could be observed  [163]. 
Although reports have been published that claim that glycosylation of the FGFR does 
not  affect  its  ligand  binding  abilities  [274,  275],  changes  in  glycosylation  may  have 
previously undescribed effects on the FGFR itself and signal transduction from it. This 
is particularly interesting in the light of the observed changes in receptor glycosylation 
of the Apert mutant receptors.
It has been shown previously that glycosylation is important for membrane localisation 
of tyrosine  kinase  receptors  [101,  263],  and  tunicamycin  treatment  of cells  inhibited 
localisation  of  the  receptor  to  the  cell  membrane  (Figure  4.4).  All  three  FGFR2 
constructs  behaved  the  same  way  and  were  no  longer  found  localised  at  the  cell 
membrane in the absence of glycosylation.  More importantly, correct glycosylation of 
the EGFR has been shown to be required for its normal endocytic behaviour [276]. This 
indicates that changes in the glycosylation of a receptor may affect the way in which it 
is internalised.  The changes  in FGFR2  glycosylation in the presence of the  S252W or 
the  P253R mutations might  therefore  be  causing the differences  observed  in terms of 
receptor  localisation  compared  to  the  wild  type  receptor.  Further  experiments  are 
required to identify the exact differences in receptor glycosylation of the Apert mutant 
receptors, to elucidate how these effects might be brought about and whether removal of 
this additional glycosylation would restore normal receptor trafficking.
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Studies elucidating the changes in receptor glycosylation that occur in the presence of 
the  Apert  syndrome  mutations  are  also  important  to  understand  the  way  in  which 
differences  in  receptor  phosphorylation  are  initiated  and  whether  they  could  be  the 
result  of  structural  changes  imposed  by  altered  receptor  glycosylation.  No  clear 
evidence exists for the way in which altered glycosylation of the extracellular domain 
can affect the intracellular structure of a receptor. However, it has been proposed that a 
similar phenomenon takes place in the FGFR3  with an N328I mutation, which causes 
hypochondroplasia and is found within a putative glycosylation site in the extracellular 
domain [277]. Duchesne et al. superimposed some of the N-glycans structures identified 
by  mass  spectroscopy  onto  putative  glycosylation  sites  in  the  two  different  crystal 
structures of the  FGFRl/FGF/heparin complexes  [162].  Some chains  seemed to make 
extensive  contact  with  receptor  and/or  ligand.  Thus  despite  reports  claiming  that 
glycosylation does not alter/affect FGF binding [274, 275], the changes in glycosylation 
may  affect  the  positioning  of  FGF,  GAGs  and  FGFR  in  the  complex.  This  could 
subsequently  alter  positioning  of individual  receptors  in  the  dimer  and  may  thereby 
transmit  the  differences  between  wild  type  and  mutant  receptors  to  the  intracellular 
domain.  This  might  then  result  in  the  differences  in  ligand-stimulated  FGFR2 
phosphorylation observed. Additionally, the lack of glycosylation was found to increase 
receptor  phosphorylation  and  dimerisation  of the  wild  type  FGFR2  (Figure  4.6  and 
[263]).  This  indicates  that  glycosylation  is  an  important  regulator  of these  receptor 
properties and alterations in glycosylation may therefore also affect ligand independent 
receptor dimerisation and phosphorylation.
The  possibility  that  the  altered  glycosylation  of the  mutant  receptors  might  be  an 
important  regulator  of receptor  phosphorylation  and  localisation  raises  the  important 
question  of whether  these  alterations  result  in  more  changes  in  signalling  from  the 
receptor  than  a  simple  upregulation  of receptor  signalling  on  the  basis  of increased 
affinity  for  FGF.  The  results  presented  in  Chapter  5  will  focus  on  the  changes  in 
downstream  signal  transduction  from  and  protein  recruitment  to  the  FGFR2  in  the 
presence of the Apert syndrome mutations. Based on the data presented in this chapter, 
any effects observed may be due to altered glycosylation, phosphorylation, localisation 
or interplay between all of these properties.
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4.3.6  Complex changes in the FGFR2 form the basis of Apert 
syndrome
Overall,  the  findings  presented  in  this  chapter  and  other  work  carried  out  in  this 
laboratory  ([224],  in  submission)  demonstrate  how  mutations  in  the  extracellular 
domain of receptors can affect their overall behaviour as well  as its overall  signalling 
capacity  in  various  ways.  Not  only  do  the  Apert  mutations  affect  the  ligand  binding 
affinity of the receptor and the requirement  for various GAGs for receptor activation, 
but they also affect receptor glycosylation. It is likely that all of these properties interact 
to  affect  receptor  phosphorylation,  localisation  and  activation  of downstream  targets. 
The  precise  contribution  of the  alteration  in  receptor  glycosylation  to  the  described 
effects in unclear and further analysis of the precise changes in glycosylation is required 
to elucidate its exact role. Nonetheless, the fact that in vivo the Apert mutations result in 
changes  in  addition to  causing  increased  receptor affinity  for  ligand  is  an  interesting 
observation that demands  further  investigation  of the  intracellular changes  that  occur 
consequently.  Certainly  these  findings  indicate  that  the  mechanisms  by  which  Apert 
syndrome  is manifested  in the whole organism  are  somewhat more complex  than the 
previously reported increase in ligand binding and altered ligand recognition specificity 
of the FGFR2. The differences between wild type and mutant receptors described in this 
work indicate a further layer of complexity to the cellular basis of Apert syndrome and 
point  out  important  factors  whose  integrity  is  required  to  initiate  the  correct  cellular 
responses to FGFR2 activation.
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Chapter 5
The Apert mutations affect 
signalling from the FGFR2 by 
altering protein recruitment
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5.1  Introduction
The  formation  of multiprotein  complexes  upon  activation  of a  given  tyrosine  kinase 
receptor has  been implicated  as  an  important factor in  creating  specificity  in  protein- 
protein  interactions  and  ultimately  in  activation  of downstream  signalling  pathways 
[126].  The  precisely  controlled  assembly  of  proteins  into  complexes  provides  a 
mechanism  for  activation  of numerous,  specific  downstream  responses  by  regulating 
recruitment of specific individual proteins to activated receptors.
Mutations  in  any  component  of  such  multiprotein  complexes  would  disrupt  correct 
assembly  and  therefore  ultimately  affect  the  downstream  signal.  Nevertheless,  the 
occurrence  of  mutations  does  not  necessarily  mean  complete  loss  of  all  signal 
generated, depending on which component of the complex is mutated. The formation of 
complexes  in  addition  to  the  existence  of a  degree  of promiscuity  in  protein-protein 
interactions  may  allow  for  a  signal  to  be  generated  to  a  certain  extent  even  in  the 
presence of mutations  [126]. Nonetheless, mutations that affect regular protein-protein 
interactions, alter the enzymatic activity of kinases (without which phosphorylation and 
the  creation  of  platforms  for  complex  assembly  is  not  possible)  or  that  remove 
phosphorylatable  tyrosines  (thereby  preventing  protein  recruitment  via  SH2  or  PTB 
domains)  may  destroy  normal  formation  of  signalling  complexes.  The  downstream 
signals  initiated  would  be  affected  by  mutation  as  a  result  of  the  altered  protein 
recruitment  to  the  receptor  and  disruption  of  protein  complexes.  Activation  of 
downstream pathways might be completely lost or only the signal duration or strength 
may be affected, depending on the severity of complex disruption.
The Apert syndrome mutations are  located  in the extracellular domain of the receptor 
and  therefore  do  not  fall  into  the  same  category  as  any  of the  types  of  mutations 
mentioned above, i.e. they are not in a position where they would be expected to result 
in  an  altered  binding  site  for  adaptor  proteins  or  directly  interfere  with  the  kinase 
activity  of the  receptor.  Previous  studies  have  described  an  affinity  increase  of the 
FGFR2 for FGF ligand in the presence of the Apert syndrome mutations [7,  161]. This 
would be expected to result in increased overall receptor phosphorylation because the 
increase  in  affinity  for  ligand  means  that  more  receptors  can  be  activated.  It  might 
therefore  be  expected to  observe  only  an  increase  but not a change  in recruitment  of 
adaptor proteins. Contrary to this hypothesis, the data presented in the previous chapter
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described various changes incurred on the FGFR2 by the Apert syndrome mutations in 
addition  to  increased  affinity  for  FGF  ligand.  The  mutations  resulted  in  altered 
interaction of the FGFR2 with both FGF and HS, and affected both the overall receptor 
phosphorylation as well as receptor glycosylation.
The observations described  in the previous chapter indicated that the Apert syndrome 
mutations  may  affect  intracellular  signalling  and  protein  recruitment  despite  being 
located  in  the  receptor  extracellular  region.  The  changes  observed  in  the  Apert 
syndrome mutant receptors did not simply reflect an increased receptor phosphorylation 
due  to  the  engagement  and  hence  activation  of more  receptors  because  of increased 
affinity  for  FGF.  It  therefore  seemed  likely  that  protein  recruitment  to  the  receptor 
would  also  be  altered  instead  of just  being  increased  downstream  of the  S252W  and 
P253R  receptors.  Subsequently,  it  was  chosen  to  investigate  the  effect  of  these 
mutations  on the  activation  of one  of the  main pathways  downstream  of the  FGFR2, 
namely  the  Erkl/2  pathway,  and  on  the  recruitment  of adaptor  proteins.  The  results 
presented in this chapter focus on the adaptor protein She and the effects of the Apert 
mutations on its phosphorylation and cellular localisation patterns. The data presented, 
in  conjunction  with  other  findings  made  in  the  laboratory,  describe  the  altered 
recruitment of an array of adaptor proteins to the FGFR2 as a result of the S252W and 
P253R mutations.
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5.2  Results
5.2.1  Erk1/2 activation is enhanced by the S252W or P253R mutant 
FGFR2
The Erkl/2 pathway is one of the main signalling pathways activated downstream of the 
FGFR. It was therefore chosen to assess the effects of the Apert syndrome mutations on 
activation  of this  kinase  to  establish  whether  the  altered  tyrosine  phosphorylation  of 
each  receptor  was  directly  translated  into  downstream  signalling  pathways.  All  three 
cell lines were stimulated with FGF9 for various periods of time and whole cell lysates 
were subjected to immunoblotting with an anti-phospho-Erkl/2 antibody as a measure 
of its activation.  HEK 293T cells do not respond to stimulation with FGF9,  a type of 
FGF that portrays a fairly high level of specificity for FGFR2IIIc (although it can also 
activate FGFR3IIIc and FGFR4  [5]). Therefore background stimulation of endogenous 
pathways  could  be  excluded  (Figure  5.1C).  In  addition,  although  this  cell  line  was 
reported to  express  FGFR2  mRNA  [225],  work  in our  laboratory  failed  to  detect the 
protein by means of western blotting using an antibody specific for the FGFR2.
The dose response experiment in the previous chapter indicated that the level of Erkl/2 
phosphory lation reached upon stimulation of either of the mutant receptors with FGF9 
was much higher than that following activation of the wildtype receptor (Figure 4.2). To 
assess  whether the  Apert  syndrome  mutations  also  affected  Erkl/2  activation  over  a 
prolonged  period  of stimulation,  cells  were  stimulated  with  FGF9  for  various  time 
periods.  The  enhanced  Erkl/2  phosphorylation  persisted  throughout  the  time  course. 
Interestingly,  the  S252W receptor led to  greater Erkl/2  activation in HEK 293T cells 
(Figure  5.1 A), whereas in PC 12  cells, expression of the P253R receptor portrayed the 
highest overall  level of Erkl/2 activation (Figure 3.7B). These cell-specific differences 
may be due to each cell type expressing slightly different (levels of) signalling proteins. 
For example PC 12 cells seem to express higher levels of the docking protein FRS2 than 
HEK  293T  cells  as  assessed  by  western  blotting.  Differences  in  recruitment  of such 
adaptor  proteins  by  the  two  mutant  receptors  might  be  responsible  for  the  different 
patterns observed in the two cell types.
In  addition  to  generally  increased  levels  of  Erkl/2  activation,  the  onset  of  Erkl/2 
phosphorylation was enhanced by the presence of the Apert mutations.  In HEK 293T 
cells  this  was  particularly  the  case  for  the  S252W  FGFR2,  which  reached  near
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maximum levels of Erkl/2 phosphorylation in response to FGF9 stimulation within five 
minutes of stimulation, whereas for the wild type receptor this only occurred after ten 
minutes of stimulation.  Similar patterns were observed in HEK 293T cells stimulated 
with FGF2 (data not shown) and PC 12 cells stimulated with FGF9 (Figure 3.7B). The 
faster onset of Erkl/2 activation in cells expressing the Apert mutant receptors is likely 
a result of the increased affinity of these receptors for FGF ligand [7, 161].
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Figure 5.1: The Apert syndrome mutations lead to enhanced Erkl/2 activation HEK 293T cells were 
serum-starved overnight and stimulated with  lOng/ml  FGF9  for various periods of time.  200pg of cell 
lysate  were  subjected  to  SDS-PAGE  and  immunoblotting  with  an  anti-phospho-Erkl/2  antibody.  To 
assess equal loading, blots were stripped and re-probed with an anti-Erkl/2 antibody (A). The amounts of 
phospho-Erkl/2  were  assessed  by  densitometry  and  represented  graphically  for  each  time  course 
experiment  (B).  The results  shown  are  representative  of three  independent experiments.  Untransfected 
HEK 293T cells were stimulated with  lOng/ml FGF9,  EGF or NGF or  IOOjiM  insulin  for ten minutes, 
lysed and subjected to SDS-PAGE and immunoblotting with an anti-phospho-Erkl/2 antibody. The blot 
was stripped and re-probed with an anti-Erkl/2 antibody (C).
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5.2.2  The Apert syndrome mutations affect the overall intracellular 
phosphotyrosine content
One of the questions that arose  from having observed the  enhanced  activation of the 
Erkl/2 pathway by the Apert mutant receptors, was whether this effect was simply due 
to the increased number of receptors activated as a result of their increased affinity for 
FGF  ligand  or whether  it was  a result  of altered  recruitment  of adaptor  proteins  and 
signalling complex formation. The fact that both the S252W and the P253R mutations 
greatly  affected  the  receptor  itself  (in  terms  of  greatly  altered  glycosylation  and 
phosphorylation patterns) indicated that perhaps the enhanced Erkl/2 activation was not 
only  the  result  of  increased  signal  transduction  from  the  FGFR2.  Particularly  the 
phosphorylation patterns of the receptor did not seem to support the hypothesis that the 
increased  affinity  resulted  simply  in  increased  signalling  via  the  normal  FGFR2 
pathways. Therefore the effects of the Apert syndrome mutations on formation of early 
signalling complexes were investigated.
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Figure 5.2: The Apert syndrome mutations affect total cellular tyrosine phosphorylation HEK 293T 
(A) or PC 12 cells (B) were serum-starved overnight and stimulated with  lOng/ml FGF9. Cells were lysed 
and  200pg/ml  of the  cells  lysates  were  subjected  to  SDS-PAGE  and  immunoblotting  with  an  anti- 
phosphotyrosine  antibody.  The  western  blots  were  stripped  and  re-probed  with  an  anti-GFP  and/or  an 
anti-Grb2 antibody to assess equal expression levels and gel loading.
As an initial indication of the effects of the changes in the Apert syndrome receptors on 
intracellular  signalling,  the  changes  in  total  cellular  tyrosine  phosphorylation  were 
assessed  (Figure  5.2).  As  expected  from  the  enhanced  Erkl/2  phosphorylation  in 
response  to  activation  of the  S252W  or  P253R  receptors,  some  proteins  were  more 
strongly phosphorylated  in cells expressing the mutant receptors.  Although one could 
propose that this trend is due to the increased affinity of the mutant receptors for ligand, 
the phosphorylation of the  S252W and  P253R receptors did not follow this enhanced 
pattern  compared  to  the  wild  type  receptor  as  described  in  Chapter  4.  Thus  other 
mechanisms must affect the way in which these proteins are recruited to the receptor to 
lead to their increased phosphorylation.
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Interestingly,  the  two  single  point  mutations  in  the  FGFR2  also  led  to  different 
phosphorylation  patterns  compared  to  the  wild  type  receptor.  This  was  particularly 
obvious in PC 12 cells (Figure 5.2B: as indicated by lines), because fewer proteins were 
phosphorylated  overall.  In  HEK  293T  cells,  the  fairly  large  level  of  background 
phosphorylation masked certain differences between the three cell lines. However, HEK 
293T stimulation, particularly with FGF2, also revealed a similar pattern (Figure 5.2A, 
data for FGF2 stimulation not shown). These findings indicate that the Apert mutations 
not only enhance the downstream response, but that they alter the type of proteins that 
are activated as a result of receptor engagement by ligand.  Additionally,  the observed 
changes  point  towards  the  formation  of different  types  of signalling  complexes  as  a 
result of the Apert syndrome mutations, which ultimately lead to altered activation of 
downstream targets such as Erkl/2.
5.2.3  She is more strongly phosphorylated in cells expressing the 
Apert mutant receptors compared to the wild type FGFR2
The She adaptor protein plays an important role in recruitment of Grb2 to a variety of
tyrosine  kinase  receptors  such  as  the  EGFR  or  TrkA.  Moreover,  its  phosphorylation 
leads  to  an  increase  in  the  association  of Grb2  with  Sos  [235],  an  essential  step  for 
activation of the Ras/Raf/MEK pathway. She has been reported to be involved in FGFR 
signalling, but its exact role has not been elucidated [103-105]. On the phosphotyrosine 
blots (Figure 5.2), bands around 50-55kDa could be identified that were more strongly 
tyrosine phosphorylated in cells expressing the mutant receptors and were identified as 
She.  This  observation  prompted  an  investigation  into  whether  She  was  involved  in 
signalling  from  the  FGFR2  and  whether  the  Apert  mutations  affected  its  role  and 
recruitment downstream of the receptor.
To investigate whether the Apert syndrome mutations in FGFR2 have an effect on She 
phosphorylation,  She  was  immunoprecipitated  from  cells  expressing  the  wild  type, 
S252W or P253R FGFR2 (Figure 5.3).  In both HEK 293T and PC12 cells, there were 
remarkable  differences  in  She  phosphorylation,  depending  on  which  receptor  was 
expressed.  In  cells  expressing  the  wild  type  receptor,  She  was  phosphorylated  upon 
stimulation in PC 12  cells.  In HEK 293T cells, the basal  level of phosphorylation was 
already quite high, which may be due to the fact that these cells are highly transformed 
and  therefore  the  level  of tyrosine  phosphorylated  proteins  is  generally  high  even  in 
serum-starved,  unstimulated  cells.  Since  the  overall  effects  of the  Apert  syndrome
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mutations described so far were similar in both PC 12 and HEK 293T cells, this basal 
She phosphorylation did not seem to interfere with general signal generation. By 30-60 
minutes of stimulation, She phosphorylation decreased in response to wild type FGFR2 
activation (Figure 5.3A and B: lane 3).
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Figure 5.3: She immunoprecipitation reveals differences in She phosphorylation as a result of Apert 
syndrome mutations HEK 293T (A) or PC12 cells (B) expressing each of the three receptor constructs 
were serum-starved overnight and stimulated with  lOng/ml FGF9 as indicated. The stimulated time points 
differ  between  the  two  experiments  as  indicated.  3mg  of  cell  lysate  were  subjected  to 
immunoprecipitation  with  an  anti-Shc  antibody  and  subsequent  immunoblotting  using  an  anti- 
phosphotyrosine  antibody.  Blots  were  stripped  and  re-probed  for  Grb2  and  She  using  appropriate 
antibodies.
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The She phosphorylation in S252W cells mirrored that of the FGFR2  (refer to  Figure 
4.2): She phosphorylation was very low in unstimulated cells but increased largely upon 
addition of FGF9. In both cell lines expression of the S252W mutant receptor negatively 
regulated  She  phosphorylation  in  unstimulated  cells,  meaning  that  the  levels  were 
reduced  compared  to  those  in  cells  expressing  the  wild  type  or  P253R  receptors.  In 
PC 12 cells, the overall level of She phosphorylation was also much greater than in wild 
type  cells.  The  fact  that  this  was  not  observed  in  HEK  293T  cells  may  be  due  to 
expression of other cell type specific proteins and slight variation between the cell lines.
In HEK 293T cells, the P253R receptor induced very high, stimulation-dependent She 
phosphorylation. In PC 12 cells this effect was not as pronounced, an effect that may be 
due to downregulation of the expression of the P253R FGFR2 within few cell passages 
for an unknown reason.  As a result the overall  level  of the response was diminished. 
Other differences between HEK 293T and PC 12 cells might also have been caused by 
variation  in  the  overall  protein  complement  (i.e.  precise  levels  of proteins  present) 
expressed  in  each  cell  line,  which  may  affect  the  way  in  which  individual  proteins 
respond to stimulation and the effects of the mutations.
It was interesting to note that She was phosphorylated for prolonged periods of time in 
both cell lines expressing the Apert mutant receptors compared to the downregulation of 
She phosphorylation after to 30-60 minutes stimulation of the wild type receptor (Figure 
5.3 A and B: lanes 6 and 9 compared with lane 3). One would expect that the enhanced 
activation of downstream signalling pathways might result in faster downregulation of 
receptor  signalling.  Since  She  phosphorylation  was  still  elevated  after  60  minutes  of 
FGF  stimulation,  the  downregulation  mechanisms  seem  to  be  changed  and  normal 
inactivation of the various pathways does not occur.
The P253R mutation resulted in increased association of She with Grb2  (Figure  5.3A 
and  B:  middle  panels  lanes  8-9  compared  to  lanes  2-3).  The  S252W  mutation  only 
resulted in increased Shc-Grb2 association in PC 12 cells, which is in agreement with the 
increased phosphorylation  level  in  these  cells.  The  changes  in  association  with  Grb2 
indicate that She is involved in FGFR2 signalling and activation of the Erkl/2 pathway 
downstream of this receptor.  In addition to increased association of She  with Grb2  in 
cells  expressing  the  Apert  syndrome  mutant  receptors,  an  unidentified  protein  of 
approximately 85kDa (p85) was found to be differentially associated with She in HEK
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293T cells depending on which receptor was expressed.  This tyrosine phosphorylated 
protein  was  primarily  associated  with  She  in  cells  expressing the  wild  type  receptor 
(Figure  5.3  A:  lanes  1-3).  Concomitant  with  the  downregulation  of  She 
phosphorylation,  less  of this  protein  was  observed  on  the  anti-phosphotyrosine  blot 
following  prolonged  FGF9  stimulation  (Figure  5.3:  lane  3),  which  may  represent 
decreased  association with  She  or simply decreased phosphorylation of the p85.  This 
protein was only minimally associated with She (or minimally phosphorylated) in cells 
expressing the S252W or the P253R receptors. These observations indicate that She is 
not  only  differentially  phosphorylated  in  cells  expressing  either  of the  Apert  mutant 
compared to the wild type FGFR2, but that it is also recruited to a different signalling 
complex.
5.2.4  Use of RFP-tagged She to investigate the interaction with 
FGFR2
The  She  immunoprecipitation  experiment  indicated that  She  is  involved  in  signalling 
downstream of the FGFR2  and that it is involved in a different signalling complex in 
cells  expressing  the  S252W  or  P253R  mutant  receptors  compared  to  the  wild  type 
FGFR2.  Based  on these  observations,  it  was  chosen to  investigate the  co-localisation 
behaviour  of the  FGFR2  and  She  in  HEK  293T  cells,  to  analyse  whether  the  Apert 
mutations  affect  the  recruitment  of  She  to  the  FGFR2  signalling  complex.  Before 
studies were carried out, it needed to be assessed whether the RFP-tagged construct was 
fully functional and could be phosphorylated like endogenous She to ensure that normal 
signalling behaviour was not affected by the addition of the RFP-tag.
Full-length C-terminally RFP-tagged  She  and  She  in which all three phosphorylatable 
tyrosine residues (Y239, Y240 and Y317) were mutated to phenylalanine (Shc3F) were 
transiently transfected into cells expressing the wild type FGFR2. Immunoprecipitation 
with an anti-Shc antibody was carried out, because the anti-RFP antibody was not very 
specific and resulted in isolation of a lot of non-specific proteins. The RFP-tagged She 
construct was fully phosphorylated (Figure 5.4) whereas the Shc3F construct could not 
be  phosphorylated.  This  confirmed  that  the  RFP-tag  did  not  interfere  with  She 
phosphorylation  by  the  receptor.  The  fully  functional  Shc-RFP  construct  could 
subsequently be employed in co-localisation studies.
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Figure 5.4:  Establishment of a  functional RFP-tagged She construct HEK 293T cells expressing the 
wild type FGFR2 were transiently transfected with the Shc-RFP or Shc3F-RFP constructs using calcium 
phosphate  precipitation.  Cells  were  serum-starved  overnight,  stimulated  with  lOng/ml  FGF9  for  15 
minutes  and  lysed.  Cell  lysates  were  subjected to  immunoprecipitation  with  an  anti-Shc  antibody  and 
subsequent immunoblotting with an anti-phosphotyrosine antibody. The western blot was stripped and re­
probed for total She using an appropriate antibody.
5.2.5  Effect of Apert mutations on co-localisation of the FGFR2 with 
She
To investigate the involvement of She  in FGFR2 signalling and possible changes that 
are implemented by the Apert syndrome mutations, C-terminally RFP-tagged She was 
transiently  co-transfected  into  HEK  293T  cells  stably  expressing  one  of the  three 
different  FGFR2-GFP  constructs  respectively.  The  cells  were  stimulated  for  various 
time  periods  and  analysed  by  confocal  microscopy.  Although  the  focal  plane  is  not 
exactly  the  same  for each  cell  presented,  a mid-section was  always  chosen to  avoid 
distortion of results by changes in protein localisation introduced by cell adhesion to the 
glass slide.
Figure 5.5A shows representative images obtained for cells co-expressing the wild type 
FGFR2 and She. Although She was partially localised at the membrane in unstimulated 
cells, its membrane localisation increased upon stimulation of cells with FGF9 (Figure 
5.5A: five minutes). Following  15 minutes of exposure to FGF9, She was temporarily 
localised  more  diffusely  throughout  the  cell,  although  it  still  co-localised  with  the 
FGFR2 at the membrane. By 30 and 60 minutes of stimulation, She almost exclusively 
co-localised  with the  wild type  receptor (refer to  graphs  indicating the  intensities  of 
GFP (green) and RFP (red) along the arbitrarily drawn line through the respective cell). 
This  co-localisation  occurred  along  the  plasma  membrane  and  inside  vesicles  after 
longer  exposure  to  growth  factor  (Figure  5.5A:  30  and  60  minutes).  Although  She 
phosphorylation started to decrease by 30 minutes of FGF9 stimulation (Figure 5.3A), 
its  co-localisation  with  the  receptor  did  not  change.  Internalisation  may  cause
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downregulation  of  She  phosphorylation  in  cells  expressing  the  wild  type  FGFR2 
without  affecting  receptor  She  co-localisation.  It  is  also  important  to  note,  that  She 
localisation  at  the  membrane  is  a  result  of expression  of the  FGFR2.  In  cells  not 
expressing this  receptor,  She  was  localised throughout the  cell  and  did  not  portray  a 
strong  localisation  pattern  at  the  plasma  membrane  even  following  stimulation  with 
different growth factors (Figure 5.5E).
The P253R FGFR2 and She portrayed a co-localisation pattern that was very similar to 
that of the wild type receptor and She (Figure 5.5C). However, in slight contrast, there 
was  hardly  any  co-localisation  of She  and  the  P253R  receptor  in  unstimulated  cells 
(Figure  5.5C:  panels  f and k) whereas  in cells expressing the wild type  receptor,  She 
was already localised near the membrane without exposure of the cells to FGF9 (Figure 
5.5A:  panels  f and  k).  Upon  stimulation,  the  co-localisation  of She  and  the  P253R 
FGFR2  increased  with  longer  exposure  of cells  to  FGF9.  By  30  to  60  minutes  of 
stimulation, almost all She co-localised with the receptor. The P253R receptor is unable 
to undergo endocytosis ([224], in submission and as observed in Figure 5.5). This was 
reflected in the lack of co-localisation of She with the P253R FGFR2 on any vesicular 
structures as was observed for the wild type receptor after prolonged exposure to FGF9 
(compare Figure 5.5A and C: panels d and e).  In the case of the P253R receptor,  co­
localisation with She took place exclusively at the plasma membrane. As a result, She, 
even though partly localised diffusely throughout the cytoplasm, was not present in any 
intracellular vesicles in these cells. The lack of endocytosis of this receptor and thus of 
She could be the regulator of the enhanced levels of She phosphorylation observed in 
cells expressing this mutant receptor (Figure 5.3A).
Cells expressing the S252W FGFR2 displayed an altogether different pattern of She co­
localisation with the receptor (Figure  5.5B).  Although She portrayed a low amount of 
co-localisation  with  the  receptor,  this  occurred  largely  in  the  ER/Golgi,  where  both 
proteins were synthesized and thus were found in the same location. However, She was 
only minimally localised at the plasma membrane in S252W cell.  This did not change 
throughout the time course of stimulation up until 60 minutes.  Strikingly however, 60 
minutes  post-stimulation,  She  co-localised  with  the  S252W  FGFR2  in  intracellular 
vesicles (Figure 5.5B: panel o). It is unclear why this occurs, but it portrays a subtle yet 
important difference from the pattern observed in cells expressing either the wild type 
or the P253R FGFR2. In the case of the S252W receptor, internalisation of the receptor
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and co-localisation with She did not result in downregulation of She phosphorylation as 
was the case for the wild type receptor.
Thus  overall,  the  Apert  syndrome  mutations affected  She phosphorylation as well  as 
altering  its  localisation  pattern.  These  aspects  could  play  an  important  role  in 
determining the ultimate downstream response created by each respective receptor. The 
altered recruitment of She is likely to be transmitted to downstream signalling pathways 
and  may  be  an  important  factor  in  changes  in multiprotein  complex  formation  after 
receptor activation.
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Figure 5.5:  Co-localisation  of She  with  the wild  type,  S252W  and  P253R  FGFR2  HEK 293T cells 
expressing the wild type (A), S252W (B, page  171) or P253R (C, page  171) FGFR2 or HEK 293T cells 
alone  (E,  page  172)  were transiently transfected  with  Shc-RFP  using Lipofectamine  2000.  HEK 293T 
cells expressing the WT FGFR2 were transfected with RFP alone. Cells were seeded on glass coverslips, 
serum-starved  overnight  and  stimulated  with  lOng/ml  FGF9  for  various  time  periods  as  indicated  or 
additionally with lOng/ml FGF2, EGF, or lOOpM insulin for five minutes (D, page 172). Cells were fixed 
in  4%  paraformaldehyde,  washed  extensively  in  PBS  and  analysed  using  a  Leica  SP2  confocal 
microscopy  system.  Images  shown  are  representative  of  at  least  10  images  obtained.  The  relative 
fluorescence  intensities of GFP and RFP along an arbitrarily drawn  line  are represented graphically in 
green and red respectively.
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5.3  Discussion
5.3.1  Activation of the Erk1/2 pathways is enhanced downstream of 
the S252W and P253R receptors
One  of the  major effects  of the Apert  syndrome  mutations  on  downstream  signalling 
was enhanced Erkl/2 activation in response to FGF9 and FGF2 stimulation. Since both 
HEK  293T  and  PC 12  cells  normally  respond  to  FGFR  stimulation  with  prolonged 
Erkl/2  activation,  no  information  regarding  the  effect  on  signal  longevity  could  be 
obtained.  However,  initial  experiments  in  different  cell  lines  indicated  that  in  ROS 
17/2.8  osteosarcoma  cells  the  mutations  also  led  to  prolonged  Erkl/2  activation 
compared to  its transient activation by the wild type  FGFR2  (Z.  Ahmed,  unpublished 
results). The earlier onset and enhancement of Erkl/2 signalling correlate well with the 
previously described increased  affinity of the mutant FGFR2  for various  FGF  ligands 
[7,  161]. FGF9 in particular does not bind to the wild type receptor strongly, but shows 
greatly enhanced affinity for the mutant receptors  [7,  160]. Nonetheless, an increase in 
Erkl/2 phosphorylation has not been reported previously. On the contrary, Mansukhani 
et al. reported that in their study the S252W mutation did not exert any effect on Erkl/2 
signalling  in  osteoblasts  [164].  However,  another  study  correlated  an  increase  in 
mitogenic  activity  in cells  expressing the  S252W  FGFR2  with  increased  affinity  for 
various FGF ligands, and reported an increased mitogenic reponse to FGF9 stimulation 
in  the  presence  of the  S252W  mutation  [160].  Although  mitogenicity  is  not  a  direct 
measure of Erkl/2 activation, this pathway certainly contributes greatly to this cellular 
process. The observed increase in Erkl/2 activation in cells expressing the Apert mutant 
receptors  presented  in  this  work  are  somewhat  in  agreement  with  the  previously 
described increased in mitogenic response.  However,  maximal  stimulation of the wild 
type receptor by addition of excess ligand does not lead to activation of Erkl/2 to a level 
comparable  with  that  induced  by  activation  of the  S252W  or  P253R  receptors.  This 
indicates  that  the  enhanced  Erkl/2  phosphorylation  levels  downstream  of the  mutant 
receptors  are  not  solely  due  to  engagement  of more  receptors  because  of increased 
ligand  affinity  but  that  additional  factors  such  as  alterations  in  the  receptor  and  its 
signalling pathways  must contribute to  the  observed phenomenon.  Thus  although the 
increased affinity of the mutant receptors for FGF may play a role in enhanced Erkl/2 
signalling, the data presented in Chapter 4 also indicate that various other changes in the 
FGFR2 underlie this differential activation of major signalling pathway.  Since various 
signals can converge on Erkl/2 activation, more complex changes in the early signalling
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events  downstream  of  the  mutant  receptors  may  be  responsible  for  the  increased 
phosphorylation of Erkl/2.
5.3.2 Enhanced Erk1/2 activation does not result in increased FGFR2 
signal downregulation
It was  interesting to  note  that the  increased  activation of the  Erkl/2  pathway did not 
result in increased downregulation of the signal. Negative feedback via phosphorylation 
of Sos  and  FRS2  by  Erkl/2  takes  place  downstream  of the  FGFR  normally  and  is 
important in regulating the  signals emanated  from the activated receptor (reviewed in 
[92]). Interestingly, the enhanced activation of Erkl/2 did not result in increased signal 
downregulation. Particularly the observation that the mutant receptors not only result in 
enhanced  but  also  prolonged  activation  of the  Erkl/2  pathway  in  ROS  17/2.8  cells 
indicates  that  their  downregulation  must  be  impaired  somehow.  This  effect  becomes 
particularly  apparent  when  assessing  the  internalisation  behaviour  of the  S252W  and 
P253R  receptors.  Both  receptors  portrayed  altered  endocytosis  following  FGF9 
stimulation and were retained at the plasma membrane to a greater extent (i.e. did not 
undergo the same level of endocytosis as the wild type receptor) ([224], in submission 
and  Figure  5.5).  In  addition  to  the  numerous  effects  of the  Apert  mutations  on  the 
FGFR2  itself, these observations  indicate that the enhanced Erkl/2  activation may be 
the result of mechanisms  other than enhancement  of the  normal  signalling pathways. 
These  findings  therefore  led  to  the  investigation  of whether  the  effects  on  Erkl/2 
signalling were simply due to ‘upregulation’ of the normal signalling pathways from the 
FGFR2 due to prolonged receptor engagement or whether the mutations actually affect 
protein recruitment to the receptor and thereby alter signalling pathways.
5.3.3 The Apert syndrome mutations affect the integrity of protein 
recruitment and phosphorylation downstream of the FGFR2
Having observed various effects of the Apert syndrome mutations on the FGFR2 itself
as well as on one of the main downstream signalling pathways it was chosen to address 
the  question  whether  the  Apert  syndrome  mutations  affect  the  integrity  of  FGFR2 
signalling  by  altering  protein  recruitment  to  the  receptor.  Differences  in  protein 
recruitment  to  the  mutant  receptors  could  be  responsible  for  the  visible  increase  in 
Erkl/2 phosphorylation since several  ‘pathways’  converge on this kinase and therefore
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an  increase  in  its  activation  could  also  reflect  changes  in  protein  recruitment  to  the 
activated receptor.
Analysis  of receptor  phosphorylation  (Figures  5.2  and  4.5)  and  phosphorylation  of 
various  cellular  proteins  by  western  blotting  with  an  anti-phosphotyrosine  antibody 
revealed that the changes introduced in total cellular phosphotyrosine content by the two 
Apert  mutations  did  not  necessarily  mirror  the  different  receptor  phosphorylation 
patterns.  Whereas  some  proteins were  more  strongly tyrosine  phosphorylated  in cells 
expressing  one  of  the  Apert  mutant  receptors,  others  were  less  phosphorylated  or 
portrayed variations in time-dependent phosphorylation changes (Figure  5.2).  Overall, 
both mutant receptors  led to  (i)  increased phosphorylation of some proteins that were 
also phosphorylated in cells expressing the wild type receptor and (ii) phosphorylation 
of proteins that were not phosphorylated in wild type cells. These data indicate that the 
S252W  and  P253R mutations  not  only  manifest the  Apert  syndrome  phenotype  as  a 
result of enhanced signalling, but also cause the activation of different/altered signalling 
pathways.
The observation that the Apert syndrome mutations do not simply upregulate the normal 
signal  induced  by  the  FGFR2  upon  stimulation,  but  activate  different  signalling 
proteins/pathways,  initiated  the  investigation  of the  effects  of  the  Apert  syndrome 
mutation on spatio-temporal recruitment of adaptor proteins to the receptor. Analysis of 
the localisation of both FRS2  and Grb2  in response to activation of the Apert mutant 
receptors compared to the wild type receptor revealed that both proteins were associated 
very differently with each of the receptors in stimulated and unstimulated states ([224], 
in  submission  and  Z.  Ahmed,  unpublished  results).  These  findings  indicated  more 
precisely, that the presence of the Apert syndrome mutations indeed affects the integrity 
of the ‘normal’ protein complex assembly and leads to altered recruitment of signalling 
proteins to the FGFR2.
5.3.4  The implications of altered She recruitment on FGFR2 
downstream signalling
The altered recruitment of She to the FGFR2 was assessed in this work,  since She has 
been implicated with a role in FGFR signalling  [100,  103-105,  278].  Analysis of She 
phosphorylation in response to FGFR2  activation revealed that  She is phosphorylated
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downstream of the FGFR2. Interestingly the level of phosphorylation was enhanced by 
both  the  S252W  and  the  P253R  mutations  (Figure  5.3).  Furthermore,  whereas  She 
phosphorylation declined with prolonged activation of the wild type receptor, the level 
of She phosphorylation increased further with longer S252W or P253R activation. This 
indicates  that  significant  changes  occur  in  the  overall  signalling  pathways  emanated 
from  the  FGFR2  in  the  presence  of these  two  mutations.  The  observed  increase  in 
phosphorylation  resulted  in  increased  Grb2  binding  and  precipitation  although  slight 
cellular differences were observed between HEK 293T and PC 12 cells (Figure 5.3A and 
B:  middle  panels).  These  findings  demonstrate  a  role  for  She  in  FGFR2  signal 
transduction and  also  implement it with a possible role  in the manifestation of Apert 
syndrome phenotypes.
In  addition  to  increased  phosphorylation,  She  portrayed  altered  recruitment  to  the 
FGFR2  in  the  presence  of the  Apert  syndrome  mutations  (Figure  5.5).  Interestingly, 
differences  in  She  recruitment  were  also  observed between the  two  mutant  receptors 
themselves. In P253R cells, the recruitment of She to the receptor was not significantly 
altered  compared to the  wild  type  receptor.  In  both wild type  and  P253R expressing 
cells She co-localised with the receptor at the plasma membrane as well as being found 
in the ER/Golgi compartments where both proteins are being synthesised (Figure 5.5A 
and C). Thus in the case of the P253R receptor, the spatio-temporal recruitment of She 
to the receptor was not greatly affected, but it was significantly more phosphorylated. In 
addition  to  the  changes  the  P253R  mutation  inflicts  on  FRS2  recruitment  and  the 
reduced endocytic behaviour of this receptor ([224], in submission), the increased She 
phosphorylation  would  be  expected  to  contribute  further  to  the  increased  Erkl/2 
phosphorylation  by  recruitment  of a  greater  amount  of the  Grb2/Sos  complex  to  the 
plasma membrane. It was recently shown that by abolishing the ability of FRS2 to bind 
to  FGFR2,  the  phenotype  of  Crouzon  syndrome  (as  well  as  the  enhanced  Erkl/2 
activation) could be reversed in mice [279]. These findings indicate that FRS2 is mainly 
responsible for mediating the effects of the Crouzon mutations, and a similar scenario 
may be the case in Apert syndrome.  We have additionally, shown that the recruitment 
and interaction of FRS2 with the FGFR2 is greatly altered in the presence of the Apert 
syndrome  mutations,  which  seems  to  indicate  that  this  may  be  one  of  the  main 
mechanisms by which Apert syndrome is manifested ([224], in submission). However, 
the increased She phosphorylation in cells expressing the P253R mutant receptor would
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also  be  expected  to  contribute  significantly  to  the  enhanced  activation  of the  Erkl/2 
pathway.
In  comparison  to  cells  expressing  the  wild  type  and  the  P253R  receptors,  cells 
expressing the S252W receptor portrayed a considerably altered She localisation pattern 
(Figure 5.5B). Whereas She was highly membrane localised with both the wild type and 
the P253R FGFR2,  in the presence of the  S252W receptor it was found to  be located 
more diffusely throughout the cell. Although co-localisation with the receptor occurred 
to a small extent at the membrane, a large amount of She was also localised in regions 
from which the receptor was excluded (Figure 5.5B). Interestingly, after 60 minutes of 
exposure of cells to FGF9,  She was  found to be highly localised with the receptor in 
intracellular  vesicles.  This  indicates  that  indeed  She  is  differentially  recruited  to  the 
S252W  FGFR2  which  represents  the  formation  of  different  signalling  complexes 
compared to those assembled upon activation of the wild type FGFR2.  This may then 
greatly affect the activation of downstream targets  such as  Erkl/2.  It is  interesting to 
note  that  co-localisation  of She  with  the  S252W  receptor  after  60  minutes  of FGF9 
stimulation and with the P253R receptor occurs despite a lack of She association with 
the  unidentified  p85  that  was  found  in  immunoprecipitates  from  cells  expressing the 
wild type FGFR2. This indicates the formation of altered signalling complexes as well 
as the  fact that various  factors  must  be  involved  in regulating  She  recruitment  to the 
FGFR2.
Interestingly  the  absence  of  She  co-localisation  with  the  S252W  FGFR2  did  not 
coincide with a decreased, but rather an increased,  level of She phosphorylation.  This 
observation  indicates  that  She  may  briefly  be  membrane  localised  to  become 
phosphorylated  but  then  redistributes  to  the  cytoplasm.  This  hypothesis  would  be  in 
agreement  with  the  low  levels  of co-localisation  observed  in  the  earlier  time  points 
(Figure 5.5B: panels 1-n). The cytoplasmic She is likely to affect signalling in a different 
way  to  the  membrane  bound  She,  since  recruitment  of Grb2/Sos  at the  membrane  is 
essential  for  Ras  activation  [280].  She  may  therefore  contribute  significantly  to  the 
altered  cellular behaviour that  contributes  to  the  manifestation  of Apert  syndrome  in 
different ways  in cells expressing the  S252W mutant,  whereas other proteins  such as 
FRS2 play an important role in enhanced activation of the Erkl/2 signalling pathway.
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Altogether, the  S252W mutation was found to alter the cellular localisation of She  in 
addition to its phosphorylation, whereas the P253R mutation did not significantly affect 
the  co-localisation  with  the  receptor.  Firstly,  this  finding  indicates  that  there  are 
differences  in  early  signalling  events  downstream  of  the  S252W  and  the  P253R 
receptors. This is particularly interesting in light of both mutations causing very similar 
phenotypes  (i.e.  craniosynostosis  and  syndactyly)  in  the  whole  organism.  These 
differences  further  indicate  that  constant  localisation  of She  at  the  membrane  is  not 
required  for  its  phosphorylation.  Secondly,  the  fact  that  She  is  phosphorylated  more 
strongly  and  for prolonged  periods  in  response  to  stimulation  of either  Apert  mutant 
receptor compared to the wild type indicates that She may indeed play an important role 
in  Erkl/2  activation  downstream  of the  FGFR2.  Although  FRS2  is  the  main  Grb2- 
recruiting  component  in  FGFR  signalling,  mice  lacking  the  FRS2  binding  site  on 
FGFR1  were  able  to  activate  Erkl/2  and  undergo  the  somitogenesis  and  gastrulation 
stages of development normally  [281], which indicates that other proteins, most likely 
She, are able to activate the Erkl/2 pathway to an extent at which development remains 
unaffected.  Further  studies  would  need  to  be  carried  out  to  quantitatively  assess  the 
possible  changes  in  Grb2  recruitment  by  She  and  FRS2  in the  presence  of receptors 
containing the Apert syndrome mutations.
5.3.5  Effects of altered She recruitment and phosphorylation on 
signalling from the FGFR2
The main role of She  in response to activation of growth factor receptors  such as the 
EGFR, PDGFR or TrkA is recruitment of the Grb2/Sos complex whereby activation of 
the  Ras/Raf/MEK/Erkl/2  is  initiated.  FRS2  has  been  proposed  to  be  the  main  Grb2 
recruiting protein in FGFR signalling  [47], whereas the role of She has not been fully 
elucidated  since  phosphorylation  by,  but  no  interaction  with,  the  FGFR1  has  been 
described [104]. Nonetheless, She carries out an important function in FGFR signalling 
since it has been shown to be involved in FGFR-stimulated mitogenesis  [282]  and the 
She SH2 domain was found to block FGF1  induced Erk2 phosphorylation in Xenopus 
laevis oocytes expressing the Pleurodeles FGFR1  [283]. It was therefore interesting to 
note that She phosphorylation was both enhanced and prolonged in cells expressing the 
Apert syndrome mutations,  since this indicates that alterations in She phosphorylation 
may play a role in the enhanced Erkl/2 phosphorylation observed in response to S252W 
or P253R FGFR2 stimulation. The increased amount of Grb2 co-precipitated with She
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(Figure 5.3) also indicates that She may play a role in activation of the Erkl/2 pathway 
in  general  and  particularly  the  enhanced  activation  of this  pathway  in  response  to 
mutant FGFR2 activation. It is interesting to note, however, that She is only minimally 
membrane  localised  in  cells  expressing  the  S252W  receptor,  which  indicates  that 
increased She phosphorylation must also be involved in other functions downstream of 
the FGFR2 that do not require membrane localisation.
Apart from the FGFR2, relatively few She interacting phospho-proteins were observed 
in the  She  immunoprecipitation experiments  (Figure  5.3).  The approximately  120kDa 
phospho-protein that  co-precipitated  with  She  in  HEK  293T  cells  (and  could  also  be 
identified  upon  longer  exposure  in  immunoprecipitates  from  PC 12  cells,  data  not 
shown) could play a role in mediating functions other than Grb2 recruitment in response 
to FGFR stimulation. A 37-40kDa protein was also co-precipitated with She from both 
HEK 293T and PC 12 cells, and could be the p40 protein that binds to the pY239/pY240 
site of She described by van der Geer et al.  [198]. Most interestingly, an approximately 
85Da protein was co-precipitated (from HEK 293T cells only), and was primarily found 
in immunoprecipitates from cells expressing the wild type FGFR2.  This indicates that 
She  is  indeed  involved  in  forming  different  signalling  complexes  upon  receptor 
activation  in the  presence  of the  mutations.  This  protein  could  be  80K-H,  a tyrosine 
phosphorylated  protein  that  has  been  shown  to  be  involved  in  signalling  from  the 
FGFR1  and 3  [106, 284, 285]. 80K-H has been shown to be in complex with Grb2 and 
Sos,  but  has  not  been  shown  to  interact  with  She  directly,  although  formation  of a 
ternary  complex  cannot  be  excluded.  Alternatively  the  phospho-protein  could  be  a 
85kDa serine kinase has been shown to be phosphorylated by and associated with the 
FGFR4 but not the FGFR1  [286-288]. The role of this unidentified p85  is unclear and 
only identification of this protein (and other She interacting partners) can indicate the 
other signalling pathways that She  is involved in downstream of the FGFR2  and how 
the Apert mutations affect them. In conjunction with the various other proteins that were 
found to be differentially phosphorylated in cells expressing the Apert mutant receptors 
(Figure  5.1)  the  co-precipitation  of  these  unidentified  proteins  (particularly  p85) 
suggests  the  possibility  that  She  could  be  part  of an  altered  signalling  complex  after 
activation of the mutant receptors compared to the wild type receptors. Identification of 
the  proteins  co-precipitated  with  She  would  reveal  the  pathways  other  than  Erkl/2 
activation  that  She  is  involved  in  following  FGF  stimulation.  Additionally,  their
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identification  would  elucidate  how  these  interactions  are  affected  by  altered  She 
phosphorylation and recruitment in the presence of the Apert mutations.
5.3.6  The manifestation of Apert syndrome involves altered protein 
recruitment to the FGFR2
Mutations  in  the  FGFR,  including  the  Apert  mutations  in  the  FGFR2,  have  been 
previously described as gain-of-function when acting through various mechanisms such 
as  constitutive  activation,  illegitimate  splicing  or,  as  in  the  case  of the  S252W  and 
P253R  mutations,  through  increased  ligand  binding  affinity  and  illegitimate  ligand 
binding [173, 174]. The term ‘gain-of-function’ implies that the Apert mutations simply 
result in enhanced activation of the regular signalling pathways as a result of a greater 
number of receptors being engaged by ligand at any given time.
On the contrary, the results presented in this work,  in conjunction with other findings 
made  in  the  laboratory,  indicate  that  Apert  syndrome  is  manifested  by  altered 
recruitment of signalling proteins and formation of different signalling complexes rather 
than  simply  the  increased  activation  of  regular  FGFR2  signalling  pathways.  The 
differences  in  She phosphorylation and  localisation in cells  expressing the  S252W  or 
P253R  receptors  as  well  as  changes  in  recruitment  of  FRS2  and  Grb2  ([224],  in 
submission and Z. Ahmed, unpublished results) indicate that altered protein recruitment 
to  the  FGFR2  forms  the  basis  for  Apert  syndrome.  In  conjunction  with  the  changes 
observed in total intracellular tyrosine phosphorylation, these findings indicate that the 
term  gain-of-function  is  perhaps  inappropriate,  since  additional  mechanisms  such  as 
altered  formation  of  multiprotein  complexes  contribute  to  the  upregulation  of 
downstream pathways such as Erkl/2 and hence the manifestation of Apert syndrome. 
In vivo, the alteration of receptor specificity for ligand recognition is thought to be an 
important determinant of Apert syndrome. However, the intracellular changes described 
herein  clearly  show  that  Apert  syndrome  is  not  merely  the  result  of  ‘incorrect' 
activation of FGFR2 signalling by paracrine signalling (reviewed in [149]), but that the 
mutations also  greatly affect the integrity of intracellular signalling.  This  is important 
for the understanding of the molecular basis of Apert syndrome, because such changes 
may  result  in  activation  of different  pathways  that  would  normally  not  be  initiated 
downstream of the FGFR2 and may thereby result in the phenotypic symptoms of Apert 
syndrome.  This  study  investigated  the  effects  of changes  in  multiprotein  assembly
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downstream of the Apert mutant receptors on activation of the Erkl/2 kinase. However, 
further investigation of the effects on pathways such as the PI3K and PLCy pathways 
may reveal the overall extent to which changes in protein complex formation as a result 
of the two  extracelluar mutations affect  signal  generation downstream of the  FGFR2. 
Altogether, the findings presented in this chapter indicate the presence of an additional 
layer  of complexity  to  the  way  in  which  the  S252W  and  P253R  mutations  result  in 
Apert syndrome.
It is also interesting to note that the two Apert mutant receptors do not employ the same 
mechanism  to  achieve  similar  overall  cellular  outcomes  such  as  enhanced  Erkl/2 
activation. This was revealed by the difference in recruitment of She (as well as Grb2 
and  FRS2  as  assessed  in  separate  studies  ([224],  in  submission  and  Z.  Ahmed, 
unpublished results)  to  the  S252W  or the  P253R receptors.  This  indicates  an  overall 
change in the assembly of protein complexes in response to receptor activation and very 
different  effects  depending  on  the  exact  mutation  present.  It  is  possible  that  the 
differences  in  the  intracellular  effects  caused  by  either  the  S252W  or  the  P253R 
mutations are important in mediating the phenotypic  differences observed in terms of 
the severity of syndactyly and craniofacial abnormalities  [264]. These observations are 
interesting, because they show that individual mutations in the extracellular domains of 
tyrosine kinase receptors such as the FGFR2 are able to introduce very pronounced and 
unique effects on signalling complex formation. This significantly advances the general 
understanding of how mutations affect signal transduction by resulting in the formation 
of  entirely  different  protein-protein  interactions  intracellularly,  which  then  affects 
various cellular pathways and later the  specificity of signalling from a given receptor. 
Additionally, it was shown that individually different cellular mechanisms can underlie 
the overall gain-of-function properties of the Apert mutant receptors.
5.3.7  Altered protein recruitment to the S252W and P253R receptors 
may be the result of the combined changes in the FGFR2
To date it is not clear exactly how the altered protein recruitment to either of the Apert
mutant  receptors  is  mediated.  Receptor  phosphorylation  would  be  one  of the  main 
factors  dictating  which  proteins  are  recruited  and  when,  and  is  therefore  a  major 
determinant of multiprotein complex assembly. However, replacing all phosphorylation 
sites  on  FGFR1  with  phenylalanine,  with  the  exception  of Y653  and  Y654  whose
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phosphorylation is required for kinase activation, neither affected the phosphorylation 
levels  of  She,  FRS2  or  Erkl/2  kinase,  nor  the  Sos  gel  shift  in  response  to  FGF 
stimulation  [103].  Mitogenesis  or  PC 12  cell  differentiation  in  response  to  FGF  were 
also  not  significantly  affected  by  the  absence  of these  phosphorylation  sites  [103]. 
These data would therefore indicate that receptor phosphorylation is not the single most 
important  component  in  protein  recruitment  to,  and  signal  transduction  from  the 
FGFR2. Only mutation of FGFR2 tyrosine residues alone and in various combinations 
may  indicate  whether  phosphorylation  of  individual  residues  is  an  important 
determinant of the differential recruitment of adaptor proteins. Further, it would also be 
interesting to elucidate whether stoichiometric differences in phosphorylation of various 
tyrosine residues in the presence of the Apert syndrome mutations are a factor affecting 
the changes in protein recruitment observed.
An  important  factor  that  has  to  be  taken  into  account  when  analysing  the  altered 
intracellular  signalling  events  that  occur  in  response  to  activation  of  receptors 
containing  the  S252W  or  the  P253R  mutations  is  glycosylation.  Correct  receptor 
glycosylation has been  shown to  be  important not  only  in receptor  synthesis,  quality 
control (reviewed in [257]) and localisation to the plasma membrane [258, 259], but in 
the  case  of the  EGFR  has  also  been  shown  to  be  an  important  factor  in  preventing 
premature endocytosis [276]. Thus as described in Chapter 4, the altered glycosylation 
pattern  of  the  mutant  receptors  may  play  a  role  in  the  differences  in  receptor 
internalisation  observed.  Changes  in  endocytic  behaviour  may  consequently  affect 
protein recruitment to the receptor and thereby affect the signalling events downstream 
of the  Apert  mutant  receptors.  Additionally,  changes  in  FGFR2  glycosylation  may 
affect both ligand-dependent and independent dimerisation (refer to Chapter 4), which 
may  in  turn  affect  receptor  phosphorylation  and  the  availability  of binding  sites  for 
various signalling proteins and thereby contribute to the formation of altered signalling 
complexes downstream of the mutant receptors compared to the wild type FGFR2.
Although  the  exact  mechanism  by  which  the  S252W  and  P253R  mutations  result  in 
altered protein recruitment to and complex assembly downstream of the FGFR2  is not 
clear, it seems that the various changes they incur on the FGFR2 play an important role 
in  causing  the  changes.  Changes  in  receptor  glycosylation,  phosphorylation, 
internalisation and ligand binding are expected to all contribute to the observed changes 
in recruitment of various  adaptor proteins to  the  FGFR2.  This  supports  the  idea that
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Apert  syndrome  is  not  purely  a  result  of increased  affinity  of the  receptor  for  FGF 
ligand.  Instead  the  two  point  mutations  in  the  extracellular  domain  greatly  change 
numerous receptor properties, which in turn combine to cause significant changes in the 
recruitment of signalling proteins and subsequently result in the manifestation of Apert 
syndrome.
5.3.8  Concluding remarks
The  data presented  in the previous chapter revealed a number of effects  of the  Apert 
syndrome mutations on the FGFR2, including its phosphorylation and glycosylation as 
well  as  its  ligand  binding  properties.  The  data  presented  in this  chapter  complement 
these findings and revealed that the changes in the receptor affect not only the activation 
of one of the major downstream signalling pathways (namely the Erkl/2 pathway), but 
also  result  in  greatly  altered  protein  recruitment  and  phosphorylation.  This  altered 
recruitment  of  adaptor  proteins  such  as  She  (shown  herein),  FRS2  ([224],  in 
submission) and Grb2  (Z.  Ahmed,  unpublished results) provides a mechanism for the 
manifestation  of Apert  syndrome  that  is  different  from just  ‘increased  activation’  of 
receptor signalling due to an increased affinity of the receptors for ligand.
Despite it not being clear how exactly such altered protein recruitment is attained, the 
fact that the Apert syndrome mutations affect the recruitment of signalling proteins to 
the FGFR2 highlights the importance of correct protein complex assembly to activate 
the  desired  signalling  pathway  (i.e.  at  the  correct  magnitude  and  for  the  required 
duration). The importance of this was particularly obvious in the case of PC 12 cells, in 
which the cellular behaviour in response to FGF stimulation was greatly affected by the 
enhanced  Erkl/2  activation  in  cells  expressing  the  Apert  syndrome  mutations.  As 
described  in  Chapter  3,  the  enhanced  activation  of the  Erkl/2  pathway  resulted  in 
proliferation  instead  of differentiation,  which  is  the  normal  cellular  response  to  FGF 
stimulation.  Thus  even  if the  Apert mutations  initially  only  affected  recruitment  of a 
single protein to the receptor this would have a knock-on effect on recruitment of all 
proteins  normally  assembled  into  an  FGFR2-specific  complex.  Most  importantly,  the 
previously  described  gain-of-function  [173]  that  has  been  attributed  to  the  Apert 
mutations  seems to  be  a result  of altered  protein  recruitment  and  complex  formation 
rather  than  simply  increased  signal  transduction  via  the  same  ‘pathways’  due  to 
increased affinity of the receptor for ligand.
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Chapter 6
Recruitment of She to the FGFR2 
signalling complex requires the 
SH2 and PTB domains
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6.1  Introduction
Despite various attempts, few proteins that associate directly with the FGFR1 have been 
identified.  Of the  six major sites  subject to  autophosphorylation (refer to  Figure  3.9), 
PLCy  binds  to  pY766  and  Crk  binds  to  Y463,  whereas  FRS2  binds  to  the  receptor 
constitutively  and  independently  of tyrosine  phosphorylation  in  the  juxtamembrane 
region.  The  proteins  Sef and  Grbl4  have  also  been  shown  to  bind  directly  to  the 
FGFR1, but their binding sites have not been described  [108,  122, 289,  290].  Grb2  is 
able to bind to the EGFR directly via its SH2 domain, but such an interaction could not 
be detected  in case  of the  FGFR  [104].  FRS2  has  been  widely  accepted  as the  main 
docking protein recruiting Grb2 to the FGFR and is subsequently a major component in 
activation  of  the  Ras-Raf-MEK  pathway  downstream  of  the  FGFR  [9].  However, 
knockout mice lacking functional FRS2 display no defect in FGFR1  signalling during 
somitogenesis and gastrulation, which indicates that other proteins such as She must be 
sufficient for activation of the Erkl/2  pathway downstream of the  activated FGFR at 
least under certain circumstances [281].
Numerous  studies  have  shown  that  She  is  phosphorylated  in  response  to  FGF 
stimulation of cells expressing the FGFR1, FGFR3 or FGFR4 [100,  101,  103,  104, 278,
291].  Co-precipitation of She was only demonstrated in the case of the  FGFR3  [106] 
and the FGFR1  in mammalian cells expressing v-Src  [105].  The latter, although not a 
physiologically accurate  system,  indicated that direct interaction between the receptor 
and She is possible and that a She binding site is present on the FGFR1. The She SH2 
domain  has  been  shown  to  block  Erk2  activation  downstream  of  the  Pleurodeles 
FGFR1  (which is homologous to the human FGFR1) in Xenopus laevis oocytes, which 
does not necessarily indicate direct binding, but suggests that such an event occurs via 
the SH2 domain. A direct interaction between full-length She and the FGFR1  has not 
been described in mammalian cells under more physiological conditions despite reports 
that various FGFR-derived peptides are able to bind to the She SH2 and PTB domains 
[104, 282, 292].
Despite several reports outlining the involvement of She in FGFR signalling,  its exact 
role  and  perhaps  more  importantly,  the  way  in  which  it  is  recruited  to  the  receptor 
remains  unknown.  She  is  able  to  bind  to  receptors  such  as  the  EGFR,  TrkA,  insulin 
receptor or PDGFR via either its SH2 or PTB domain, or a combination of both [50, 71,
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293],  but direct  interaction with the  FGFR in vivo  has  not been shown conclusively. 
Various studies failed to detect interaction of She with the FGFR [103,  104]. A recent 
report  suggested  a possible binding  site  on FGFR1  for the  She  PTB  domain.  Studies 
showed that the phospho-peptide based on the sequence surrounding Y730 was able to 
block  its  mitogenic  function  in  FGFR1  signalling  [282].  Sequence  alignment  of the 
FGFR1  and FGFR2 confirmed that Y730 and the surrounding amino acid sequence are 
conserved between the two receptors. On the other hand, the She SH2 domain has been 
shown to bind both the EGFR and the PDGFR directly [49, 50, 293], and may therefore 
play  a role  in  She  recruitment to  the  FGFR alone  or in addition to the  PTB  domain. 
Synthetic  peptides  corresponding  to  the  sequence  surrounding  phosphorylated  Y766, 
Y730 and  Y558  can bind to the  She  SH2  domain  [104,  292].  The absence of reports 
indicating the direct interaction of She with the FGFR may be due to the fact that the 
interaction  is  of low  affinity  or  only  occurs  transiently,  which  makes  detection  by 
methods such as co-immunoprecipitation difficult.
In addition to various reports having revealed a role for She downstream of the FGFR, 
the  data presented  in  Chapter  3  confirmed  that  She  is  involved  in  FGFR  signalling, 
although its exact role and mode of recruitment to the activated receptor remain elusive. 
On the basis of the observation that She co-localises with the FGFR2, it was chosen to 
investigate whether these two proteins interact directly with each other and if so, which 
domain of She is critical for this interaction.  Co-localisation studies were used to gain 
insight into which She domains were found in the same cellular location as the receptor. 
Although useful,  cellular co-localisation of two  proteins  does not necessarily  indicate 
direct  interaction  of the  two  proteins  analysed.  Immunoprecipitation  and  pulldown 
experiments  were  also  not  able  to  conclusively  indicate  which  She  domain  mediated 
recruitment to the receptor.  Fluorescent lifetime imaging (FLIM) was therefore chosen 
as a technique that allows investigation of the potential direct interaction between She 
and the FGFR2 intracellularly.
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6.2  Results
6.2.1  Co-precipitation of She and the FGFR2
Co-localisation of She with the wild type FGFR2 was detected in both HEK 293T and 
PC 12  cells  (Figure  5.5  and  data  not  shown)  and  the  FGFR2  was  observed  in  She 
immunoprecipitates  previously  (Figure  5.3).  On  the  basis  of these  observations,  the 
interaction between She and the FGFR2 was investigated in more detail.  She and the 
FGFR2 could be co-precipitated.  She was detected  following immunoprecipitation of 
the FGFR2 using an anti-GFP antibody and, vice versa, the FGFR2 was present in She 
immunoprecipitates (Figure 6.1).
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Figure 6.1:  She and the FGFR2 can be co-immunoprecipitated HEK293T and PC12 cells expressing 
the wild type FGFR2-GFP were serum-starved and stimulated with  lOng/ml FGF9 for  15 minutes. Cells 
were lysed and lysates (2mg) were subjected to immunoprecipitation using an anti-Shc antibody (A) or an 
anti-GFP  antibody  (B).  The  western  blots  were  probed  with  the  respective  other  antibody  and  then 
stripped  and  re-probed  with  an  anti-Shc  or  anti-GFP  antibody  to  indicate  even  precipitation  of the 
respective target proteins.
Similar results were obtained for both HEK 293T and PC 12 cells, confirming that this 
observation was not cell-specific. The fact that fairly low amounts of proteins were co- 
precipitated with the respective binding partner could be due to a number of reasons 
such as weak affinity or interaction of only a limited pool of receptor with She.  Such
187limited  interaction  could  be  a  result  of  low  stoichiometry  of  binding  site 
phosphorylation  or  blocking  of  the  She  binding  site  by  other  FGFR2-interacting 
partners.  Particularly,  a  low  affinity  of  this  interaction  would  make  detection  by 
immunoprecipitation difficult, because cell lysis disrupts the cellular environment and 
thereby alters the relative protein concentrations,  which may result in dissociation of 
low  affinity  protein  interactions.  Consequently  the  relatively  low  levels  of  protein 
detected do not rule out direct interaction between these two proteins.
6.2.2  Construction and expression of Shc-RFP constructs
The exact role of She in FGFR signalling has not been fully elucidated,  and it is not
known which of the three She domains are important for this function. Several potential 
binding sites for the PTB domain and the SH2 domain have been identified [104, 282,
292].  Co-localisation  studies  are  valuable  to  determine  whether  proteins,  or  part  of 
proteins, are found in the same cellular localisation. Although this technique does not 
allow  assessment  of whether  proteins  interact  directly  it  was  chosen  to  investigate 
whether the  SH2  or  PTB  domain  of She  primarily  co-localised  with  the  FGFR2  to 
obtain an indication of their relative roles in recruitment to this receptor.  Several  She 
constructs  were  created  and  tagged  with  mRFP  to  investigate  the  co-localisation 
behaviour of the different domains with the FGFR2 (Figure 6.2A).
To create the ShcR401 A construct, the full-length protein was left intact, but the critical 
arginine in the SH2 domain was mutated to alanine, which abolishes recognition of, and 
binding  to  phosphotyrosine  motifs  [294].  To  create  a  ShcAPTB  construct  that  was 
impaired  in  both  the  ability  to  bind  phosphotyrosine  and  phospholipids,  several 
mutations would have had to be made  [185].  Thus instead of completely altering the 
domain  make-up  and  possibly  greatly  affecting  domain  folding  and  structure,  the 
domain was simply removed from the construct altogether. This seemed to be the most 
efficient  method  to  completely  abolish  the  ability  to  bind  both  phospholipid  and 
phosphotyrosine simultaneously. The 3F construct was created to assess the importance 
of She  phosphorylation  on co-localisation and  interaction with the  FGFR2.  All  three 
sites known to become tyrosine phosphorylated, Y239/Y240 and Y317, were replaced 
with phenylalanine. All constructs were transiently transfected into HEK 293T cells and 
lysates  were  subjected  to  SDS-PAGE  and  immunoblotting  with  an  anti-RFP  and  an 
anti-Shc antibody to ensure that the constructs expressed fusion proteins of the correct
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molecular weight (Figure 6.2B: top and bottom panel respectively). All constructs led to 
expression of a protein of the expected molecular weight that could be detected with 
both antibodies.  The PTB domain on its own could not be detected with the anti-Shc 
antibody, because all anti-Shc antibodies available in the laboratory were raised against 
the SH2 domain.
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Figure  6.2:  Expression  of  various  Shc-RFP  constructs  The  various  She  constructs  created  are 
represented in diagrammatic form (A). HEK 293T cells were transiently transfected with the six different 
RFP-tagged  constructs  using  calcium  phosphate  precipitation.  The  cells  were  lysed  and  200pg  of the 
lysates  subjected  to  SDS-PAGE  and  immunoblotting  with  an  anti-RFP  (top  panel)  and  an  anti-Shc 
(bottom panel) antibody (B).
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1896.2.3  Co-localisation of the FGFR2 with various She domains
To determine whether the PTB or SH2 domain of She were responsible for observed co­
localisation with the FGFR2 (Figure 5.5A), the various She constructs were transiently 
transfected into HEK 293T cells stably expressing the wild type GFP-tagged FGFR2. 
As a control, cells expressing the wild type FGFR2-GFP were also transfected with RFP 
on  its  own,  which  portrayed  no  co-localisation  with  the  FGFR2  (Figure  5.5D).  Co­
localisation observed between any constructs and FGFR2-GFP was therefore not due to 
RFP targeting the constructs to the cellular compartments containing the FGFR2.
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Figure 6.3: Co-localisation of the FGFR2 and She constructs HEK 293T cells expressing FGFR2-GFP 
were  transiently  transfected  with  each  She  construct  using  Lipofectamine  2000.  Cells  were  seeded  on 
glass  coverslips,  serum-starved  overnight,  stimulated  with  FGF9  as  indicated  and  fixed  in  4% 
paraformaldehyde.  Confocal  microscopy  using  a  Leica  SP2  system  was  carried  out.  Data  shown  is 
representative of at least five cells imaged for each cell line and time point. ShcAPTB (A), ShcR401 A (B, 
page  191),  PTB  domain (C,  page  191),  SH2  domain (D,  page  192),  Shc3F (E,  page  192).  The relative 
fluorescence  intensities  of GFP  and  RFP  along an  arbitrarily drawn  line  are represented graphically  in 
green and red respectively.WT-FGFR2-GFP
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The  SH2 domain and the  ShcAPTB construct (Figure 6.3D  and A respectively)  were 
both  primarily  not  membrane  localised.  Whereas  the  larger  ShcAPTB  construct  was 
localised throughout the cytoplasm but was excluded from the nucleus, the SH2 domain 
alone also localised to the nucleus. Since RFP on its own was also located in the nucleus 
(Figure 5.5D), it is possible that this is simply due to the smaller nature of this construct 
that  does  not  confer  nuclear  exclusion.  Additionally,  the  SH2  domain  on  its  own 
showed  some  degree  of plasma  membrane  localisation  and  a  small  amount  of co­
localisation of the SH2 domain with the FGFR2 could be detected in unstimulated and 
stimulated  cells  (Figure  6.3D:  fluorescence  intensity  graphs).  Nonetheless,  the  SH2 
domain  in  the  absence  of  the  PTB  domain  was  not  sufficient  to  mediate  major 
localisation of She to the plasma membrane.
In contrast to the ShcAPTB construct, the ShcR401 A construct was membrane localised 
after FGF9  stimulation of cells  expressing  FGFR2-GFP  (Figure  6.3B).  The  construct 
generally behaved like the normal full-length construct, apart from the fact that it was 
not as clearly co-localised with the receptor in unstimulated cells (Figure 6.3B: panel g 
and  fluorescence intensity  graph)  After 60  minutes  of exposure of cells to  FGF9, the 
two proteins still co-localised, albeit more on intracellular vesicles,  as was previously 
observed for full-length She (Figure 5.5A).
The  PTB  domain  on  its  own  generally  portrayed  a  more  diffuse  pattern  than  the 
ShcR401A construct,  but also co-localised with the  FGFR2 on the plasma membrane 
and on intracellular vesicles (Figure 6.3C). Like the SH2 domain on its own, the smaller 
size of this fusion protein meant that it was not excluded from the nucleus. In addition, 
the PTB domain was somewhat prone to degradation when over-expressed (as assessed 
by  western blotting,  data not  shown).  The presence  of smaller  fragments  containing 
mostly  RFP  could  account  for  some  of the  diffuse  RFP-staining  observed.  It  was 
interesting  to  note  that  the  PTB  domain  also  did  not  strongly  co-localise  with  the 
FGFR2  in  unstimulated  cells,  whereas  full-length  She  was  already  localised  at  the 
plasma membrane pre-stimulation (Figure 5.5A: panels f and k). This lack of strong co­
localisation may indicate the requirement for all functional  She domains to be present 
for targeting of the PTB domain to the FGFR2.
Co-localisation  of  Shc3F  was  also  assessed  (Figure  6.3E).  The  absence  of 
phosphorylation did not prevent  She  from co-localising with the FGFR2.  Overall, the
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co-localisation  pattern  was  very  similar  to  that  of  full-length  She:  membrane 
localisation  was  somewhat  decreased  after  15  minutes  of FGF9  stimulation  but  the 
FGFR2 and Shc3F greatly co-localised 60 minutes post-stimulation (Figure 6.3E: panels 
g and i respectively). These findings indicate that She recruitment to the FGFR2 is not 
an event that occurs as a result of phosphorylation. More likely the reverse occurs and 
membrane targeting is required for phosphorylation by the receptor to occur.
6.2.4  Co-precipitation analysis of the interaction of individual She 
domains with the FGFR2
Even though co-localisation studies provide a good indication of whether two proteins 
are found in the same region of a cell, the resolution achieved by confocal microscopy is 
not high enough to allow observations regarding direct proteins-protein interactions to 
be made. To confirm whether the different constructs and the receptor demonstrated the 
same co-precipitation as co-localisation patterns, cells expressing the wild type FGFR2 
were  transiently  transfected  with  the  various  She  constructs  and  cell  lysates  of 
stimulated and unstimulated cells were subjected to anti-GFP immunoprecipitation.
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Figure 6.4:  Co-precipitation of FGFR2 and She constructs HEK 293T cells expressing FGFR2-GFP 
were transiently transfected with equal amounts of each Shc-construct as well as REP on its own using 
calcium phosphate precipitation. Cells were serum-starved overnight and stimulated with  lOng/ml FGF9 
for  15  minutes.  Cell  lysates  were  immunoprecipitated  with  an  anti-GFP  antibody  overnight  and 
precipitants were subjected to  SDS-PAGE  and immunoblotting using anti-RFP,  anti-Shc  and  anti-GFP 
antibodies. She FL: She full length
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Following  immunoprecipitation,  the  western  blots  were  probed  with  an  anti-RFP 
antibody (Figure 6.4: upper panel). Unfortunately, the antibody detected a large number 
of non-specific background bands of similar size as some of the constructs. This made 
identification of whether or not a certain RFP-tagged construct was co-precipitated with 
the GFP-tagged receptor very difficult and inaccurate. Consequently, the same blot was 
re-probed using an anti-Shc antibody, which excluded many of the background bands 
(Figure 6.4: middle panel). All constructs co-precipitated with the receptor, which was 
in contrast with the results obtained from the co-localisation studies. However, the PTB 
domain  and  ShcR401A  only  precipitated  to  a  very  small  extent  compared  to  their 
expression levels (Figure 6.2), whereas full-length She, Shc3F and the SH2 domain co- 
precipitated with the receptor very well. It is possible that the SH2 domain is normally 
excluded  from  interaction  with  the  receptor  in  vivo,  because  the  binding  of specific 
binding partners is highly regulated in the cellular context. In the cell lysate changes in 
the relative protein concentration might occur which might cause interactions to become 
somewhat more dynamic. As a result the SH2 domain on its own or the SH2 domain of 
the  ShcAPTB  construct  could  co-precipitate  with  the  receptor,  despite  minimal  co­
localisation  having  been  observed  (Figure  6.3D).  Particularly  the  individual  SH2 
domain  may  bind  non-specifically  to  various  phosphorylated  tyrosines  on  different 
proteins associated with the receptor because of a lack of specificity when not in the 
context of the CHI  and PTB domains.  The full-length She and Shc3F constructs most 
dominantly co-precipitated with the FGFR2, which may indicate that both the functional 
SH2 and PTB domains are required for interaction with the FGFR2 (Figure 6.4: middle 
panel).  Both of these constructs also repeatedly displayed lower expression levels  but 
greatest FGFR2 co-precipitation, which could be representative of increased association 
with the receptor.
It was not possible to unambiguously detect whether or not the PTB domain on its own 
co-precipitated with the receptor because the anti-RFP antibody was poor and the She 
antibody does not detect the PTB domain.  The reverse immunoprecipitation using the 
anti-RFP antibody to precipitate the She constructs was extremely dirty (due to a large 
amount of background immuno-reactivity of the antibody) and unambiguous analysis of 
whether or not the FGFR2 was co-precipitated was not possible.
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Figure 6.5:  Pulldown  of the FGFR2  using GST-tagged  She  and  She  SH2  and  PTB  domains Full- 
length Shc-GST, SH2(Shc)-GST and PTB(Shc)-GST on glutathione sepharose were incubated with HEK 
293T  WT  cell  lysates  from  unstimulated  and  FGF9-stimulated  cells  overnight.  The  kinase  inhibitor 
genistein was added to full length She to avoid phosphorylation of SHc by potentially active kinases in 
the cell lysates. The beads were washed extensively and the precipitated proteins were subjected to SDS- 
PAGE  and  immunoblotting  with  an  anti-phosphotyrosine  antibody  and  reprobed  with  an  anti-GFP 
antibody after stripping the membrane. The same trend was observed in two independent experiments.
To confirm whether the SH2 domain mediated stronger interaction with the FGFR2 than 
the  PTB  domain,  GST-tagged  full-length  She  and  its  SH2  and  PTB  domains  were 
expressed  in E.coli and used to  pull  down the receptor from unstimulated and FGF9 
stimulated  HEK  293T  cells  expressing  the  FGFR2-GFP  (Figure  6.5).  All  three 
constructs were able to co-precipitate the FGFR2. However, the SH2 domain was able 
to precipitate the FGFR2 much more efficiently than the PTB domain (Figure 6.5: anti- 
GFP  blot  lower  panel),  which  is  in  agreement  with  the  RFP-immunoprecipitation 
experiment (Figure 6.4).  The PTB  domain was able to interact with the receptor,  but 
only to  a minimal  extent.  Precipitation of the  receptor  by  full-length  She  was  more 
efficient than by either domain alone, despite the fact that a lot less GST-fusion protein 
had  to  be  used  since  bacterial  expression  of full-length  She  was  very poor and  low 
yields of recombinant protein were  obtained.  The observation that neither full-length 
She  nor  any  of  the  individual  domains  could  interact  with  the  fully  glycosylated 
receptor, indicates the presence of some mechanism regulating interaction of She with 
the  FGFR2.  For  correct  and  efficient  interaction  all  She  domains  are  required  to  be 
present. The kinase inhibitor genistein was added to full-length She to avoid possible 
phosphorylation by active kinases in the lysates. This did not have any effect on FGFR2 
co-precipitation (Figure 6.5: lanes 3-4 versus 1-2), which suggests that phosphorylation 
has no effect on interaction with the receptor. This confirms the results obtained from 
the RF'P-immunoprecipitation and co-localisation experiments (Figures 6.3E and 6.4).
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The co-localisation studies indicated the possibility of the PTB domain being important 
for receptor binding.  However,  the low amounts  of receptor co-precipitation with the 
individual  PTB  domain  indicate  that  direct  interaction  is  minimal.  Membrane 
localisation is probably the result of the PTB domain binding to phospholipids in the 
plasma membrane.  If this was the  case  then the  SH2  domain could be the  main  She 
component  responsible  for  complex  formation  with  the  FGFR2.  For  this  to  occur 
efficiently  it  may  have  to  be  preceded  by  membrane  localisation  via  PTB 
domain/phospholipids  interaction,  which could  explain the  respective  absence  or  low 
level of co-localisation of the  ShcAPTB and SH2 domain with the receptor.  The  SH2 
domain might also require presence of the PTB domain for efficient interaction with the 
receptor,  since full-length GST- and RFP-Shc were more strongly associated with the 
receptor than individual domains or incomplete protein constructs (Figures 6.4 and 6.5).
6.2.5  FLIM analysis revealed the absence of direct interaction 
between She and the FGFR2
To resolve discrepancies  arisen by the  use of different techniques  and to  confirm the 
hypothesis  that  the  PTB  domain  is  required  for  membrane  localisation  but  the  SH2 
domain interacts with the receptor,  fluorescence  lifetime imaging microscopy (FLIM) 
was employed.  GFP on its own portrayed an average lifetime of around 2.1ns, which 
did not alter significantly in the presence of RFP (Figure 6.6G:  left and middle panels 
respectively).  The  lifetime  histogram  represents  the  lifetime  of all  pixels  within  the 
image taken,  and thereby  indicates the  distribution across the whole cell.  The  overall 
lifetime  of GFP  was  fairly  uniform,  tightly  centred  around  the  peak  at  2.1ns.  The 
FGFR2-GFP shows a slightly different pattern on the lifetime histogram (Figure 6.6G: 
right panel). Although still centred around a peak of 2.1, the shape of the curve is much 
broader with various smaller peaks present. These changes may be due to differences in 
the local environment throughout the cell, which may affect GFP lifetime locally [295]. 
Differences  in membrane  or juxtamembrane  environment  might  affect the  lifetime  of 
GFP and therefore create regions in which lifetimes shorter or longer than 2.1ns were 
detected.
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Figure 6.6:  FLIM was used to determine which  She domain  is  required  for direct interaction with 
the  FGFR2  HEK  293T  cells  expressing  FGFR2-GFP  were  transiently  transfected  with  each  Shc- 
construct as well as  RFP on  its own using  Lipofectamine 2000.  She (A, page  198),  ShcAPTB (B, page 
198), ShcR401A (C, page  199), PTB domain (D, page  199), SH2 domain (E, page 200), Shc3F (F, page 
200), GFP/RFP controls (G). Cells were seeded on glass coverslips, serum-starved overnight, stimulated 
with  FGF9  for  15  minutes  and  fixed  in 4%  paraformaldehyde.  FLIM  analysis  was  carried  out using a 
Leica TCS SP2 inverted microscope. Fluorescence decays were obtained using a single exponential decay 
model. The lifetime histograms represent the overall spread of GFP-lifetime across the entire cell. Images 
shown are representative of at least five independent cells analysed.
FLIM  analysis  revealed  that  She  does  not  interact  directly  with  the  FGFR2  (Figure 
6.6A). The peak of the lifetime histogram was very similar to that of the receptor on its 
own.  In unstimulated cells the lifetime average was shifted somewhat and  stimulated 
cells  portrayed  small  pockets  of very  short  lifetime,  which  could  be  interpreted  as 
restricted binding in certain regions. However, the similarity of the image to that of the 
FGFR2  on  its  own  suggests  that  no  binding  occurs  and  that  any  clusters  of shorter 
lifetime might simply reflect changes in the environment in which GFP is located.
The  ShcAPTB  construct  did  not  portray  any  change  in  the  average  lifetime,  which 
indicates that no direct interaction was taking place (Figure 6.6C). The peak was fairly
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sharp  and  there  was  no  indication  of  any  areas  of  shorter  lifetimes,  which  is  in 
agreement with the finding that ShcAPTB did not co-localise with the FGFR2. The SH2 
domain on  its own  would  have  been expected to  portray  similar characteristics to the 
ShcAPTB  construct,  since  these  two  behaved  similarly  in  the  co-localisation  studies 
with  the  exception  of some  low  level  membrane  localization  of the  SH2  domain.  In 
unstimulated cells there was no interaction of the SH2 domain w ith the receptor despite 
the  high  level  of  basal  receptor  phosphorylation  (Figure  6.6F).  Interestingly,  upon 
stimulation  (and  subsequently the  phosphorylation  of additional  tyrosine  residues) the 
peak shifted slightly to an average  lifetime of around 2.0 with a bias towards the  left, 
which is representative of a larger population of molecules with even  shorter lifetime. 
There were isolated clusters in which the SH2 domain was now able to interact directly 
with  the  FGFR2  (indicated  by  the  isolated  dark  blue  regions  with  a  GFP  lifetime 
between  1.5-1.7ns).  Thus  when  over-expressed,  the  SH2  domain  could  indeed  bind 
directly to the receptor in isolated clusters. This was confirmed by the fact that in cells 
that over-expressed the SH2 domain at extremely high levels portrayed direct binding to 
the FGFR2 throughout the cell with a very short average lifetime (data not shown). It is 
possible  that  this  is  due  to  either  displacement  of other  proteins  from  sites  such  as 
pY766  or  due  to  binding  to  one  of  the  various  tyrosine  residues  shown  to  be 
phosphorylated but lacking an identified binding partner.
It  was  interesting  to  note  that  the  ShcR401A  and  the  PTB  domains  both  portrayed 
isolated clusters of shorter lifetime throughout the cells (Figure 6.6D and E respectively: 
dark  blue  spots).  Thus  although  the  average  lifetime  of GFP  was  only  slightly  left- 
shifted  compared  to  that  obtained  for  cells  only  expressing  FGFR2-GFP  and  no  RFP 
construct, the spread w as much larger and a proportion of the overall lifetimes measured 
in  the  cell  were  very  short  (1.5-1.7ns.  particularly  in  unstimulated  cells  expressing 
ShcR401 A).  It is unclear why the lifetimes are shorter for the ShcR401A construct than 
they  are  for  the  PTB  domain  on  its  own.  This  may  simply  be  due  to  slight  cell-cell 
variations.  Another  explanation  could  be  that  in  isolated  regions  the  binding  of the 
construct  to  the  membrane  via the  PTB  domain  positions  the  RFP  molecule  in  close 
enough proximity to the GFP moiety attached to the receptor to cause FRET to occur. 
However, the overall patterns observed were not greatly different from full-length She 
or  cells  not  expressing  any  RFP-tagged  construct.  This  indicates  that  no  direct 
interaction of She  with the FGFR2  via the  PTB  domain occurs,  which correlates with
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the  fairly  low  levels of precipitation of the  receptor by the  GST-PTB  domain  (Figure 
6.5).
The  triple  tyrosine  mutant,  Shc3F,  showed  a  similar  FLIM  pattern  to  the  ShcR401A 
construct.  This was in agreement with the co-localisation patterns observed.  However, 
some more clusters in which shorter GFP lifetime was observed were present compared 
to the full-length She in stimulated cells. It is unclear why this occurs and whether these 
observations  are  simply  due  to  cell-cell  variation  or  alterations  in  the  environment 
surrounding the GFP molecule.
Thus altogether. She does not interact with the FGFR2 in vivo. Association of She with 
the FGFR2 therefore has to occur indirectly via interaction with other proteins in larger 
multiprotein  complexes.  Overall,  the  PTB  domain,  even  when  over-expressed  in 
isolation, was unable to bind to the receptor.  On the other hand, the  SH2 domain was 
able to bind to the receptor when expressed  in  isolation,  although this interaction was 
prevented in the context of the full-length protein.
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6.3 Discussion
6.3.1 The She SH2 domain can potentially bind to the FGFR2
FGF9  stimulation  of PC 12  and  FIEK  293T  cells  expressing  the  FGFR2  was  able  to
induce  She  phosphorylation.  Moreover  it  was  found  to  co-precipitate  and  co-localise 
with the receptor in both cell systems (Figures 5.5A, 6.1  and data not shown), indicating 
a  role  downstream  of the  FGFR2.  Flowever,  FLIM  analysis  of  full-length  She  and 
various truncated constructs/domains revealed that no direct protein-protein interaction 
takes  place  between  the  FGFR2  and  She.  although  the  SH2  domain  theoretically 
possesses the ability to interact directly with the receptor when over-expressed in vivo 
(Figure 6.2E).  Klint et al.  have previously shown that the isolated She  SH2  domain is 
able  to  bind  to  various  FGFR1 -derived  synthetic  peptides,  particularly  that 
corresponding  to  the  sequence  surrounding  Y766  [104].  Another  study  also 
implemented  the  corresponding  residue  in  the  chicken  bFGFR  as  the  highest  affinity 
binding site for the She SH2 domain and proposed that Y728 and Y556 (corresponding 
to  Y730  and  Y558  in  human  FGFR1)  were  minor  She  SH2  binding  sites  [292]. 
Although  in  vitro  studies  using  isolated  bacterially  expressed  domains  and  synthetic 
peptides do not necessarily represent true cellular events, these data provide support for 
the fact that the isolated SH2 domain may be able to displace PLCy from its binding site 
(pY766) or is able to bind to another site when expressed in isolation and present at high 
concentrations.  This  would explain  the  observed  interaction  between the  SFI2  domain 
and the receptor and the high levels of receptor co-precipitation of these two proteins. 
This interaction must be prevented in the context of the full-length She protein since no 
association of the full-length She protein with the FGFR2 was observed (Figure 6.6A). 
This  further  indicates  that  the  interaction  of the  SH2  domain  with  the  receptor  is  an 
artefact produced  by the overexpression of this single domain  in the absence of other, 
regulatory components of the whole protein.
6.3.2 Full-length She does not bind directly to the FGFR2
The  She  PTB  domain  and  a  full-length  construct  with  a  non-functional  SFI2  domain
both co-localised with the receptor at the plasma membrane (whereas neither the SH2 
domain nor the ShcAPTB construct were able to do so). This indicated an important role 
for  the  PTB  domain  in  terms  of She  recruitment  to  the  membrane  and  the  activated 
receptor.  Since  the  FRS2  PTB  domain  binding  site  does  not  contain  the  consensus
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NPXpY sequence required for She PTB domain binding [108] and no such sequence is 
found on FGFR2, the motif around pY730 could have been a candidate region for She 
PTB domain binding. This region portrays similarities to sequences of known She PTB 
interacting regions and was able to bind She when phosphorylated [282].  In this report 
Dunican  et  al.  implicate  the  PTB  domain  as  the  moiety  interacting  with  the  pY730 
peptide.  However, this is not shown conclusively and other studies suggested that this 
residue could be part of a She SH2 domain binding site [104], which could indicate that 
the binding described by Dunican et al.  occurs via the SH2 rather than the PTB domain. 
The FLIM data presented in this study revealed that neither the PTB domain alone nor 
any other She constructs were able to interact with the receptor. Support for the lack of 
She association with the receptor is obtained from the fact that She phosphory lation was 
found  to  be  unaltered  in  response  to  stimulation  of  receptors  lacking  all  major 
phosphorylation sites [103], which indicates that there is no requirement for FGFR-Shc 
interaction. The FLIM data have revealed that in the case of the FGFR2, neither Y730 
nor any other tyrosine residues form a binding site for She in vivo.
6.3.3  Regulation of the interaction of She with the FGFR2
Several  factors  could  play a role  in  preventing the  interaction of She  and the  FGFR2
despite  the  existence  of possible  binding  sites.  Firstly, the tyrosine residues  that  form 
the basis for proposed/hypothetical  She  SH2  or PTB domain binding sites may not be 
phosphorylated  at  all  or  only  to  a  low  extent  in  vivo.  For  example.  Y730  is 
stoichiometrically less phosphorylated than other tyrosine residues in the C-terminal tail 
of FGFR1  [103],  and a recent study was unable to detect  Y730 phosphorylation at all 
[15]. The low  levels of phosphorylation and the fact that this site is effectively buried in 
the three dimensional structure of the receptor [296] w ould make this site unsuitable for 
She  PTB  or  SH2  domain  binding.  Furthermore,  the  binding  of other proteins  such  as 
PLCy or Crk to the receptor at certain sites may prevent access to potential binding sites 
even if they were phosphory lated. The clusters in which interaction between the FGFR2 
and the SH2 domain were observed using FLIM could be explained by the displacement 
of PLCy  from  the  Y766  site  or non-specific  binding  to  other phosphorylated  tyrosine 
residues  on  the  receptor.  Although  the  isolated  domain  may  be  able  to  bind  different 
regions  on the  receptor,  this  binding  is  prevented  in the context of the  whole  protein. 
The reason for this is unclear, but the FGFR system seems to utilise FRS2 as the main 
Grb2-recruiting  protein  so  that  association  with  She  is  not  required.  She  may  play
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another role downstream of the FGFR2, for which interaction with the receptor needs to 
prevented  so  that  its  SH2  and/or  PTB  domains  are  available  to  interact  with  other 
proteins to initiate correct signalling complex formation.
6.3.4  A model for the role of the three She domains in recruitment to 
and indirect interaction with the FGFR2
6.3.4.1  The PTB domain is required  for membrane recruitment whereas the 
SH2 domain mediates interaction with proteins in a signalling complex
Overall,  the  data  presented  in  this  work  implement  the  PTB  domain  with  a  role  in
membrane  localisation  via  binding  of phospholipids.  Although  the  PTB  domain  co­
precipitated with the receptor, this interaction seemed to be weak and the PTB domain 
was  unable  to  interact  directly  with  the  receptor.  This  observation  suggests  that 
phospholipid  binding  is  more  important  in  terms  of membrane  localisation.  Previous 
studies  have  shown  the  lack  of  localisation  of  the  ShcAPTB  construct  to  the 
membranous  fraction,  whereas  full-length  She  was  associated  with  the  membrane 
fractions of unstimulated T cells, BaF cells and COS cells [185]. This process was thus 
mediated by the  PTB domain, which is  in agreement with the results presented herein 
(Figure 6.3).
Both phospholipid  and phosphotyrosine  binding have been shown to be  important  for 
She  phosphorylation  in response to  IL3  stimulation  [185].  Since the  She  PTB  domain 
was  also  able to  bind the  FGFR2  (Figure  6.4),  albeit  not very  efficiently  or with  low 
affinity,  a  similar  mechanism  could  take  place  in  FGFR2  signalling.  The 
phosphotyrosine  binding  event  may  be  secondary  to  membrane  recruitment  via 
phospholipid  binding  and  may  be  important  for  stabilisation  of  the  protein  in  the 
vicinity of the FGFR2 so that efficient phosphorylation of She can occur.  Phospholipid 
binding  would  therefore  allow  She  to  be  more readily  available  for recruitment to the 
receptor.  Further studies  using  full-length  She  with  PTB  domain  mutations  abolishing 
phospholipid  or  phosphotyrosine  binding  independently  would  be  able  to  reveal  the 
importance  of  each  individual  property  in  She  membrane  recruitment  and 
phosphory lation by the FGFR2.
The recruitment of She to the plasma membrane via the PTB domain would allow the 
SH2 domain to be brought to the vicinity of its binding partners in the FGFR2 signalling
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complex,  followed  by  their  interaction  (Figure  6.7).  The  SH2  domain  alone  is  not 
sufficient to mediate this binding in vivo and has to be preceded by She recruitment to 
the membrane via the PTB domain. This would explain why the SH2 domain and the 
ShcAPTB construct did not significantly localise at the membrane despite their ability to 
co-precipitate with the receptor.  In the cell  lysate interaction of the SH2  domain with 
the  FGFR2  is  possible,  but  in  the  cellular  context  it  is  prevented  because  the  SH2 
domain is not found in the vicinity of its binding partner(s).
FGFR2  FGFR2  FGFR2
Unidentified
targets?
Erk1/2
Figure  6.7:  Diagrammatic  representation  of the  proposed  way  in  which  She  is  recruited  to  the 
FGFR2  The  She  PTB  domain  mediates  recruitment  to  the  membrane  via  interaction  with 
phosphatidylinositol  (Ptdlns).  Activation  of the  FGFR2  by  ligand  leads  to  autophosphorylation  and 
recruitment of signalling proteins.  It is unclear whether one or more proteins are important in mediating 
the  interaction  of She  with  the  FGFR2,  but  one  of them  may  be  the  unidentified  phospho-protein  of 
85kDa. Its/their phosphorylation allows interaction with the She SH2 domain. Both phosphorylation sites 
on She are able to recruit Grb2 and subsequently Sos, but the Y239/Y240 site may also be involved in 
recruiting other proteins that activate unknown targets downstream of the FGFR2.
6.3.4.2 The recruitment of She to the membrane via the PTB domain may be 
an important regulator of She phosphorylation by the FGFR2
In addition to being  important in mediating interactions of the  She  SH2 domain with
receptor associated proteins, the recruitment of She to the plasma membrane via its PTB 
domain may also  be an important regulator of its phosphorylation.  Studies  in T cells 
have revealed that constitutive anchoring of She to the membrane via addition of the 
Ras  famesylation  motif  leads  to  its  phosphorylation  and  activation  of  signalling 
pathways in the absence of receptor stimulation [297]. Moreover, She phosphorylation 
by  c-Src  is  phosphatidylinositol(4,5)bisphosphate  (PIP2)  dependent,  whereas 
phosphorylation by the EGF receptor is PIP2 independent [298]. The She PTB domain
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can bind the EGFR directly, which may replace the requirement for PIP: binding. This 
indicates  that  She  recruitment  to  plasma  membrane  via  the  PTB  domain  (where 
phospholipid  or  phosphotyrosine  binding  may  occur)  might  represent  an  important 
mechanism  in  the  regulation  of She  phosphorylation  and  subsequent  adaptor  protein 
binding,  and  could  explain  how  She  phosphorylation  by  the  FGFR  can  occur  in  the 
absence  of  all  major  autophosphorylation  sites.  It  is  unclear  which  changes  the 
expression of the FGFR2 incurs on the plasma membrane environment that would lead 
to  increased  She  localisation  to  the  membrane  compared  to  regular  HEK  293T  cells 
(Figure  5.5).  Although  She  phosphorylation  was  not  required  for  indirect  association 
with the receptor or membrane recruitment it is crucial for interaction with proteins such 
as Grb2.  Thus the controlled recruitment of She to the FGFR2  signalling complex via 
both the PTB and the SH2 domains may be an important mechanism in controlling the 
precise  activation  of  downstream  signalling  pathways  by  regulating  She 
phosphorylation.
6.3.4.3  Phosphorylation does not affect She recruitment to or interaction with 
the FGFR2 signalling complex
Recent  studies  have  indicated that  in  vitro,  phosphorylation of She  is required  for the 
SF12 domain to open up and bind tyrosine phosphorylated ligand ([299], in submission). 
Such  a  model  would  add  an  additional  layer  of regulation  to  protein  recruitment  to 
RTKs  and  activation  of  downstream  signalling  pathways.  One  could  imagine  She 
becoming membrane localised via PTB  domain interactions with the membrane in the 
absence of phosphorylation.  Phosphory lation would then be required for it to not only 
allow Grb2/Sos recruitment but also to stabilise its interaction with activated receptors 
and other signalling proteins via the SH2 domain. However, in the system investigated 
in  this  study,  unphosphorylated  She  (Shc3F  or  She  in  the  presence  of genistein)  co­
precipitated  and  co-localised  equally  well  with  the  FGFR2.  This  indicates  that  the 
model based on observ ations made in vitro does not seem to hold true for this particular
svstem.
*
An explanation for the fact that Shc3F behaves in the same way as full-length She could 
be that  in vitro  its regulation  is very  much "black and white",  i.e.  the  SH2  domain  is 
either closed (in the unphosphorylated protein) or open (in the phosphorylated state) for 
ligand binding.  In contrast, in vivo She may have the ability to bind some proteins via 
the  SH2  domain  in  the  absence  of tyrosine  phosphorylation  under certain  conditions.
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This hypothesis was supported by results obtained from pulldown experiments carried 
out  in  other  cellular  systems  (data  not  shown).  In  vivo,  factors  in  addition  to  She 
phosphorylation may be involved in regulating the ability of She to bind ligands via the 
SH2 domain. For example, the binding of the PTB domain to the plasma membrane or a 
PTB binding site on a receptor such as the EGFR may already initiate transition into an 
open conformation in the absence of She phosphorylation. Phosphorylation events in the 
CHI  domain  might  subsequently  stabilise  the  open  conformation  so  that  binding  of 
ligands via the SH2 domain is prolonged and more stable.
Overall,  the  data  presented  in  this  work  indicate  a  role  for  the  She  PTB  domain  in 
membrane  recruitment  and  for  the  SH2  domain  in  binding  to  FGFR2-interacting 
proteins  (Figure  6.7).  This  dual  binding  event  is  required  to  ensure  correct  protein 
localisation  and  recruitment  to.  and  binding  within  the  signalling  complex  formed 
downstream  of  the  FGFR2.  In  the  absence  of  one  of  these  domains,  these  highly 
regulated  events  are  disrupted  and  the  correct  recruitment  of She  to  the  receptor  is 
prevented.  In the absence of the PTB domain. She cannot co-localise with the receptor 
(i.e.  is  not  recruited  correctly)  (Figure  6.3A  and  D),  whereas  the  absence  of the  SH2 
domain prevents stable, indirect interaction with the FGFR2 (Figures 6.4 and 6.5). Since 
full-length  She  constructs  co-precipitated  more  efficiently  with  the  receptor than  any 
individual  domains  or  deletion  constructs,  it  seems  that  additional  complexity  and 
specificity  is  added  to  protein  interactions  involving  She  by  the  presence  of all  three 
domains.  Although  She  phosphorylation  did  not  affect  recruitment  or  binding  to  the 
FGFR2  ternary  complex,  this  does  not  rule  out  a contribution  of the  CHI  domain  in 
correct positioning of the domains to allows interaction with the membrane and  other 
proteins in a signalling complex induced by FGFR2 activation.
6.3.5  She recruitment to the FGFR2 is mediated via indirect 
association and formation of multiprotein signalling complexes
The absence of direct protein-protein interaction between She and FGFR2 indicates that
co-precipitation must occur via formation of ternary complexes. Co-precipitation could 
also  take  place  if She  was  bound  to  a  protein  that  either directly  interacted  with  the 
receptor or was found in a complex surrounding the receptor. Thus based on the model 
described,  it  seems  to  be  the  She  SH2  domain that  interacts  with  proteins  to  form  a 
signalling complex surrounding the FGFR2.
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Identification of She binding partners mediating its recruitment to the FGFR2 is crucial 
to clearly understand the role of individual She domains in FGFR signalling in general. 
She  has been  shown to  bind  to  various  signalling  proteins  such  as  for example  Gab2 
[197], c-Cbl [196], SHIP1, an unidentified protein pi45 (downstream of FGFR1  [104]) 
and others, some of which may be involved in FGFR signalling and could therefore be 
target  proteins  for  the  recruitment  of  She  into  a  signalling  complex  including  this 
receptor.  A tyrosine phosphory lated protein of approximately 40 kDa was observed in 
anti-Shc and anti-GFP (i.e. anti-FGFR2) immunoprecipitates, and could be a candidate 
protein  for  mediating  interaction  between  the  two  proteins  (Figure  5.3A).  Another 
candidate for She recruitment to the FGFR2 signalling complex is c-Cbl.  She has been 
shown  to  interact  with  c-Cbl  via  its  SH2  domain,  and  a  120kDa phosphoprotein  was 
observed in anti-Shc IPs HEK 293T cells and after longer exposure of the blot in PC 12 
cells (Figure  5.3).  The  85kDa unidentified protein described in Chapter 5  may also be 
involved  in  mediating  interaction of She  with the  FGFR2.  A tyrosine phosphorylated 
protein  of similar  molecular weight  was  observed  in  the  GST-SH2  domain  pulldown 
(Figure  6.5).  Therefore  this  protein  may  be  a  likely  candidate  to  mediate  the  indirect 
interaction  between the  FGFR2  and  She  via  its  SH2  domain.  Fewr  proteins  have  been 
described that bind to the FGFR. and the number of proteins shown to bind the She SH2 
domain  are  also  limited.  It  is  thus  difficult  to  indicate  potential  proteins  mediating 
recruitment of She to the FGFR2. The adaptor protein Grbl4, which has been shown to 
bind directly to the FGFR1  [290], has recently been shown to possess an NPXY motif 
that leads to interaction with IRS-1  in a phosphorylation-independent manner [300]. An 
interaction of this motif with the  She  PTB domain has not been  indicated to date,  but 
would present a possibility of mediating the indirect interaction of She with the FGFR2. 
However, since the SH2 domain was found to mediate interaction with the FGFR2, the 
interaction  of the  She  PTB  domain  with  Grbl4  does  not  seem  to  play  a  role  in  She 
recruitment to this  receptor.  Altogether,  it  seems that  She  is recruited to a fairly  large 
protein complex that connects it to the FGFR2. Further work is required to identify Shc- 
interacting proteins in FGFR signalling as well as the exact role of She in the signalling 
complex formed upon FGFR activation.
One  of the  functions  of  She  downstream  of the  FGFR  (and  many  other  RTKs)  is 
recruitment of the Grb2/Sos complex to the plasma membrane. However, it may also be 
involved  in  signalling  pathways  other than  the  Erkl/2  pathway.  Various  reports  have
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implicated She with a role in signalling from activated tyrosine kinase receptors that is 
independent of mitogenic  signalling (i.e.  Grb2 recruitment and Erkl/2 activation). The 
Y239/Y240 phosphorylation site has been shown to be important in signalling to c-myc 
and to have the ability to interact with proteins other than Grb2 in vitro [198,  199. 301, 
302].  A  mutant  She  protein  with  a  CHI  domain  deletion  (which  still  retained 
Y239/Y240,  but  was  only  minimally  phosphorylated  on  these  sites  and  did  not  bind 
Grb2) did not affect activation of the Erkl/2 pathway but interfered with transformation 
as  a result  of ErbB2  overexpression  [200].  These  observations  indicate  that  She  may 
also play an important role in various other signalling processes that are distinct from its 
role as a Grb2 recruiting adaptor protein (Figure 6.7). Since FRS2 is primarily involved 
in  Grb2  recruitment  [47],  different  functions  of She  may  be  of particular  interest  in 
FGFR signalling. It would therefore be particularly interesting to determine the proteins 
that mediate  She  interaction with the  FGFR2  as well  as proteins that may bind to the 
two  phosphorylated  sites  in  the  CHI  domain  and  may  be  important  in  regulation  of 
secondary' pathways (other than Erkl/2 activation). The assembly of a specific complex 
in the absence of direct interaction with the FGFR2 may be important in regulating the 
specific and precise activation of such targets in response to activation of this receptor 
compared to other RTKs.
6.3.6  Regulation of signalling specificity by the absence of direct 
interaction between She and the FGFR2
In  conclusion,  the  findings  presented  in  this  chapter present  a detailed  study  into  the 
way in which She is recruited to activated FGFRs. Although the FGFR2 was used, and 
differences  may  exist  in  terms  of the  interaction  of She  with  other  members  of the 
FGFR family, the  lack of studies reporting interaction of She  with any  FGFR indicate 
that these results may be transferable between FGFR1-4.  It  interesting to  note that  in 
the case of signalling from the FGFR, direct association of She with the receptor is not 
required  for its functionality.  The data thus indicate that different receptor systems are 
able to discriminate activation of various pathways even if potential binding sites for a 
number of proteins exist. For example, the FGFR possesses potential She SH2 and PTB 
domain binding sites, but through tight regulation of the order and the stoichiometry of 
receptor  phosphorylation  [15],  direct  interaction  of  She  with  the  receptor  can  be 
prevented.  Previous  work  implemented  FRS2  as  the  major  component  mediating 
Grb2/Sos recruitment.  This indicates that regulation of which signalling complexes are
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formed  in response  to  various  activated  receptor  already  occurs  at the  level  of which 
proteins  are  able  to  bind  the  receptor  in  the  cellular context.  Thus  although  potential 
binding sites exist on receptors, prevention of direct binding of adaptor protein such as 
She  or  FRS2  leads  to  formation  of different  signalling  complexes  and  therefore  may 
play an important role in regulation of downstream signalling pathways.  Prevention of 
binding  may  be  regulated  by  various  mechanisms  such  as  lack  of  a  binding  site, 
structural obstruction of access to a site, lack of phosphory lation of the tyrosine residue 
required for tight binding or competition with another protein for the same or a nearby 
site.  Furthermore,  the  work  presented  in  this  thesis  indicates  that  although  She  is 
involved in Grb2 recruitment to the FGFR, it may also carry out other roles in response 
to  FGFR activation.  This  indicates  the  requirement  for  further  studies  elucidating  the 
proteins  that  are  able  to  interact  with  the  receptor  as  well  as  She  following  FGF 
stimulation  and  the  exact  cellular  roles  that  She  carries  out  in  response  to  FGFR 
activation.  Further,  this  emphasizes  that  the  differential  recruitment  and/or 
phosphorylation  of  proteins  by  various  receptors  may  play  an  important  role  in 
determining the exact functions they carry out.
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7.1 Conclusions
The aim of this work was to use two different model systems to investigate differences 
in  protein  recruitment  to  various  tyrosine  kinase  receptors  and  the  role  they  play  in 
generating  signalling  specificity.  PC 12  cells  were  used  as  a  well-characterised  model 
system to explore how the assembly of different complexes downstream of the EGFR, 
FGFR and TrkA affects the signal generated by each receptor despite recruitment of the 
same signalling proteins. The Apert syndrome mutations in FGFR2 were used to create 
a model  system to  investigate the  effects that  receptor extracellular domain mutations 
have  on  protein  recruitment  and  generation  of  specific  signals.  Additionally,  the 
FGFR2  was  used  to  investigate  the  interaction  of this  RTK  with  She  and  whether 
differences  in  the  ability  of  proteins  to  bind  to  various  receptors  affects  their 
involvement  in  protein  complexes  and  thus  the  downstream  signal  initiated.  The 
investigations  revealed  three  main  findings  regarding  signals  initiated  from  various 
activated RTKs.
Firstly,  intrinsic  differences within receptor systems were  found to regulate  signalling 
specificity. The presence of different binding sites on each receptor can be regulated by 
the amino acid sequence or by differential and highly controlled phosphorylation. In this 
way,  recruitment  of proteins  can  be  controlled,  as  was  observed  in  the  case  of the 
EGFR, FGFR and TrkA. For example, the presence of different binding sites for FRS2 
on the three  receptors  seemed to  determine the  way  in which this protein  is involved 
(i.e. the level of its phosphorylation and subsequently the amounts and types of proteins 
it can bind). Similarly, it was found that the FGFR2 does not interact with She directly. 
Although  other  FGFRs  may  portray  a  different  behaviour,  this  finding  also  indicates 
that  the  direct  binding  of  a  protein  to  a  receptor  may  regulate  its  involvement  in 
signalling  from  this  RTK  family.  The  fact  that  She  is  unable  to  bind  directly  to  the 
FGFR correlates with the lower levels of She phosphorylation observed in response to 
FGF compared to EGF stimulation.  Using the PC 12 model  system and  FLIM  analysis 
of the interaction between She and FGFR2 it was shown that the recruitment of proteins 
is  regulated  by  intrinsic  differences  in  the  receptors.  Additional  factors  such  as  the 
occupation  of  binding  sites  by  other  proteins  that  may  thereby  form  the  basis  of 
different signalling complexes may also play an important role in regulation of the exact 
involvement  of  specific  proteins  in  signalling  from  any  given  RTK.  However,  the 
differences observed could be a result of intrinsic variation in the intracellular regions of
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the different receptors and were found to be an important regulator of signal specificity 
and integrity.
The second conclusion that could be drawn from the data presented was that integrity of 
the  receptor  system  is  essential  for  the  generation  of  correct  and  specific  signals. 
Mutations affecting the interaction between receptor and ligand are able to disturb this 
highly  regulated  system  and  the  normal  cellular  responses  to  receptor  engagement. 
Using the  Apert  syndrome  mutations  in the  FGFR2  as  a model  system,  it was  shown 
that even small changes in the extracellular domain are able to affect the recruitment of 
signalling  proteins  to,  and  the  integrity  of  signals  initiated  from  RTKs.  The  Apert 
syndrome mutant FGFR2s exhibit increased affinity for FGF  ligand.  It was found that 
the recruitment of adaptor proteins such as She, FRS2 and Grb2 as well as activation of 
the Erkl/2 pathway were grossly affected despite the mutations being removed from the 
site of protein binding/recruitment.  This indicates that even a small  disturbance of the 
signalling system can grossly affect the highly regulated pattern of protein recruitment 
that is required for the generation of specific signals by different receptors.
Finally,  analysis  of  the  changes  in  receptor  glycosylation,  localisation  and 
phosphorylation in the presence of the Apert syndrome mutations revealed that various 
different  factors  need  to  be  tightly  controlled  to  allow  activation  of  the  correct 
downstream signals. The intrinsic signalling specificity of each type of receptor may not 
only rely on intracellular properties such as binding sites for protein recruitment, but the 
overall  integrity  of  the  receptor  including  the  extracellular  region  may  be  a  major 
determinant  of  signalling  specificity.  Receptor  glycosylation,  localisation  and 
interaction with ligands (both FGFs and HSPGs) were found to be altered in the Apert 
syndrome  mutants.  These  factors  may  affect  receptor  structure  and  positioning  in  a 
functional  dimer  and  are  likely  to  affect  receptor  phosphorylation.  Thereby  the 
combination  of  these  factors  contributes  to  the  regulation  of  cellular  responses  to 
stimulation  of a  particular  receptor.  Changes  in  one  or  more  of these  properties,  as 
observed  in  the  case  of the  Apert  syndrome  mutations  in  the  FGFR2,  may  therefore 
have detrimental effects on the integrity of the signals initiated. This work has indicated 
that all of these factors may contribute to altered recruitment of proteins to a receptor 
and  thereby  interfere  with  correct  (and  specific)  activation  of downstream  signaling 
pathways.
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In  conclusion,  this  work  presents  evidence  to  support the  idea that  specificity  in  cell 
signalling  is controlled  by a number of different  factors.  In conjunction,  these  factors 
affect protein recruitment, the type, strength, and longevity of the signal. Mutations that 
lead to alteration of some of these factors can grossly affect the signal generated and its 
effects  on  cellular  responses.  Recruitment  of  different  proteins  to  RTKs  and  tight 
regulation of this process plays a major role in generating signalling specificity.  It was 
shown  that  this  aspect  is  partly  controlled  by  intrinsic  differences  between  RTKs, 
although  a  number  of  factors  were  found  to  affect  it.  The  specific  recruitment  of 
proteins  into  unique  multiprotein  complexes  allows  cells  to  differentiate  between  the 
activation  of  different  pathways,  which  is  an  important  aspect  in  the  regulation  of 
cellular responses to different extracellular stimuli.
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